{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "STX.L",
  "generated_at": "2026-02-11T17:10:44.604394Z",
  "top_card": {
    "ticker": "STX.L",
    "company_name": "Shield Therapeutics plc",
    "sector": "Healthcare",
    "market_cap_gbp": 112139686,
    "days_active": 576,
    "apex_score_100": 60,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "CROWDED",
    "action": "SELL/TAKE_PROFITS",
    "thesis_one_liner": "SELL/TAKE_PROFITS - CROWDED timing with 60/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Shield Therapeutics plc",
      "sector": "Healthcare",
      "industry": "Drug Manufacturers - Specialty & Generic",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 112139686,
      "current_close_price": 10.5
    },
    "basics": {
      "ticker": "STX.L",
      "current_price": 10.5,
      "ath": 184.8142,
      "atl": 1.063,
      "ath_date": "2020-01-08",
      "atl_date": "2024-04-25",
      "week_52_high": 12.5,
      "week_52_low": 2.1,
      "week_52_high_date": "2025-12-04",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 94.32,
      "data_start": "2020-01-02",
      "data_end": "2026-02-11",
      "total_bars": 1544
    },
    "latest_signal": {
      "date": "2024-07-15",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.6,
      "drawdown_pct": 87.55,
      "ai_score": 9.0,
      "rsi": 18.2,
      "cycle_position": 0.1818,
      "holding_period_days": 576,
      "current_pnl_pct": 556.25,
      "rally_state": "rallying",
      "distance_from_high_pct": -17.11,
      "Rally_Count": 1,
      "days_since_last_high": 10,
      "last_high_date": "2026-01-16",
      "lock_in_reached": true,
      "lock_in_date": "2026-01-16",
      "best_rally_pct": 662.5
    },
    "best_historical_signal": {
      "signal_date": "2024-04-25",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 1.225,
      "peak_price": 12.5,
      "peak_date": "2025-12-04",
      "rally_pct": 920.41,
      "days_to_peak": 588,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "STX.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.1125,
        "current_return_pct": 38.8,
        "best_rally_pct": 75.33,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 9,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1306,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 69.68,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 8,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1305,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5085,
        "current_price": 10.1125,
        "current_return_pct": 55.37,
        "best_rally_pct": 96.27,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 9,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1302,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.3628,
        "current_price": 10.1125,
        "current_return_pct": 58.93,
        "best_rally_pct": 100.76,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 6,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1301,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.2414,
        "current_price": 10.1125,
        "current_return_pct": 62.02,
        "best_rally_pct": 104.67,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1298,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-27",
        "signal_date": "2022-10-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1187,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-28",
        "signal_date": "2022-10-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.1125,
        "current_return_pct": 38.8,
        "best_rally_pct": 71.57,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1186,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-31",
        "signal_date": "2022-10-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1183,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-13",
        "signal_date": "2022-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.8,
        "current_price": 10.1125,
        "current_return_pct": 48.71,
        "best_rally_pct": 83.82,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1140,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-14",
        "signal_date": "2022-12-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9214,
        "current_price": 10.1125,
        "current_return_pct": 46.1,
        "best_rally_pct": 80.6,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1139,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-19",
        "signal_date": "2022-12-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9,
        "current_price": 10.1125,
        "current_return_pct": 46.56,
        "best_rally_pct": 81.16,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1134,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-05",
        "signal_date": "2023-01-05",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.6,
        "current_price": 10.1125,
        "current_return_pct": 53.22,
        "best_rally_pct": 89.39,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1117,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-06",
        "signal_date": "2023-01-06",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.5,
        "current_price": 10.1125,
        "current_return_pct": 55.58,
        "best_rally_pct": 92.31,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1116,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-02-27",
        "signal_date": "2024-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.42,
        "current_price": 10.1125,
        "current_return_pct": 317.87,
        "best_rally_pct": 404.13,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 4,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 699,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-02",
        "signal_date": "2024-04-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.0,
        "current_price": 10.1125,
        "current_return_pct": 405.63,
        "best_rally_pct": 510.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 664,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-03",
        "signal_date": "2024-04-03",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.9,
        "current_price": 10.1125,
        "current_return_pct": 432.24,
        "best_rally_pct": 542.11,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 663,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.775,
        "current_price": 10.1125,
        "current_return_pct": 469.72,
        "best_rally_pct": 587.32,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 662,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-05",
        "signal_date": "2024-04-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.1125,
        "current_return_pct": 494.85,
        "best_rally_pct": 617.65,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 661,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.1125,
        "current_return_pct": 494.85,
        "best_rally_pct": 617.65,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 658,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 10.1125,
        "current_return_pct": 512.88,
        "best_rally_pct": 639.39,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 657,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-12",
        "signal_date": "2024-04-12",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.1125,
        "current_return_pct": 563.11,
        "best_rally_pct": 700.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 654,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-16",
        "signal_date": "2024-04-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.1125,
        "current_return_pct": 563.11,
        "best_rally_pct": 700.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 650,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-17",
        "signal_date": "2024-04-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.48,
        "current_price": 10.1125,
        "current_return_pct": 583.28,
        "best_rally_pct": 724.32,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 649,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-25",
        "signal_date": "2024-04-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.225,
        "current_price": 10.1125,
        "current_return_pct": 725.51,
        "best_rally_pct": 895.92,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 641,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-26",
        "signal_date": "2024-04-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 640,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-29",
        "signal_date": "2024-04-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 637,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 636,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-07-15",
        "signal_date": "2024-07-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.6,
        "current_price": 10.1125,
        "current_return_pct": 532.03,
        "best_rally_pct": 662.5,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 560,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 411.07,
      "median_rally_pct": 470.76,
      "best_rally_pct": 920.41,
      "worst_rally_pct": 70.68
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 17:06:21 UTC",
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "UPTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 60/100 indicates strong opportunity quality",
      "Timing regime: CROWDED",
      "Historical profile: 1 rallies, 662% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "STX.L",
      "latest": [
        {
          "title": "FDA Grants additional Exclusivity for ACCRUFeR",
          "announcement_date": "9th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "9 Feb 2026 07:00\nRNS Number : 2151S\nShield Therapeutics PLC\n09 February 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA Grants additional 3 Years Exclusivity for ACCRUFeR\u00ae\nLondon, UK, 09 February 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA) has granted to Shield an additional 3 years of Data Exclusivity for ACCRUFeR\u00ae (ferric maltol). This is due to the new clinical investigation conducted by Shield that was essential to the approval of the extension of the indication to include pediatric patients 10 years of age and older. This exclusivity remains in place until 19 December 2028 in addition to the\nACCRUFeR\u00ae/FeRACCRU\u00ae patent coverage valid until the mid-2030s.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nDr Jackie Mitchell, VP of Regulatory, Quality, Clinical and Regulatory Affairs of Shield, commented:\n\"This exclusivity is a significant milestone for Shield and recognises the value of the essential clinical investigation conducted to support the pediatric indication, reflecting the strength of the Phase 3 FORTIS trial. We are well positioned to continue expanding access to ACCRUFeR\u00ae and addressing unmet needs in both adult and pediatric populations.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/PZopny\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is the final study in the comprehensive pediatric development program that Shield committed to implement with both the European EMA and the US FDA.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBVLLBQLLZBBB",
          "rns_number": "RNS Number : 2151S"
        },
        {
          "title": "Total Voting Rights",
          "announcement_date": "30th Jan 2026",
          "release_time": "7:05 am",
          "source": "RNS",
          "content": "Today 07:05\nRNS Number : 0034R\nShield Therapeutics PLC\n30 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 30 January, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,997,016\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/P2AzZr\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRPPUUPGUPQPGB",
          "rns_number": "RNS Number : 0034R"
        },
        {
          "title": "Approval for ACCRUFeR in China expected in Q1 2026",
          "announcement_date": "30th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 0029R\nShield Therapeutics PLC\n30 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\nFiling for marketing authori\nsation\nfor the approval for ACCRUFeR\u00ae in China\nexpected in Q1 2026 and will include the pediatric data\nTerms of the China License Agreement with ASK updated to include a $7.9Mdevelopment milestone to Shield by 31 January 2026\nShield to use the\nASK development milestone payment to settle all payments andterminate the AOP Milestone Monetisation Agreement\nLondon, UK, January 30, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces that its partner in China, Beijing Aosaikang Pharmaceutical Co. Ltd (\"ASK\"), expects to submit the file for marketing authorisation to the China National Medical Products Administration (\"NMPA\") for the approval for ACCRUFeR\u00ae in China in Q1 2026. The Company and ASK have agreed to update various terms of the China License Agreement including a development milestone of $7.9M to Shield by 31 January 2026. Shield will use the ASK development milestone to settle its obligations under the AOP Milestone Monetisation Agreement and terminate the agreement.\nASK plans to include the positive data from Shield's Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that was used to receive US FDA approval to extend the indication for ACCRUFeR\u00ae in the US to include children 10 years and older with iron deficiency (ID) in its NMPA filing for Marketing Authorisation for ACCRUFeR\u00ae in China. The NMPA filing is anticipated in Q1 2026.\nIn addition to ASK agreeing to pay Shield a development milestone of $7.9M, the Company and ASK have agreed to update various terms of the China License Agreement including a milestone of up to $3M linked to the final price for ACCRUFeR\u00ae in China, and revised royalties of up to 10% based on annual net sales of ACCRUFeR\u00ae. The updated milestones replace the $11.4M milestone which was conditional upon receipt of a subsequently expected marketing approval in China.\nThe Company will use the $7.9M development milestone payment from ASK to settle all its obligations under the terms of the AOP Milestone Monetisation Agreement. The final payment amount to AOP will fully discharge the Company's financial obligations to AOP under that agreement. This payment is significantly below the amount which would have been due to AOP if the full $11.4M marketing approval milestone payment had been received by Shield from ASK.\nSantosh Shanbhag, CFO at Shield, commented:\n\"\nWe are pleased to see the continued progress of our partner ASK towards the planned submission for marketing authorisation of ACCRUFeR\u00ae in China in the first quarter of 2026. We believe that the inclusion of the recently approved US pediatric Phase 3 data strengthens the overall submission package and supports the long\u2011term value of ACCRUFeR\u00ae in this important market. In parallel, the amended terms of the agreement with ASK allows Shield to use the development milestone payment from ASK to fully cover the final payment due to AOP and terminate the AOP Milestone Monetisation Agreement earlier and at lower cost than previously planned. This further simplifies our capital structure and places Shield in a stronger financial position as we continue to execute our commercial strategy.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/y0z57r\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is America's #1 branded prescription oral iron for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEAFFNAEEKEAA",
          "rns_number": "RNS Number : 0029R"
        },
        {
          "title": "Q4 2025 Trading Update",
          "announcement_date": "21st Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 6821P\nShield Therapeutics PLC\n21 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ4 2025 Trading Update\nGenerated positive Cash flow in Q4 2025 with Total Group Revenues of c. $50m for full year 2025\nACCRUFeR\u00ae revenues grew 56% to c. $46m in 2025 with 21% increase in average net selling price to $223and 33% growth in total prescriptions to c.199,000\nCompany expects to deliver an operating profit in 2026\nLondon, UK, 21 January 2026:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nannounces that, in line with the Company's guidance, Shield has achieved positive operating cash flow in Q4 2025 and provides an\nunaudited full year\u00a0trading update for the year ended 31 December 2025 (\"FY25\").\nThis period reflects the transition of the Company to a sustainable enterprise\ndriven by continued ACCRUFeR\u00ae growth in the US and effective cost and working capital management. The Company also announces that it expects to deliver an operating profit in 2026.\nThe Company reported total revenues of c. $50m for FY25 ($32m revenues and other income in FY24) with ACCRUFeR\u00ae revenues growing 56% in the US and contributing $46m ($29m in FY24) through 21% growth in average net selling price to $223 and 33% growth in total prescriptions to c.199,000.\nQ4 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenues\nof $13.5m ($11.2m Q4 2024).\n\u00b7\nACCRUFeR\u00ae prescriptions\nof c. 61,000 (c. 41,000 in Q4 2024) representing the highest dispenses in any quarter since launch. Consignment-based prescriptions decreased c. 21% (c. 22% in Q4 2024) that were dispensed at a subsidised price to patients and were not yet reimbursed by payors.\n\u00b7\nACCRUFeR\u00ae average net selling price\nof $222\n($237 in Q4 2024) impacted by an increase in covered rebated prescriptions compared to prior quarters.\n\u00b7\nCash and cash equivalents\nof $11.6m as\nof 31 December 2025 (\n$8.6m\nas of 30 September 2025), achieving positive operative cash flow of $1m excluding the receipt of net proceeds of $1.96m from the amended Senior Secured Debt Financing announced in the quarter.\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"Reaching cash flow positivity is a significant milestone in the Company's history that allows us to continue to grow our business without the need for further external financing. The efforts of the sales teams, together with our strategic marketing initiatives, delivered our strongest year on record for ACCRUFeR\u00ae, achieving new highs in prescription volumes, net selling price, and revenues. ACCRUFeR\u00ae's strong performance in the fourth quarter along with a strengthened balance sheet exiting 2025 gives us the momentum and financial flexibility to achieve our 2026 strategic priorities.\"\nInvestor Presentation\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q4 2025 Trading Update\nvia the Investor Meet Company platform\nat\u00a02:00 pm\u00a0(GMT) on 22 January 2026.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 1.00 pm (BST) on 22 January 2026 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTURUURNWUAUUR",
          "rns_number": "RNS Number : 6821P"
        },
        {
          "title": "Block listing 6 Monthly Return",
          "announcement_date": "2nd Jan 2026",
          "release_time": "11:06 am",
          "source": "RNS",
          "content": "2 Jan 2026 11:06\nRNS Number : 4870N\nShield Therapeutics PLC\n02 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBlock Listing 6 Monthly Return\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n39,794\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n39,794\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics plc 2016 Company Share Option Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n341,020\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n341,020\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nThe Shield Therapeutics plc 2016 Long Term Incentive Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n24,273\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n24,273\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention and Performance Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n2,870,838\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n15,000,000\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\n6,137,791\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n11,733,071\nName of contact:\nLucy Huntington-Bailey\nTelephone number of contact:\n+44 (0) 191 511 8500\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n+44 (0) 191 511 8500\ninfo@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christoper Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLREAFFAEESKEFA",
          "rns_number": "RNS Number : 4870N"
        }
      ],
      "themes": [
        "drilling",
        "operations",
        "regulatory"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 894,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "UPTREND"
    },
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-2nd Jan 2026-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494470Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block listing 6 Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/block-listing-6-monthly-return-9rnvqiy6mq62ana.html",
          "rns_number": "RNS Number : 4870N",
          "full_content": "2 Jan 2026 11:06\nRNS Number : 4870N\nShield Therapeutics PLC\n02 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBlock Listing 6 Monthly Return\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n39,794\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n39,794\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics plc 2016 Company Share Option Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n341,020\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n341,020\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nThe Shield Therapeutics plc 2016 Long Term Incentive Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n24,273\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n24,273\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention and Performance Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n2,870,838\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n15,000,000\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\n6,137,791\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n11,733,071\nName of contact:\nLucy Huntington-Bailey\nTelephone number of contact:\n+44 (0) 191 511 8500\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n+44 (0) 191 511 8500\ninfo@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christoper Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsid",
          "content_length": 5944
        },
        "ingested_at": "2026-01-21T02:12:57.494504Z"
      },
      {
        "event_id": "RNS-2nd Jan 2026-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494536Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/total-voting-rights-k43gdm20gso03dc.html",
          "rns_number": "RNS Number : 3615N",
          "full_content": "2 Jan 2026 07:00\nRNS Number : 3615N\nShield Therapeutics PLC\n31 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 31 December, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,828,251\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPGMUPUPAGAG",
          "content_length": 4172
        },
        "ingested_at": "2026-01-21T02:12:57.494554Z"
      },
      {
        "event_id": "RNS-2nd Jan 2026-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494569Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/total-voting-rights-t5fatroh5y2kuie.html",
          "rns_number": "RNS Number : 3615N",
          "full_content": "2 Jan 2026 07:00\nRNS Number : 3615N\nShield Therapeutics PLC\n31 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 31 December, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,828,251\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPGMUPUPAGAG",
          "content_length": 4172
        },
        "ingested_at": "2026-01-21T02:12:57.494582Z"
      },
      {
        "event_id": "RNS-22nd Dec 2025-fdaappro",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494597Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA approves extension for ACCRUFeR\u00ae",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/fda-approves-extension-for-accrufer0174-h7gfhs7ui8kz9jm.html",
          "rns_number": "RNS Number : 3781M",
          "full_content": "22 Dec 2025 07:00\nRNS Number : 3781M\nShield Therapeutics PLC\n22 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA approves extension of the indication for ACCRUFeR\u00ae to includechildren 10 years and older with iron deficiency (ID)\nLondon, UK, 22 December 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA), following a priority review of the clinical supplement, has approved the extension of the indication for ACCRUFeR\u00ae (ferric maltol) to include adolescents. ACCRUFeR\u00ae is now indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nAnders Lundstrom, CEO of Shield, commented:\n\"We are delighted with the FDA approval of ACCRUFeR\u00ae, making it available to the adolescent population, who now can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is t",
          "content_length": 5924
        },
        "ingested_at": "2026-01-21T02:12:57.494615Z"
      },
      {
        "event_id": "RNS-22nd Dec 2025-fdaappro",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494628Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA approves extension for ACCRUFeR\u00ae",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/fda-approves-extension-for-accrufer174-zorbtfam1paepd0.html",
          "rns_number": "RNS Number : 3781M",
          "full_content": "22 Dec 2025 07:00\nRNS Number : 3781M\nShield Therapeutics PLC\n22 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA approves extension of the indication for ACCRUFeR\u00ae to includechildren 10 years and older with iron deficiency (ID)\nLondon, UK, 22 December 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA), following a priority review of the clinical supplement, has approved the extension of the indication for ACCRUFeR\u00ae (ferric maltol) to include adolescents. ACCRUFeR\u00ae is now indicated for the treatment of iron deficiency in adult and pediatric patients 10 years of age and older.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nAnders Lundstrom, CEO of Shield, commented:\n\"We are delighted with the FDA approval of ACCRUFeR\u00ae, making it available to the adolescent population, who now can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is t",
          "content_length": 5924
        },
        "ingested_at": "2026-01-21T02:12:57.494645Z"
      },
      {
        "event_id": "RNS-18th Dec 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494659Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Application",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/block-listing-application-dnwe4ssaznelobb.html",
          "rns_number": "RNS Number : 1001M",
          "full_content": "18 Dec 2025 07:13\nRNS Number : 1001M\nShield Therapeutics PLC\n18 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBlock Listing Application\nLondon, UK, 18 December 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency,\nhas today made an application to the London Stock Exchange for a block listing of 15,000,000 ordinary shares of 1.5 pence each in the Company (\"Block Listing Shares\") to be admitted to trading on the London Stock Exchange (\"Admission\") and to be allocated to the schemes listed below.\nThe 15,000,000 Block Listing Shares are to be issued under the following schemes:\n\u00b7\nShield Therapeutics Retention and Performance Share Plan\nAdmission is expected to occur on 23 December 2025.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n+44 (0) 191 511 8500\ninfo@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nALSFIFIDFALTLIE",
          "content_length": 4183
        },
        "ingested_at": "2026-01-21T02:12:57.494672Z"
      },
      {
        "event_id": "RNS-11th Dec 2025-shieldwi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494685Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Shield Wins Gold at Titan Branding Awards",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/STX/shield-wins-gold-at-titan-branding-awards-d8t8urpta7ug0v5.html",
          "rns_number": "RNS Number : 0971L",
          "full_content": "11 Dec 2025 07:00\nRNS Number : 0971L\nShield Therapeutics PLC\n11 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nShield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR's Brand Transformation\nLondon, UK, December 11, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces that it has been awarded Gold at the 2025 Titan Brand Awards for Best Rebranding Effort, Best Healthcare Rebranding for ACCRUFeR\u00ae.\nThe Titan Brand Awards represent international recognition for outstanding achievements in branding, highlighting effective brand strategies, creative thinking, and strong communication that help organisations distinguish themselves in competitive markets. This prestigious recognition elevates ACCRUFeR\u00ae into the ranks of globally respected brands, both within the pharmaceutical industry and across broader sectors, underscoring its position as a trusted name on the world stage.\nAndy Hurley, CCO at Shield, commented:\n\"We are proud to receive the \"Best Rebranding Effort\" award for ACCRUFeR\u00ae, recognising the team's dedication to transforming ACCRUFeR\u00ae,\u00a0into a highly differentiated, patient-focused brand. These efforts have enabled us to highlight the real impact of ACCRUFeR\u00ae, in the vastly prevalent ID/IDA market which is a serious condition with a significant unmet need for patients and HCPs. Our refreshed brand is contemporary, engaging, and underscores our commitment to improving lives, and has enabled ACCRUFeR\u00ae to be the #1 branded prescription oral iron in the US ID/IDA market. This is the first step in our digital marketing initiative driving growth of ACCRUFeR\u00ae.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nMarketing Agency\nReingold, Inc.\nAlexandra Gray, Public Relations Director\n+1 804 317 3352\nagray@reingold.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRATMBMTMTBBTBA",
          "content_length": 4952
        },
        "ingested_at": "2026-01-21T02:12:57.494697Z"
      },
      {
        "event_id": "RNS-3rd Dec 2025-amendsse",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494710Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Amends Senior Secured Debt Financing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/amends-senior-secured-debt-financing-74c9z7ygb3wtsjy.html",
          "rns_number": "RNS Number : 0453K",
          "full_content": "3 Dec 2025 07:04\nRNS Number : 0453K\nShield Therapeutics PLC\n03 December 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nAmends Senior Secured Debt Financing with improved terms\nAvailable funds of up to $50 million including $15 million towards future M&A transactions\nLondon, UK, December 3, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces the amendment of its senior term debt financing. This strategic financial update, executed through SWK Holdings Corporation (\"SWK\") with improved terms and the addition of Runway Growth Finance Corp. (\"Runway\") to the lending syndicate, strengthens the Company's financial position by lowering debt related costs and provides flexibility to drive further growth and explore suitable M&A opportunities.\nThe revised term extends the loan facility from $20 million to up to $50 million including $15 million to be made available for future M&A opportunities and a $10 million accordion feature. The original maturity date of 28 September 2028 is maintained, while the interest only period has been extended to 15 quarters compared to 9 quarters from the original close of Q4 2023. The interest rate will be reduced, beginning 15 January 2026, to 3 Month CME Term SOFR (\"SOFR\") + 8.75% compared to the prior interest rate of SOFR + 9.25%. Further, the SOFR is subject to a floor of 3.5%, reduced from the original floor of 5%. Shield will be required to pay an\norigination\nfee of 0.5%, and an exit fee of 5% only on incremental funds drawn from the additional capital of $30 million made available to Shield.\nShield will grant Runway warrants to acquire new ordinary shares that will represent 5% of any incremental capital drawn down by the Company above $20 million. As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. New warrants\nover 906,468 new ordinary shares will be issued to Runway linked to the additional $2 million drawn, with an expiration date of six years after closing and a strike price of 8.4p per Ordinary Share based on a 20-day VWAP (Volume Weighted Average Price) to 1 December 2025. There is no penalty for prepaying the loan prior to the maturity date. The financial covenant of minimum liquidity has been lowered to no less than the greater of i) trailing one quarter of cash burn or ii) $2.0 million compared to the greater of i) trailing one quarter of cash burn or ii) $2.5 million. All other terms remain unchanged.\nSantosh Shanbhag, CFO at Shield, commented:\n\"We are pleased with the continued momentum of ACCRUFeR\u00ae growth in the US which has put Shield on a path to turning cash flow positive by the end of 2025. This positive shift in the Company's financial performance has enabled Shield to evaluate multiple options to refinance the current term debt and secure improved terms with its current debt provider, SWK. It has also enabled us to lower our debt related costs and access up to $30 million of additional capital to provide further flexibility to our future growth opportunities, including potential future M&A, as a way of further leveraging the commercial platform we have built in the U.S.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nTransaction Investment Banker\nBaycross Capital\nPaul Enderle* / Eric Brown*\n*Security transactions via StillPoint Capital LLC.\n+1 617-273-8477\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mecha",
          "content_length": 8628
        },
        "ingested_at": "2026-01-21T02:12:57.494725Z"
      },
      {
        "event_id": "RNS-14th Nov 2025-initiati",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494739Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Initiation of a Phase II Clinical Trial in Japan",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/initiation-of-a-phase-ii-clinical-trial-in-japan-se4b8586a443dl4.html",
          "rns_number": "RNS Number : 5863H",
          "full_content": "14 Nov 2025 07:03\nRNS Number : 5863H\nShield Therapeutics PLC\n14 November 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nInitiation of a Phase II Clinical Trial for ACCRUFeR\u00ae (Ferric Maltol) for the\nTreatment of Pulmonary Arterial Hypertension (PAH) in Japan.\nLondon, UK, 14 November 2025\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\ntoday announced that its partner, MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc. has initiated a Phase II clinical trial for ACCRUFER\u00ae (ferric maltol), a new drug candidate for Pulmonary Arterial Hypertension (PAH), for patients in Japan. This trial is an exploratory study to support a Phase III trial and follows confirmation by the Pharmaceuticals and Medical Devices Agency (PMDA) of the development plan for the drug as a PAH treatment in Japan, based on previous clinical results in Europe, UK and USA.\nSubject to the results of this trial, MEDLEAP plans to conduct a Phase III trial (Pivotal Study) and proceed with regulatory submission and launch preparations from 2028 onwards. MEDLEAP positions this drug as a core pipeline in the PAH field.\nTrial Details:\nTrial Name\n:\nAn Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of Ferric Maltol in Patients with Pulmonary Arterial Hypertension (PAH)\nTarget Disease\n: Pulmonary Arterial Hypertension\nTrial Design\n: Multi-center, randomised, placebo-controlled, double-blind study\nNumber of Subjects\n: Approximately 26 (planned)\nPrimary Endpoint\n: 12-week 6-minute walk distance change from baseline\nSecondary Endpoints\n: Cardiac function-related efficacy parameters, safety, tolerability, etc\nTrial Location\n: Japan\nDr Jackie Mitchell, VP of Quality, RA and Clinical Development at Shield, commented:\n\"Shield is delighted with the rapid progress our partner MEDLEAP Pharma has made in agreeing a PAH development plan with PMDA and initiating the Japanese clinical program to develop ACCRUFER for this exciting new indication.\"\nProfessor Masaharu Kataoka, Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan School of Medicine, commented:\n\"\nIron deficiency anemia is highly prevalent in PAH patients and is associated with various clinical manifestations of PAH, including symptoms, exercise tolerance, right heart function, and hemodynamic parameters. Therefore, efficient iron supplementation is recommended. However, existing treatments face challenges in long-term iron supplementation management due to gastrointestinal side effects and low absorption efficiency, creating a need for new therapeutic options. In this context, we look forward to establishing Japan-originated evidence through clinical trials of Ferric Maltol, a completely new compound that overcomes these challenges and enables long-term administration, in PAH patients.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients and is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/FeRACCRU\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nPAH (Pulmonary Arterial Hypertension) market in 2024 is estimated to be worth over $230M in Japan. Iron supplementation is strongly recommended for PAH patients with iron deficiency anemia according to both European and Japanese guidance (ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 2022 and Japan Pulmonary Hypertension and Pulmonary Circulation Society Guidance 2024) [Recommendation Class I]. (1) Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023; 61(1):2200879. (2) Japanese Pulmonary Hypertension and Pulmonary Circulation Society. Pulmonary Hypertension Treatment Guidance2024.\nAbout Shield",
          "content_length": 7851
        },
        "ingested_at": "2026-01-21T02:12:57.494753Z"
      },
      {
        "event_id": "RNS-11th Nov 2025-accrufer",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494766Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ACCRUFeR Pediatric PK Results to be Presented",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/accrufer-pediatric-pk-results-to-be-presented-euvb8tuno99fftz.html",
          "rns_number": "RNS Number : 9586G",
          "full_content": "11 Nov 2025 07:00\nRNS Number : 9586G\nShield Therapeutics PLC\n11 November 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae Pediatric Pharmacokinetic (PK) Results Will be Presented at the American Society of Hematology (ASH) Conference\nResults from PK Sub study of Positive Phase 3 Pediatric Trial (FORTIS) confirmed ferric maltol's suitability for iron replacement in children 1 month and above\nLondon, UK, 11 November 2025\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\ntoday announced the presentation (Abstract/Video and in person Poster) of a PK study (conducted as a sub-study of the positive FORTIS efficacy, tolerability and palatability pediatric ferric maltol clinical trial) at the American Society of Hematology (ASH) National Conference on 06 December 2025 in Orlando, Florida.\nAbstract available online via the\nASH\nConference website\n:\nASH 2025 Annual Meeting - Presentation\nAbstract/Poster Details:\nTitle\n:\nPresentation ID 1126: Pharmacokinetics of ferric maltol oral suspension in children and adolescents (1 month to 17 years); A study of iron and maltol metabolism following single and multiple dosing\nPresenter\n: Dr Andrew Freiberg MD\n(Associate Professor of Pediatrics,\nPenn State Health, Pennsylvania, United States\n)\nKey Results\n:\n\u00b7\nThe PK profile in children and adolescents demonstrated ferric maltol's suitability for iron replacement in all age groups\n\u00b7\nIron was well-absorbed at the age-appropriate doses used in the Phase 3 study\n\u00b7\nMaltol was rapidly metabolised and excreted in the urine with no accumulation in any age group\n\u00b7\nFirst data that confirms maltol metabolism and rapid excretion in the urine in infants 1 month to less than 2 years\nThe FORTIS study, including the PK data, is pivotal in supporting the Clinical Supplement assigned Priority Review by the US FDA to extend the indication for ACCRUFeR\u00ae to include adolescents aged 10 years and above.\nDr Jackie Mitchell, VP of Quality, RA and Clinical Development at Shield, commented:\n\"This first publication of results confirming effective iron absorption and maltol metabolism in children as young as 1 month supports the potential use of ferric maltol as an effective iron-replacement therapy in infants as well as older children, and is an important milestone for Shield in\nthe expansion of ACCRUFeR\u00ae to an infant population where there is an unmet need for a safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients and is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/FeRACCRU\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout\nthe FORTIS/ST10-01-305 Phase 3 study and PK Sub-study\nThe FORTIS study compared the safety, tolerability and effectiveness of an oral liquid suspension of ferric maltol with oral ferrous sulphate liquid in children with iron deficiency anaemia (IDA).The open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate (N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment. The composite primary endpoints were:\n\u00b7\nFrequency of treatment emergent adverse events (TEAEs)/serious adverse events (TESAEs)\n\u00b7\nFrequency of discontinuations from the study as a result of TEAEs\n\u00b7\nChange in haemoglobin (Hb) concentration from baseline to week 12\nTwenty children (2-17 years) participated in the PK study over two assessment days (Day 1 & Day 7-10). On Day 1, after a baseline blood samp",
          "content_length": 7711
        },
        "ingested_at": "2026-01-21T02:12:57.494783Z"
      },
      {
        "event_id": "RNS-7th Nov 2025-accrufer",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494796Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ACCRUFeR receives Authorisation by Korean Ministry",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/accrufer-receives-authorisation-by-korean-ministry-2vqq4oa6pn3ihpm.html",
          "rns_number": "RNS Number : 6560G",
          "full_content": "7 Nov 2025 07:03\nRNS Number : 6560G\nShield Therapeutics PLC\n07 November 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS)\nLondon, UK, 07 November 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on addressing iron deficiency, is pleased to announce that the Korean Ministry of Food and Drug Safety (MFDS) has granted regulatory approval for ACCRUFeR\u00ae (Ferric Maltol) in the Republic of Korea (South Korea) for the treatment of iron deficiency in adult subjects.\nThis approval is an important milestone and follows the successful completion of a pharmacokinetic (PK) study which confirmed that the absorption of iron from ACCRUFeR\u00ae was comparable between patients in South Korea and the patient population enrolled in the key clinical studies supporting ACCRUFeR\u00ae effectiveness and safety and the subsequent submission of a New Drug Application (NDA) by Korea Pharma (\"KP\") in 2024. This approval marks a significant step forward in expanding access to ACCRUFeR\u00ae for patients in South Korea suffering from iron deficiency.\nShield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales of ACCRUFeR\u00ae in South Korea.\nAnders Lundstrom, Chief Executive Officer, commented\n:\nWe are delighted with this approval of ACCRUFeR\u00ae in South Korea and commend Korea Pharma for their dedication and expertise throughout the regulatory process. This achievement reinforces our commitment to making ACCRUFeR\u00ae available to patients globally and highlights the strength of our international partnerships. Shield looks forward to supporting Korea Pharma in the commercial launch of ACCRUFeR\u00ae in South Korea and continuing its mission to improve the lives of patients with iron deficiency worldwide.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nKorea ID/IDA Market\nThere are currently 5.2M people in Korea living with ID/IDA as\nstated in the 'Prevalence and risk factors for iron deficiency anemia in the Korean population: results of the fifth Korea National Health and Nutrition Examination Survey'.\nAbout Korea Pharma Co.,Ltd\nKorea Pharma is a prescription pharmaceutical company focusing on CNS (central nervous system) and GI (gastro-intestinal) products. Korea Pharma has previously signed an exclusive distribution agreement\nW\nith Norgine BV, a global PEG-based bowel cleansing agent development company, for d\nistribution of PLENVU\n\u00ae\n,\nthe world's first one-litre PEG (\npolyethylene glycol)\nbowel preparation drug, and is developing a liquid type PEG laxative.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for ",
          "content_length": 5948
        },
        "ingested_at": "2026-01-21T02:12:57.494810Z"
      },
      {
        "event_id": "RNS-23rd Oct 2025-q32025tr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494823Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q3 2025 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/q3-2025-trading-update-cc1xxueusfo5rc9.html",
          "rns_number": "RNS Number : 5478E",
          "full_content": "23 Oct 2025 07:00\nRNS Number : 5478E\nShield Therapeutics PLC\n23 October 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ3 2025 Trading Update\nStrongest quarterly performance to date with c. 15% ACCRUFeR\u00ae prescription growth over Q2 2025\nc. 54,000 ACCRUFeR\u00ae prescriptions with$13.1m net revenues and an average net selling price of $237\nGuidance remains to turn cash flow positive by the end of 2025\nLondon, UK, 23 October 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nprovides an unaudited Q3 2025 trading update.\nIn the third quarter of 2025, Shield reported unaudited ACCRUFeR\u00ae net revenues of $13.1m, c. 54,000 total prescriptions and an average net selling price of $237, this compared to $7.2m, c. 44,000 and $167 respectively in Q3 2024. Given the strong momentum entering Q4 2025 with September generating >40% of Q3 2025 revenues, the Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.\nQ3 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenue\nof $13.1m (Q2 2025: $12.8m and Q3 2024: $7.2m).\n\u00b7\nACCRUFeR\u00ae average net selling price\nof $237\n(Q2 2025: $231 and Q3 2024: $167).\n\u00b7\nACCRUFeR\u00ae prescriptions\nof c. 54,000, with c. 22% consignment-based prescriptions that were dispensed at a significantly subsidised price to patients and were not yet reimbursed by payors.\n\u00b7\nCash and cash equivalents\nof $8.6m as\nof 30 September 2025 ($10.8m as of 30 June 2025) including receipt of net proceeds from placing announced in the period.\n\u00b7\nThe company remains on track to\nturn cash flow positive by the end of 2025\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"I am very pleased to see ACCRUFeR\u00ae's strong performance continue into Q3 2025. The combined efforts of the Shield and Viatris Sales team along with our strategic marketing initiatives have driven continued strong performance in Q3, marking our strongest quarter on record with a new high in prescription volumes, net selling price, and revenues. This was further underscored in September, which delivered the highest net revenue month to date representing >40% of the Q3 ACCRUFeR\u00ae revenues. This performance has reinforced our alignment with full-year performance targets enabling us to stay on track to turning cash flow positive by the end of 2025\"\nInvestor Presentation\nvia Investor Meet Company\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q3 2025 Trading Update via the Investor Meet Company platform at\u00a03:00 pm\u00a0(BST) on 23 October 2025.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 2.00 pm (BST) or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout ",
          "content_length": 6888
        },
        "ingested_at": "2026-01-21T02:12:57.494837Z"
      },
      {
        "event_id": "RNS-14th Oct 2025-grantofs",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494851Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Grant of Share Options to Chief Executive Officer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/grant-of-share-options-to-chief-executive-officer-hm6pe29ibkskarl.html",
          "rns_number": "RNS Number : 3454D",
          "full_content": "14 Oct 2025 15:01\nRNS Number : 3454D\nShield Therapeutics PLC\n14 October 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nGrant of Share Options to Chief Executive Officer\nLondon, UK, 14 October 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency,\nannounces\nthat on 13 October 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company (\"Ordinary Shares\") under Shield Therapeutics' Retention and Performance Share Plan (\"RPSP\") to the Group CEO as part of his 2025 annual equity grant.\nIn accordance with the\nrequirements of the EU Market Abuse Regulations the following options have been granted\nto Anders Lundstrom, Chief Executive Officer, who is deemed a PDMR:\nName\nOption Plan\nNumber of Ordinary Shares under Option\nVesting Date\nAnders Lundstrom\nRPSP\n1,547,262\nThree equal traches over three years from the date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting.\nThe proportion of total option awards to Anders Lundstrom is approximately 0.1% of the total number of AIM securities in issue at this time\n.\nAnders Lundstrom currently holds 585,000 ordinary shares in the Company.\n1.\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\na)\nName\nAnders Lundstrom\n2.\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification/\namendment\nInitial Notification\n3.\nDetails of the Issuer\na)\nName\nShield Therapeutics plc\nb)\nLEI code\n213800G74QWY15FC3W71\n4.\nDetails of the\ntransaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv\n) each place where transactions have been conducted\na)\nDescription of the financial instrument\nIdentification code\nOptions over new Ordinary Shares\nISIN: GB00BYV81293\nb)\nNature of the transaction\nGrant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan.\nc)\nPrice(s) and volumes(s)\n2025 RPSP Award\nPrice (\u00a3)\nVolume\n0.015\n1,547,262\nd)\nAggregated information\n- Aggregate volume\n- Price\nAwards granted over 1,547,262 shares in total\n1.5p exercise price\ne)\nDate of the transaction\n13 October 2025\nf)\nPlace of the transaction\nOutside of trading venue\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority t",
          "content_length": 5643
        },
        "ingested_at": "2026-01-21T02:12:57.494865Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494877Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/total-voting-rights-nosbhu4xv5q065h.html",
          "rns_number": "RNS Number : 5071B",
          "full_content": "1 Oct 2025 08:00\nRNS Number : 5071B\nShield Therapeutics PLC\n01 October 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 01 October, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 1,061,802,812 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPURGBUPAGBU",
          "content_length": 4151
        },
        "ingested_at": "2026-01-21T02:12:57.494890Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-positive",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494902Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Positive efficacy and tolerance in pediatric trial",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/positive-efficacy-and-tolerance-in-pediatric-trial-gbky5w30i1zdh0h.html",
          "rns_number": "RNS Number : 5065B",
          "full_content": "1 Oct 2025 07:02\nRNS Number : 5065B\nShield Therapeutics PLC\n01 October 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae Phase 3 pediatric trial presentation at the American Association of Pediatrics (AAP) Conference\nPositive efficacy and tolerance in pediatric trial (FORTIS)\nLondon, UK, 01 October 2025\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\ntoday announced the presentation (virtual and in person) of the positive efficacy, tolerability and palatability results for the ferric maltol pediatric FORTIS clinical trial at the American Association of Pediatrics (AAP) National Conference on 29th September 2025 in Denver, Colorado.\nAbstract available online via the\nAAP\nConference website\n:\nBrowse Poster Hall\nThe Poster can be viewed via the Shield website:\nPublications | Shield Therapeutics plc\nPoster Presentation Details:\nTitle: P4.017: \"Efficacy And Safety Of A Novel Oral Iron (Ferric Maltol) In Children And Adolescents; A Randomized, Multicenter, Open-Label, Active Comparator Study\"\nPresenter: Dr David Gass MD MS\n(\nAssociate professor of pediatrics. Carolinas Medical Centre, Charlotte\n)\nKey Results (as previously disclosed)\n:\n\u00b7\nClinically and statistically significant Hb improvements vs. baseline were observed across all groups (ferric maltol arms and ferrous sulfate arm (P\n\u00b7\nNo patient discontinued ferric maltol treatment due to an adverse event compared to one patient who discontinued from the ferrous sulfate arm.\n\u00b7\nTreatment related adverse events (AEs) were reported in 6.5% of patients treated with ferric maltol and 13% of patients treated with ferrous sulphate. No treatment related serious AEs (SAEs) were reported in either group.\nDr Jackie Mitchell, VP of Quality, RA and Clinical Development at Shield, commented:\n\"This first publication of results confirming the safety and effectiveness of ferric maltol treatment in children as young as 2 months is an important milestone for Shield to\nfurther the expansion of ACCRUFeR\u00ae in this additional patient population who can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients and is now the leading\n#1 branded prescription oral iron in the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/FeRACCRU\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage until the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further i",
          "content_length": 5478
        },
        "ingested_at": "2026-01-21T02:12:57.494916Z"
      },
      {
        "event_id": "RNS-15th Sep 2025-\u00a31.5mill",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494932Z",
        "source": "LSE_RNS",
        "data": {
          "title": "\u00a31.5 million placing supporting growth of ACCRUFeR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/16315-million-placing-supporting-growth-of-accrufer-7zvvh5bm63nuamg.html",
          "rns_number": "RNS Number : 3037Z",
          "full_content": "15 Sep 2025 07:00\nRNS Number : 3037Z\nShield Therapeutics PLC\n15 September 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n\u00a31.5 million placing supporting growth of ACCRUFeR\u00ae\nLondon, UK, September 15, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the completion of a placing (the \"Placing\") to raise gross proceeds of \u00a31.5 million through the issue of\n20,000,000\nnew ordinary shares (\"New Ordinary Shares\") in the capital of the Company at a price of 7.5 pence per share (the \"Issue Price\"). This Placing resulted from unsolicited institutional investor demand.\nThe Issue Price represents a premium of approximately 5% to the 30-day VWAP (Volume Weighted Average Price) of\n7.13\npence per existing Ordinary Share to 12 September 2025, being the last trading day prior to the publication this announcement. The Placing Shares, in aggregate, represent approximately 1.9% of the existing issued ordinary share capital of the Company.\nCMC Markets UK Plc, trading as CMC CapX, acted as the Company's sole placing agent in respect of the Placing.\nApplication has been made to London Stock Exchange plc for the Placing Shares to be admitted to trading on AIM (\"Admission\"). Admission is expected to take place on 19 September 2025. The Placing Shares will be fully paid and will rank\npari passu\nin all respects with the existing Ordinary Shares.\nFollowing Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 1,061,690,484 with equal voting rights. No shares are held in treasury.\nThis figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.\nSantosh Shanbhag, CFO at Shield, commented:\n\"We are pleased with the continued momentum of ACCRUFeR\u00ae growth in the US which has now become the #1 branded prescription oral iron in the market today. This placing is in the best interests of the Company by broadening its institutional shareholder base and whilst we remain confident in turning cash flow positive by the end of 2025 it also further strengthens the Company's working capital position allowing the Board and management to focus completely on accelerating sales of ACCRUFeR\u00ae\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nPlacing Agent\nCMC Markets UK Plc\nThomas Smith\n+44 (0)20 3003 8255\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the",
          "content_length": 6835
        },
        "ingested_at": "2026-01-21T02:12:57.494946Z"
      },
      {
        "event_id": "RNS-4th Sep 2025-accrufer",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494960Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ACCRUFeR\u00ae assigned Priority Review in US by FDA",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/accrufer174-assigned-priority-review-in-us-by-fda-bfw1iel80d8ikkh.html",
          "rns_number": "RNS Number : 9329X",
          "full_content": "4 Sep 2025 07:03\nRNS Number : 9329X\nShield Therapeutics PLC\n04 September 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae assigned Priority Review in the US by FDA in children with iron deficiency anemia (IDA)\nPending successful review, approval in the US is anticipated in 2026\nLondon, UK, September 4, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA) has accepted ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) as a Clinical Supplement and assigned Priority Review to extend the indication for ACCRUFeR\u00ae/FeRACCRU\u00ae to include adolescents aged 10 years and above.\nFollowing the positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children with (IDA), Shield submitted a clinical supplement application to the FDA in June 2025 for the approval of ACCRUFeR\u00ae/FeRACCRU\u00ae in the pediatric population. FDA has granted Priority Review for the supplement as it supports the extension of the label to a pediatric population based on a final agreed pediatric study report. Pending successful review, approval is anticipated in 2026.\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nShield's licensing partner in the EU, Norgine B.V., also filed a regulatory submission to the EMA in Q2 2025 for the approval of\nFeRACCRU\n\u00ae (ferric maltol) in the adolescent population. Pending successful review, approval is also anticipated in 2026.\nDr Jackie Mitchell, VP of Quality, RA and Clinical Development at Shield, commented:\n\"\nWe are delighted to be able to progress a further significant expansion of the patient population to adolescents, who can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferri",
          "content_length": 6250
        },
        "ingested_at": "2026-01-21T02:12:57.494976Z"
      },
      {
        "event_id": "RNS-3rd Sep 2025-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.494990Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim results for the six months ended 30 Jun 25",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/interim-results-for-the-six-months-ended-30-jun-25-zeirmw2ywlx968h.html",
          "rns_number": "RNS Number : 8828X",
          "full_content": "3 Sep 2025 14:17\nRNS Number : 8828X\nShield Therapeutics PLC\n03 September 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nInterim results for the six months ended 30 June 2025 - Replacement\nThis announcement replaces the version published on 21 August 2025.\nThe only change is the reclassification of the cash received from the $10.0 million equity financing from AOP in January 2025 within the Group statement of cash flows for the six months ended 30 June 2025. Net cash flows from operating activities has been updated from $8,258 to ($1,742) offset by cash raised from equity placing changing from $nil (zero) to $10,000,000.\nCash and cash equivalents at period end remain unchanged.\nAll other details in the version published on 21 August 2025 remain unchanged.\nThe full amended text is shown below.\nTotal Revenues grew 1.8x compared to H1 2024 to $21.4 million\nc.84,000 ACCRUFeR\u00ae prescriptions sold, with c.1.4x increase in average net selling price from H1 2024 to $214\nSignificant progress in global partnerships in Canada, Republic of Korea, China, and Japan\nGuidance remains on track to turn cash flow positive by the end of 2025\nLondon, UK, August 21, 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nannounces its unaudited interim results for the six months ended 30 June 2025, reporting a substantial increase in Group revenues, ACCRUFeR\u00ae prescription sales and average net selling price.\nThe Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.\nFinancial Highlights H1 2025\n\u00b7\nGroup revenues:\n$21.4 million, increasing 1.8x over H1 2024 ($12.1 million)\no\nACCRUFeR\u00ae revenue\n: $19.2 million, increasing 1.8x over H1 2024 ($11.0 million)\no\nEx-US revenue\n: $2.2 million in milestones and royalties from global partners in Europe, Canada and Japan (H1 2024: $1.1 million)\n\u00b7\nGroup Loss significantly narrowed\n: $9.5 million loss compared to $15.5 million loss in H1 2024 driven primarily by higher ACCRUFeR\u00ae revenues alongside streamlining business expenditures within the Group.\n\u00b7\nCash and cash equivalents\n: $10.8 million (31 December 2024: $6.5 million). The increase in cash balance was primarily driven by the addition of $10.0 million of gross proceeds from the equity funding received post year end, the continued growth in ACCRUFeR\u00ae revenues in the US,\nthe milestone payments received from VITAL-NET, Inc. of c.$335,000 supporting the exclusive licensing agreement in Japan for ACCRUFeR\u00ae, and from Norgine BV in Europe of c.\n$552,000\nsupporting the pediatric filing process with the EMA.\nOperational Highlights H1 2024\n\u00b7\nCommercialisation of\nACCRUFeR\u00ae\nin the US:\nContinued growth and strong market results with our partner, Viatris Inc.\no\nACCRUFeR\u00ae total prescriptions\ngrew to c.84,000, increasing 1.3x over H1 2024 (c.65,200). The growth was primarily driven within the six large states of\nTexas, New York, Florida, Georgia, California, and North Carolina and by expanding the efforts in digital marketing initiatives to increase HCP and patient awareness.\nC\nonsignment-based prescriptions which are dispensed at a significantly subsidised price to patients represented c.25% of the total prescriptions in H1 2025 compared to c.44% in H1 2024.\no\nACCRUFeR\u00ae average net selling price\nsteadily increased to $231 in Q2 2025 driven by successful execution of our market access strategies and reducing the impact of consignment-based prescriptions. Average net selling price in H1 2025 was $214, increasing c.1.4x from $158 in H1 2024.\n\u00b7\nGlobal ACCRUFeR\u00ae/FeRACCRU\u00ae development programs:\nContinued progress in commercial and development stage partnerships in Canada, Japan, China, and the pediatric study:\no\nKye Pharmaceuticals (\"Kye\") in Canada\n: Kye launched ACCRUFeR\u00ae in Canada in March 2025, following the approval from Health Canada for ACCRUFeR\u00ae (ferric maltol) as a prescription drug for the treatment of adults with iron deficiency anemia (IDA). ACCRUFeR\u00ae is currently the sole prescription-only oral treatment option indicated for IDA in Canada and is available by prescription through pharmacies across Canada. In accordance with the collaborative agreement, Shield is eligible to receive further milestone payments upon the achievement of specified calendar net sales targets and will also receive double-digit royalties on net sales of ACCRUFeR\u00ae for the term of the agreement.\no\nVITAL-NET in Japan:\nThe Company entered into an exclusive licence agreement in April 2025 with VITAL-NET, Inc. for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) in iron deficiency (ID) patients in pulmonary hypertension (PH) and inflammatory bowel disease (IBD). Shield received an initial payment of c. $665,000,\nc.$335,000\nof which was received in Q2 2025, and expects regulatory and sales milestones, along with double-digit royalties on net sales. VITAL-NET will undertake and be responsible for all costs, including clin",
          "content_length": 40582
        },
        "ingested_at": "2026-01-21T02:12:57.495004Z"
      },
      {
        "event_id": "RNS-27th Aug 2025-datapubl",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495018Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Data published -European Journal of Heart Failure",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/data-published-european-journal-of-heart-failure-fjk0bnt0i6eryk0.html",
          "rns_number": "RNS Number : 8365W",
          "full_content": "27 Aug 2025 07:13\nRNS Number : 8365W\nShield Therapeutics PLC\n27 August 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nPositive efficacy and safety results in subjects with Heart Failure (HF) and Iron Deficiency Anemia (IDA) treated with\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol)\nData recently published in the European Journal of Heart Failure\nLondon, UK, August 27, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces positive efficacy and safety results in the ORION-HF study showing improvements in haemoglobin and other iron markers, exercise capacity, and quality of life (QoL) in patients with heart failure (HF) and iron deficiency anemia (IDA), after 16 weeks of treatment with FeRACCRU\u00ae (ferric maltol). These results were published in the European Journal of Heart Failure on 21 July 2025.\nThe ORION-HF study was a multicenter, European, open-label, prospective clinical study, to investigate the impact of orally formulated ferric maltol (30 mg bid) in 50 patients with symptomatic HF and IDA.\nPositive and clinically meaningful efficacy and safety results were achieved in the study:\n\u00b7\nSignificant increase in haemoglobin (Hb) concentration (Primary endpoint)\n: Oral ferric maltol treatment resulted in significantly increased haemoglobin (from 11.4 [10.9-11.9] to 12.8 [11.8-13.8] g/dl) from baseline to week 16 (p\n\u00b7\nStatistically significant differences from baseline to week 16 in 6-minute walk test (6MW) (p\no\nOral ferric maltol treatment resulted in significant increase in distance walked in 6MW test (from 298 [220-405] to 335 [255-430] meters).\no\nOral ferric maltol treatment resulted in a significant increase in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (from 65 [44-82] to 76 [55-86] score points).\n\u00b7\nStatistically significant differences from baseline to week 16 in Other Iron Markers (ferritin, iron, transferrin saturation)\n(p\n\u00b7\nFerric maltol was well-tolerated with no serious related adverse events reported\no\nAdverse event profiles\nwere\nc\nonsistent with previous Phase 3 studies.\no\nAEs (N=19) were mainly GI related.\nThese positive results published in the European Journal of Heart Failure (\nOral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure - Kempf - European Journal of Heart Failure - Wiley Online Library\n, ) are consistent with results reported from an earlier study in patients with pulmonary hypertension (PH) and anemia published in the European Respiratory Society (\nOral iron supplementation with ferric maltol in patients with pulmonary hypertension | European Respiratory Society\n).\nShield's licensing partner in Japan (VITAL-NET, Inc. (VITAL-NET)) has recently had an IND approved to further investigate the impact of ferric maltol treatment in Japanese patients with PH and anemia in Japan.\nProfessor Johann Bauersachs, Director of the Department of Cardiology and Angiology at Hannover Medical School, and lead author of the HF publication\n, said: \"We still have a significant clinical unmet need for an effective and well tolerated oral iron therapy for the treatment of heart failure. Ferric maltol could be the practicable oral alternative to intravenous therapy for the treatment of heart failure reducing the challenges of i.v therapy.\"\nAnders Lundstrom, CEO, Shield Therapeutics commented:\n\"We are delighted that we once again have clinically and statistically relevant results in new patient populations for ACCRUFeR\u00ae/FeRACCRU\u00ae and we are excited that our partner, VITAL-NET will further investigate this important new therapeutic area where ferric maltol promises to bring significant clinical benefit.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\n",
          "content_length": 6917
        },
        "ingested_at": "2026-01-21T02:12:57.495031Z"
      },
      {
        "event_id": "RNS-21st Aug 2025-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495044Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim results for the six months ended 30 Jun 25",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/interim-results-for-the-six-months-ended-30-jun-25-39o3holtrb5mgia.html",
          "rns_number": "RNS Number : 2993W",
          "full_content": "21 Aug 2025 12:06\nRNS Number : 2993W\nShield Therapeutics PLC\n21 August 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nInterim results for the six months ended 30 June 2025\nTotal Revenues grew 1.8x compared to H1 2024 to $21.4 million\nc.84,000 ACCRUFeR\u00ae prescriptions sold, with c.1.4x increase in average net selling price from H1 2024 to $214\nSignificant progress in global partnerships in Canada, Republic of Korea, China, and Japan\nGuidance remains on track to turn cash flow positive by the end of 2025\nLondon, UK, August 21, 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nannounces its unaudited interim results for the six months ended 30 June 2025, reporting a substantial increase in Group revenues, ACCRUFeR\u00ae prescription sales and average net selling price.\nThe Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.\nFinancial Highlights H1 2025\n\u00b7\nGroup revenues:\n$21.4 million, increasing 1.8x over H1 2024 ($12.1 million)\no\nACCRUFeR\u00ae revenue\n: $19.2 million, increasing 1.8x over H1 2024 ($11.0 million)\no\nEx-US revenue\n: $2.2 million in milestones and royalties from global partners in Europe, Canada and Japan (H1 2024: $1.1 million)\n\u00b7\nGroup Loss significantly narrowed\n: $9.5 million loss compared to $15.5 million loss in H1 2024 driven primarily by higher ACCRUFeR\u00ae revenues alongside streamlining business expenditures within the Group.\n\u00b7\nCash and cash equivalents\n: $10.8 million (31 December 2024: $6.5 million). The increase in cash balance was primarily driven by the addition of $10.0 million of gross proceeds from the equity funding received post year end, the continued growth in ACCRUFeR\u00ae revenues in the US,\nthe milestone payments received from VITAL-NET, Inc. of c.$335,000 supporting the exclusive licensing agreement in Japan for ACCRUFeR\u00ae, and from Norgine BV in Europe of c.\n$552,000\nsupporting the pediatric filing process with the EMA.\nOperational Highlights H1 2024\n\u00b7\nCommercialisation of\nACCRUFeR\u00ae\nin the US:\nContinued growth and strong market results with our partner, Viatris Inc.\no\nACCRUFeR\u00ae total prescriptions\ngrew to c.84,000, increasing 1.3x over H1 2024 (c.65,200). The growth was primarily driven within the six large states of\nTexas, New York, Florida, Georgia, California, and North Carolina and by expanding the efforts in digital marketing initiatives to increase HCP and patient awareness.\nC\nonsignment-based prescriptions which are dispensed at a significantly subsidised price to patients represented c.25% of the total prescriptions in H1 2025 compared to c.44% in H1 2024.\no\nACCRUFeR\u00ae average net selling price\nsteadily increased to $231 in Q2 2025 driven by successful execution of our market access strategies and reducing the impact of consignment-based prescriptions. Average net selling price in H1 2025 was $214, increasing c.1.4x from $158 in H1 2024.\n\u00b7\nGlobal ACCRUFeR\u00ae/FeRACCRU\u00ae development programs:\nContinued progress in commercial and development stage partnerships in Canada, Japan, China, and the pediatric study:\no\nKye Pharmaceuticals (\"Kye\") in Canada\n: Kye launched ACCRUFeR\u00ae in Canada in March 2025, following the approval from Health Canada for ACCRUFeR\u00ae (ferric maltol) as a prescription drug for the treatment of adults with iron deficiency anemia (IDA). ACCRUFeR\u00ae is currently the sole prescription-only oral treatment option indicated for IDA in Canada and is available by prescription through pharmacies across Canada. In accordance with the collaborative agreement, Shield is eligible to receive further milestone payments upon the achievement of specified calendar net sales targets and will also receive double-digit royalties on net sales of ACCRUFeR\u00ae for the term of the agreement.\no\nVITAL-NET in Japan:\nThe Company entered into an exclusive licence agreement in April 2025 with VITAL-NET, Inc. for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) in iron deficiency (ID) patients in pulmonary hypertension (PH) and inflammatory bowel disease (IBD). Shield received an initial payment of c. $665,000,\nc.$335,000\nof which was received in Q2 2025, and expects regulatory and sales milestones, along with double-digit royalties on net sales. VITAL-NET will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing authorisation and commercialisation of ACCRUFeR\u00ae in Japan.\no\nASK Pharma (\"ASK\") in China\n: ASK has successfully completed the Phase 3 confirmatory study in adult patients with IBD and IDA, which is the final study required to support the filing of a new drug application (NDA) in China for the commercialisation of ACCRUFeR\u00ae/ FeRACCRU\u00ae. The Company expects the NDA to be filed with the Chinese National Medical Products Administration (NMPA) later in 2025, and pending successful review, approval in China is anticipated by the end of 2026.\no\nPediatric study",
          "content_length": 39161
        },
        "ingested_at": "2026-01-21T02:12:57.495059Z"
      },
      {
        "event_id": "RNS-23rd Jul 2025-q22025tr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495071Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q2 2025 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/q2-2025-trading-update-4zo70ngn24twkta.html",
          "rns_number": "RNS Number : 2109S",
          "full_content": "23 Jul 2025 07:00\nRNS Number : 2109S\nShield Therapeutics PLC\n23 July 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ2 2025 Trading Update\nQ2 2025 ACCRUFeR\u00ae net revenues doubled over Q1 2025 to $12.8m,\n47,000 prescriptions, and an average net selling price of $231\nCash and cash equivalents remain robust at $10.8m at period end\nGuidance remains on track to turn cash flow positive by the end of 2025\nLondon, UK, 23 July 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nprovides an unaudited Q2 2025 trading update.\nIn the second quarter of 2025, Shield reported unaudited ACCRUFeR\u00ae net revenues of $12.8m, doubling Q1 2025 net revenues of $6.4m. ACCRUFeR\u00ae total prescriptions grew strongly to c. 47,000 prescriptions with an average net selling price of $231 compared to c. 36,800 and $187 respectively in Q1 2025. The Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.\nQ2 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenue\nof $12.8m (Q1 2025: $6.4m and Q2 2024: $6.9m).\n\u00b7\nACCRUFeR\u00ae average net selling price\nof $231\n(Q1 2025: $187 and Q2 2024: $171).\n\u00b7\nACCRUFeR\u00ae prescriptions\nof c. 47,000, with c. 23% consignment-based prescriptions that were dispensed at a significantly subsidised price to patients and were not yet reimbursed by payors.\n\u00b7\nCash and cash equivalents\nof $10.8m as of 30 June 2025 ($10.5m as of 31 March 2025). The increase in cash balance compared to Q1 2025 was primarily driven by the milestone payments received from VITAL-NET, Inc. of $665k supporting the exclusive licensing agreement in Japan for ACCRUFeR\u00ae, and from Norgine BV in Europe of \u20ac0.5m supporting the pediatric filing process with the EMA.\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"I am excited to see the robust performance for ACCRUFeR\u00ae in Q2 2025 which followed on from a strong end to Q1 2025. This positions us well as we build momentum behind ACCRUFeR\u00ae going into the 2nd half of the year and beyond. Shield and our partner, Viatris, are pleased with the continued adoption of ACCRUFeR\u00ae in the market, which reinforces our belief that the market potential of ACCRUFeR\u00ae is significant. We are committed to delivering further growth and making ACCRUFeR\u00ae the oral iron of choice for patients with iron deficiency, with or without anemia. Finally, cash balances increased slightly during the quarter, and these results maintain our clear trajectory toward reaching cash flow positivity by the close of 2025\n.\n\"\nInvestor Presentation via Investor Meet Company\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q2 2025 update via the Investor Meet Company platform at\u00a03:00 pm\u00a0(BST) on 23 July 2025.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 2.00 pm (BST) or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\ninvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Isaac Hooper / Nigel Birks / Harriet Ward\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product l",
          "content_length": 8132
        },
        "ingested_at": "2026-01-21T02:12:57.495087Z"
      },
      {
        "event_id": "RNS-22nd May 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495117Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/result-of-agm-w1gidoknrzd9xh3.html",
          "rns_number": "RNS Number : 8612J",
          "full_content": "22 May 2025 17:06\nRNS Number : 8612J\nShield Therapeutics PLC\n22 May 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nResults of 2025 Annual General Meeting\nLondon, UK, 22 May, 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia (\"ID/IDA\")\n,\nannounces the voting\nresults for each resolution set out in the Notice of Annual General Meeting 2025. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.\nThe following table shows the votes cast on each resolution:\nVOTESFOR\n%\nVOTES AGAINST\n%\nWITHHELD VOTES\nResolution 1\n668,835,432\n99.98%\n133,164\n0.02%\n357,039\nResolution 2\n668,122,080\n99.89%\n757,837\n0.11%\n445,718\nResolution 3\n668,296,332\n99.91%\n583,585\n0.09%\n445,718\nResolution 4\n668,137,993\n99.89%\n741,976\n0.11%\n445,666\nResolution 5\n668,388,581\n99.93%\n491,388\n0.07%\n445,666\nResolution 6\n668,133,181\n99.89%\n741,976\n0.11%\n450,478\nResolution 7\n667,890,103\n99.85%\n1,027,158\n0.15%\n408,374\nResolution 8\n668,672,292\n99.96%\n291,492\n0.04%\n361,851\nResolution 9\n666,908,073\n99.69%\n2,080,523\n0.31%\n337,039\nResolution 10\n666,442,645\n99.60%\n2,643,451\n0.40%\n239,539\nResolution 11\n666,424,128\n99.88%\n808,577\n0.12%\n2,092,930\nResolution 12\n666,417,127\n99.88%\n793,851\n0.12%\n2,114,657\nNotes:\n1. Number of shares in issue 1,041,690,484.\n2. Details of the votes received on the resolutions are available on the Company's website:\nhttps://www.shieldtherapeutics.com/corporate-documents/\n.\n3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol)\nis a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia\n. The Company has commercially launched its lead product ACCRUFeR\u00ae in the U.S. through an exclusive, multi-year collaboration with a commercial partner. Internationally, it has secured licensing agreements with four specialty pharmaceutical companies, enabling commercialisation across key markets. The product is currently marketed in the UK, European Union, Australia, and New Zealand as FeRACCRU\u00ae, with additional exclusive partnerships in place for China and surrounding regions, South Korea, and as\nACCRUFeR\u00ae in\nCanada.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGPKBBKABKDPPB",
          "content_length": 4648
        },
        "ingested_at": "2026-01-21T02:12:57.495132Z"
      },
      {
        "event_id": "RNS-24th Apr 2025-auditedr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495145Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Audited results for the year ended 31 Dec 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/audited-results-for-the-year-ended-31-dec-2024-zzu6fv5v8xmwpd0.html",
          "rns_number": "RNS Number : 0176G",
          "full_content": "24 Apr 2025 07:06\nRNS Number : 0176G\nShield Therapeutics PLC\n24 April 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nAudited results for the year ended 31 December 2024\n2024 Group net revenues and other income at $32.3m with ACCRUFeR\u00ae net revenues growing 153% to $29.3m\nSubstantial progress made in expanding global patient access of ACCRUFeR\u00ae/FeRACCRU\u00ae\nLondon, UK, 24 April 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nconfirms its audited results for the year ended 31 December 2024.\n2024 reflected a significant step-up in revenue, alongside making substantial progress in expanding global patient\u00a0access of ferric maltol.\nThe Company reported total revenues and other income of $32.3m for FY24 (FY23: $17.5m) and has seen strong improvements in ACCRUFeR\u00ae prescriptions with a 95% growth in total prescriptions to c.150,000 in 2024 generating $29.3m of ACCRUFeR\u00ae revenues (FY23: $11.6m), an increase of 153%.\nDuring the final quarter of 2024, the Company took a decisive step to strengthen its balance sheet by securing $10.0m in equity funding from its largest shareholder AOP Health International Management AG (\"AOP\"), alongside a small contribution from a RetailBook Offer. This funding, which was completed at a premium to the prevailing share price, was received in January 2025. Shield held cash and cash equivalents of $6.5m as at 31 December 2024 (31 December 2023 was $13.9m), with an additional $10m of gross proceeds received on 3 January 2025. The strengthened balance sheet, along with the previously announced savings to the Group's operating cost base, will help the Company achieve its aim of becoming cash flow positive by the end of calendar 2025.\n2024 Financial Highlights\n\u00b7\nTotal 2024 net revenue and other income\nof $32.3m ($17.5m FY23).\no\nACCRUFeR\u00ae net revenue\nof $29.3m, a 153% increase over 2023 reported revenues.\no\nEx-U.S. revenue\nof $2.9m of royalty and milestone related revenue from partners.\n\u00b7\nLoss for the year\nof $27.2m compared to $33.3m in FY23.\n\u00b7\nCash and cash equivalents\nof $6.5m as of 31 December 2024, with an additional $10.0m of gross proceeds from the equity funding received post year end, expected to provide sufficient capital to allow the Company to become cash flow positive by the end of the year.\n2024 Operational Highlights\n\u00b7\nCommercialisation of\nACCRUFeR\u00ae\nin the US:\nContinued growth and strong market results with our partner, Viatris Inc.\no\nACCRUFeR\u00ae Prescriptions\nof c.150,000 for FY24, almost double FY23.\no\nACCRUFeR\u00ae average net price\nof $184 for FY24 and exiting Q4 2024 at $237 driven by successful execution of market access strategies.\no\nRealignment of US sales team\nin Q4 2024 focusing on\u00a0territories with highest potential, optimal coverage and strong ACCRUFeR\u00ae performance.\n\u00b7\nGlobal ACCRUFeR\u00ae/FeRACCRU\u00ae development programs:\nContinued progress in development stage partnerships in Canada, Republic of Korea, China, and the pediatric program.\no\nKye Pharmaceuticals (\"Kye\") in Canada\n: ACCRUFeR\u00ae approved by Health Canada, the only oral iron therapy approved as a prescription drug in Canada. The team at Kye announced the launch of ACCRUFeR\u00ae in March 2025. For the remaining term of the agreement, Shield will receive additional revenue-based milestone payments along with double-digit royalties on net sales of ACCRUFeR\u00ae.\no\nKorea Pharma (\"KP\") in Korea\n: KP filed a New Drug Application for ACCRUFeR\u00ae in the Republic of Korea (South Korea) following the successful completion of a pharmacokinetic (PK) study. Pending a successful review, approval of ACCRUFeR\u00ae in Korea is anticipated in 2025.\no\nASK Pharma (\"ASK\") in China\n: ASK announced completion of the recruitment of adult patients with IBD and IDA in the Phase 3 confirmatory study, which is the final study required to support the filing of an NDA in China for the commercialisation of\nACCRUFeR\u00ae/ FeRACCRU\u00ae\n. The Company expects the NDA to be filed with the Chinese National Medical Products Administration (NMPA) in 2025.\no\nPediatric study:\nResults from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305), confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric suspension in children with iron deficiency anemia (IDA).\nThe trial was the final study in the comprehensive pediatric development program that Shield committed to implement with both the European EMA and the US FDA.\n2024 Annual Report and Notice of Annual General Meeting\nThe Annual Report and Accounts and Notice of AGM will be sent to shareholders and\nin accordance with AIM Rule 26, these documents will also be available to view on the Company's website:\nResults, Reports & Presentations | Shield Therapeutics plc\nas of 25 April 2025\n.\nThis\u00a0year the Company's AGM will be held at 2.00\npm (BST) on 22 May 2025 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, NE8 3DF.\u00a0If you wish to attend the AGM in your capacity as ",
          "content_length": 27010
        },
        "ingested_at": "2026-01-21T02:12:57.495163Z"
      },
      {
        "event_id": "RNS-22nd Apr 2025-licencea",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495177Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Licence Agreement in Japan for ACCRUFeR\u00ae",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/licence-agreement-in-japan-for-accrufer174-zuiogu4r0cp8ula.html",
          "rns_number": "RNS Number : 6440F",
          "full_content": "22 Apr 2025 07:01\nRNS Number : 6440F\nShield Therapeutics PLC\n22 April 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nLicence Agreement in Japan for ACCRUFeR\u00ae\nExclusive Japan licence\nagreement with\nVITAL-NET, Inc.\nShield to receive an initial payment of ~$665,000 plus regulatory and sales milestones, and double-digit royalties on net sales\nLondon, UK, 22 April, 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia (\"ID/IDA\")\n, announces that it has entered into an exclusive licence agreement (\"the Agreement\") for ACCRUFeR\u00ae with VITAL-NET, Inc. (\"VITAL-NET\") in Japan. VITAL-NET will undertake and be responsible for all costs, including clinical and regulatory, related to activities required to achieve marketing authorisation and commercialisation of ACCRUFeR\u00ae in Japan.\nShield will receive an initial payment of circa $665,000 and is eligible to receive additional milestone payments related to the regulatory approval of ACCRUFeR\n\u00ae and upon the achievement\nof specified net sales targets by VITAL-NET. For the term of the agreement, Shield will also receive double-digit royalties on net sales of ACCRUFeR\u00ae. VITAL-NET to be responsible for, and cover costs of all development and regulatory activity.\nAnders Lundstrom, Chief Executive Officer for Shield, commented:\n\"This partnership aligns with our commitment to keep expanding our global footprint for ACCRUFeR\u00ae. Japan, the third largest pharmaceutical market in the world, is an important market to enter as Iron deficiency is a prevalent health concern in Japan, especially among women, children, and the elderly. ACCRUFeR\u00ae offers a new option for those who need a more effective treatment to restore their iron levels and improve their overall health. We look forward to working together with VITAL-NET to making ACCRUFeR\u00ae available to the people of Japan.\"\nTakeshi Ichijo, CEO of VITAL-NET, commented:\n\"\"We are excited to have entered into the agreement with Shield Therapeutics for the supply, development and marketing of ACCRUFeR\u00ae. Iron deficiency (ID) patients in pulmonary hypertension (PH) and inflammatory bowel disease (IBD) are our important areas, we believe that our experience will be of great use. We will endeavour to provide the drug to Japanese patients suffering from ID.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nIron deficiency and iron deficiency anemia (ID/IDA) poses a significant health challenge in Japan, with the country accounting for approximately 39% of ID cases among the seven major markets, which include the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan\n[1]\n. The ID/IDA treatment landscape in Japan primarily consists of oral and intravenous (IV) iron supplements. Oral iron products, including both over-the-counter and prescription formulations, dominate the market in terms of volume\n[2]\n.\nThe Japanese iron deficiency therapy market is poised for growth. This growth is attributed to factors such as the introduction of novel therapies, an increasing IDA prevalence, and heightened awareness regarding anemia management\n[3]\n.\nJapan's ID/IDA market is characterized by a robust demand for both oral and IV iron supplements, influenced by regional demographics and recent pharmaceutical innovations\n2\n. The market is expected to expand steadily, driven by ongoing advancements in treatment options and a growing focus on addressing iron deficiency and iron deficiency anemia\n3\n.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol)\nis a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet n",
          "content_length": 8814
        },
        "ingested_at": "2026-01-21T02:12:57.495191Z"
      },
      {
        "event_id": "RNS-17th Apr 2025-q12025tr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495204Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q1 2025 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/q1-2025-trading-update-7c6urch8ka66gfg.html",
          "rns_number": "RNS Number : 4930F",
          "full_content": "17 Apr 2025 11:23\nRNS Number : 4930F\nShield Therapeutics PLC\n17 April 2025\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ1 2025 Trading Update\nQ1 2025 ACCRUFeR\u00ae net revenues at $6.4m; March rebound representing c.50% of Q1 revenues and $220 net price\nRemains on track to be cash flow positive by end of 2025\nLondon, UK, 17 April 2025:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nprovides an unaudited Q1 2025 trading update.\nIn the first quarter of 2025, Shield reported unaudited net revenues of $6.4m from c.36,800 prescriptions of ACCRUFeR\u00ae. Whilst the first quarter of the year is traditionally softer than the other quarters, the early part of Q1 2025 saw significant weather disruptions in the US, which led to office closures and subsequently affected prescription numbers across prescription oral iron products in the market. ACCRUFeR\u00ae was further impacted due to nearly 20% sales force vacancy in January and February. While March showed a recovery reflecting the fully staffed sales force, the impact of these weather-related events, coupled with the realignment of the US sales team, influenced the figures for Q1 2025. The Company continues to remain positive in its goal of becoming cash flow positive by the end of 2025.\nQ1 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenue\nof $6.4m (Q1 2024: $4.1m) with March representing nearly 50% of total Q1 net product revenues.\n\u00b7\nACCRUFeR\u00ae average net price\nof $187 for Q1 with March at $220\n(Q1 2024: $139).\n\u00b7\nACCRUFeR\u00ae Prescriptions\nof c.36,800, with c.27% consignment-based prescriptions that were dispensed at a significantly subsidised price to patients and were not reimbursed by payors.\n\u00b7\nCash and cash equivalents\nof $10.5m as of 31 March 2025. Additionally, Shield has signed an amendment to improve the revenue covenants associated with the existing SWK $20m debt financing (additional details detailed below).\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"We are entering Q2 with clear momentum behind ACCRUFeR\u00ae and a continued focus on our strategic priorities. Despite early challenges in the year, prescription growth has recovered well, supported by a fully operational sales force and strong execution across the business. Our continued progress in global markets, including recent milestones in Canada, China, and the pediatric program, reflects the significant value of ACCRUFeR\u00ae and our commitment to expanding patient access worldwide. I am confident that our disciplined approach and dedicated team will position us to ensure that the Company is\ncash flow positive by the end of 2025\n.\n\"\nNotice of Results and Investor Presentation via Investor Meet Company\nShield expects to issue its audited full year results by the end of April 2025.\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q1 2025 update via the Investor Meet Company platform at\u00a03.30 pm\u00a0(BST) on 17 April 2025.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 2.00 pm (BST) or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\ninvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption com",
          "content_length": 8871
        },
        "ingested_at": "2026-01-21T02:12:57.495218Z"
      },
      {
        "event_id": "RNS-11th Mar 2025-accrufer",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495231Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ACCRUFeR\u00ae launched in Canada",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/accrufer174-launched-in-canada-d4g67lmu26sz8v8.html",
          "rns_number": "RNS Number : 0672A",
          "full_content": "11 Mar 2025 07:00\nRNS Number : 0672A\nShield Therapeutics PLC\n11 March 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae launched in Canada\nACCRUFeR\u00ae is the sole prescription-only oral treatment for iron deficiency anemia in Canada\nLondon, UK, 11 March 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency,\nannounces that\nit has launched ACCRUFeR\u00ae in Canada in\npartnership with its Canadian partner,\nKye Pharmaceuticals, Inc. (\"Kye\").\nThis follows\napproval in\nAugust 2024\nfrom\nHealth Canada\nfor ACCRUFeR\u00ae (ferric maltol)\u00a0as a prescription drug for the treatment of adults with iron deficiency anemia (\"IDA\")\n.\nACCRUFeR\u00ae is currently the sole prescription-only oral treatment option indicated for IDA in Canada and is available by prescription through pharmacies across Canada.\nShield will be responsible for all manufacturing and supply to the Canadian market.\nIn accordance with the collaborative agreement\nShield is eligible to receive\nfurther\nmilestone payments upon the achievement of specified calendar net sales targets and will also receive double-digit royalties on net sales of ACCRUFeR\n\u00ae for the term of the agreement.\nIron deficiency is a public health concern with an estimated 6-7% of people living in Canada being iron deficient (ID), and ~2% of the population classified as having IDA. ACCRUFeR\u00ae is approved as a\nprescription medicine in Canada for adults with IDA who are unresponsive or intolerant to other oral iron preparations.\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"We continue to expand the global footprint for ACCRUFeR\u00ae with the launch in Canada. We are delighted with the progress by Kye following approval of ACCRUFeR\u00ae by Health Canada in August 2024. Both organisations continue to demonstrate excellent collaboration in making ACCRUFeR\u00ae available to patients in Canada with iron deficiency as quickly as possible.\"\nJulian Oliver, Commercial Lead General Medicines and Business Operations, Kye Pharmaceuticals, commented\n:\n\"The availability of ACCRUFeR\u00ae across Canada provides patients and physicians with a valuable treatment option between over-the-counter iron supplements and more invasive intravenous iron preparations. We are proud to bring an evidence-based oral iron-therapy to Canada that has demonstrated long-term efficacy and safety in both placebo-controlled and active comparator clinical trials. We look forward to supporting efforts across Canada to raise awareness, enhance screening, and improve access to treatment of ID and IDA, making a meaningful difference in patient care.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR\u00ae/ F",
          "content_length": 6914
        },
        "ingested_at": "2026-01-21T02:12:57.495245Z"
      },
      {
        "event_id": "RNS-13th Feb 2025-pdmrtran",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495258Z",
        "source": "LSE_RNS",
        "data": {
          "title": "PDMR Transaction Notification",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/pdmr-transaction-notification-ki5ryf6eprllhcz.html",
          "rns_number": "RNS Number : 0703X",
          "full_content": "13 Feb 2025 16:15\nRNS Number : 0703X\nShield Therapeutics PLC\n13 February 2025\nShield Therapeutics plc\n(\"Shield Therapeutics\" or the \"Company\")\nPDMR Transaction Notification\nLondon, UK, 13 February 2025:\nShield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company specialising in iron deficiency, confirms that Mr Anders Lundstrom, Chief Executive Officer, acquired 575,000 Ordinary Shares in the Company on 13 February 2025 at a price of 3.7p per share. Mr Lundstrom now holds a beneficial interest in 585,000 Ordinary Shares.\nThe notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n1.\nDetails of the person discharging managerial responsibilities / person closely associated\na.\nName\nAnders Lundstrom\n2.\nReason for the notification\na.\nPosition/status\nChief Executive Officer\nb.\nInitial notification\n/Amendment\nInitial\n3.\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na.\nName\nShield Therapeutics plc\nb.\nLEI\n213800G74QWY15FC3W71\n4.\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na.\nDescription of the\nFinancial instrument, type\nof instrument\nIdentification code\nOrdinary shares of 1.5p each in the capital of the Company\nISIN of Ordinary Shares: GB00BYV81293\nb.\nNature of the transaction\nAcquisition of Ordinary Shares\nc.\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n3.7p\n575,000\nd.\nAggregated information\n\u00b7\nAggregated volume\n\u00b7\nPrice\n575,000\n\u00a321,275\ne.\nDate of the transaction\n13 February 2025\nf.\nPlace of the transaction\nAIM\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as pa",
          "content_length": 5188
        },
        "ingested_at": "2026-01-21T02:12:57.495272Z"
      },
      {
        "event_id": "RNS-13th Feb 2025-grantofs",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495285Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Grant of Share Options",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/grant-of-share-options-hikqc8z3a94m7io.html",
          "rns_number": "RNS Number : 9221W",
          "full_content": "13 Feb 2025 07:00\nRNS Number : 9221W\nShield Therapeutics PLC\n13 February 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nGrant of Share Options\nLondon, UK, 13 February 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency,\nannounces\nthat on 12 February 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company (\"Ordinary Shares\") under Shield Therapeutics' Retention and Performance Share Plan (\"RPSP\") to the Group's Chief Executive Officer (\"CEO\") as part of his onboarding.\nThe following options have been granted to Anders Lundstrom, CEO, who is deemed a PDMR:\nName\nOption Plan\nNumber of Ordinary Shares under Option\nVesting Date\nAnders Lundstrom\nRPSP\n5,000,000\nThree years from date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting.\nThe proportion of total options awarded to Anders Lundstrom is approximately 0.5% of the total number of AIM securities in issue at this time\n.\nAnders Lundstrom currently holds 10,000 ordinary shares in the Company.\n1.\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\na)\nName\nAnders Lundstrom\n2.\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification/\namendment\nInitial Notification\n3.\nDetails of the Issuer\na)\nName\nShield Therapeutics plc\nb)\nLEI code\n213800G74QWY15FC3W71\n4.\nDetails of the\ntransaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv\n) each place where transactions have been conducted\na)\nDescription of the financial instrument\nIdentification code\nOptions over new Ordinary Shares\nISIN: GB00BYV81293\nb)\nNature of the transaction\nGrant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan.\nc)\nPrice(s) and volumes(s)\n2025 RPSP Award\nPrice (\u00a3)\nVolume\n0.037\n5,000,000\nd)\nAggregated information\n- Aggregate volume\n- Price\nAwards granted over 5,000,000 shares in total\n3.7p exercise price\ne)\nDate of the transaction\n12 February 2025\nf)\nPlace of the transaction\nOutside of trading venue\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution ",
          "content_length": 5522
        },
        "ingested_at": "2026-01-21T02:12:57.495299Z"
      },
      {
        "event_id": "RNS-5th Feb 2025-unaudite",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495312Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Unaudited full year trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/unaudited-full-year-trading-update-shr6aalxvaya8d2.html",
          "rns_number": "RNS Number : 8925V",
          "full_content": "5 Feb 2025 07:00\nRNS Number : 8925V\nShield Therapeutics PLC\n05 February 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUnaudited full year trading update\nGroup revenues ahead of expectations at $32.2m with ACCRUFeR\u00ae revenues growing 153% to $29.3m\n42% increase in net selling price to $237 per prescription in Q4 2024\nRemains on track to be cash flow positive by end of 2025\nLondon, UK, 5 February 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specializing in iron deficiency, provides an unaudited full year\u00a0trading update for the year ended 31 December 2024 (\"FY24\").\nThis period reflects a significant step-up in revenue, alongside successfully streamlining the cost base and strengthening the Company's balance sheet. These initiatives are part of the Company's ongoing strategy to become cash flow positive by the end of calendar 2025\n.\nThe Company expects to report total revenues of $32.2m for FY24 (FY23: $17.5m revenues and other income) and has seen strong improvements in ACCRUFeR\u00ae prescriptions with 95% growth in total prescriptions to c.150,000 in 2024 generating $29.3m of ACCRUFeR\u00ae revenues (FY23: $11.6m), an increase of 153%.\nDuring the final quarter of 2024, the Company took a decisive step to strengthen its balance sheet by securing $10.0m in equity funding from its largest shareholder AOP Health International Management AG (\"AOP\"), alongside a small contribution from a RetailBook Offer. This funding, which was completed at a premium to the prevailing share price, was received in January 2025. Shield therefore held cash and cash equivalents of $6.5m as of 31 December 2024 (31 December 2023 was $13.9m), with an additional $10m of gross proceeds received on 3 January 2025. The strengthened balance sheet, along with the previously announced savings to the Group's operating cost base, will help the Company achieve its aim of becoming cash flow positive by the end of calendar 2025.\nQ4 2024 Key Business Metrics:\n\u00b7\nStrong US ACCRUFeR\u00ae revenue\n:\u00a0$11.2m, showing a 56% growth over $7.2m in Q3 2024\n\u00b7\n42% higher average ACCRUFeR\u00ae net selling price:\n$237\u00a0per prescription compared to $167 in Q3 2024, driven primarily by the impact of pricing changes implemented within the consignment business\n\u00b7\nTotal Q4 Prescriptions:\nc.41,000, with only 22% consignment-based prescriptions that were dispensed at a significantly subsidized price to patients and were not reimbursed by payors, compared to 37% in Q3 2024. This reduction also helped achieve a higher average net selling price in the quarter\n\u00b7\nCash and cash equivalents\n: $6.5m as of 31 December 2024, with an additional $10.0m of gross proceeds received post year end, providing sufficient capital to allow the Company to become cash flow positive by the end of the year. Shield's rate of cash burn remains highly dependent on the rate of sales growth for ACCRUFeR\u00ae\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"\nWe have made significant efforts to streamline our cost base whilst driving growth in ACCRUFeR\u00ae revenues, prescriptions, and average net price, all in pursuit of achieving positive cash flow by the end of the calendar year. I am especially encouraged by the strong revenue momentum, as our team, in close collaboration with our partner Viatris, work diligently to expand our presence in the US market and position ACCRUFeR\u00ae as the therapy of choice.\n\"\nInvestor presentation\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the unaudited full year trading update via the Investor Meet Company platform at\u00a02.00pm\u00a0(GMT) on Thursday 6 February 2025.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am (GMT) or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\ninvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a",
          "content_length": 7477
        },
        "ingested_at": "2026-01-21T02:12:57.495325Z"
      },
      {
        "event_id": "RNS-27th Jan 2025-anderslu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495338Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Anders Lundstrom appointed CEO",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/anders-lundstrom-appointed-ceo-lnf5g7k0xlmxf86.html",
          "rns_number": "RNS Number : 6855U",
          "full_content": "27 Jan 2025 07:00\nRNS Number : 6855U\nShield Therapeutics PLC\n27 January 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nAnders Lundstrom appointed CEO\nLondon, UK, 27 January 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency,\nannounces that Anders Lundstrom has been appointed as Chief Executive Officer (CEO) with effect from 01 February 2025.\nAnders joined the Board of Shield in May 2021 and was appointed as interim Chief Executive Officer on 24 July 2024. He is based in Boston, Massachusetts and has strong international and US senior commercial and general management experience gained from a range of pharmaceutical and biotech companies including AstraZeneca, Biogen and Orexo, where he was president and CEO. Upon taking on the CEO role on a permanent basis\nAnders will step down from his position as Chair of the Remuneration Committee which position will be taken on by Dr. Christian Schweiger, one of the Company's non-executive Directors.\nSince Anders' appointment in July, his leadership has been instrumental in driving Shield's growth and operational efficiency. Under his guidance, the Company has experienced increases in revenues and net pricing for ACCRUFeR\u00ae in the United States and fostered strengthened relationships with key partners and shareholders. These efforts have helped provide additional support to Shield's long-term strategic goals. Anders has also played a pivotal role in streamlining operations, positioning the Company for success as it works towards its goal of becoming cash flow positive by the end of 2025.\nHans Peter Hasler, Non-Executive Chairman, commented\n:\n\"\nWe are grateful for Anders' exceptional leadership over the past months and look forward to his continued contributions in his new capacity as CEO and an Executive Director.\nAnders' experience, insight, and dedication make him the ideal person to steer Shield towards greater success in the future. Shield remains steadfast in its mission to deliver exceptional results and meet the needs of our stakeholders. With a solid foundation in place, we are confident that the Company is exceptionally well-positioned to achieve its goals and continue to thrive in the years to come.\"\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"We have worked hard to streamline our cost base, grow ACCRUFeR\u00ae revenues, prescriptions, and average net price in H2, as we strive towards becoming cash flow positive by the end of this calendar year. I believe Shield is poised for significant growth, and I look forward to working alongside our talented team and our partner Viatris Inc., to build on the company's strong foundation. Together, we will focus on advancing our mission, delivering value for our stakeholders, and making a meaningful impact in the treatment of iron deficiency and making ACCRUFeR\u00ae the oral iron of choice.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia",
          "content_length": 6230
        },
        "ingested_at": "2026-01-21T02:12:57.495352Z"
      },
      {
        "event_id": "RNS-24th Dec 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495365Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of General Meeting & Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/result-of-general-meeting-total-voting-rights-opo8wvj4iei2fsl.html",
          "rns_number": "RNS Number : 3188R",
          "full_content": "24 Dec 2024 11:25\nRNS Number : 3188R\nShield Therapeutics PLC\n24 December 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nResult of General Meeting and Total Voting Rights\nShareholder approval for $10 million Subscription and Panel Waiver\nLondon, UK, 24 December 2024:\nShield Therapeutics plc (LSE: STX) is pleased to announce that, at the General Meeting held earlier today, all Resolutions (including the Waiver Resolution)\nas set out in the Notice of General Meeting contained in the Circular published on 6 December 2024, were duly passed. Accordingly, subject to Admission, the Company has raised gross proceeds of $10 million pursuant to the Subscription and in addition the Panel Waiver has been approved. Further, as announced on 23 December 2024, the RetailBook Offer has also raised \u00a396,715.83 (before expenses) for the Company.\nAdmission and Total Voting Rights\nFollowing the General Meeting held earlier today, the Company will issue a total of 259,634,117 new Ordinary Shares (\"\nNew Ordinary Shares\n\") made up of 256,410,256 Subscription Shares and 3,223,861 RetailBook Offer Shares.\nApplication has been made to the London Stock Exchange for admission of the New Ordinary Shares to trading on AIM. It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on 30 December 2024. The New Ordinary Shares will rank pari passu in all respects with the Existing Ordinary Shares.\nFollowing Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 1,041,690,484 with equal voting rights. No shares are held in treasury.\nThis figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.\nResults of the meeting\nDetails of the results of the voting, by way of a poll vote, at the General Meeting are set out below. Resolutions 1 to 2 are ordinary resolutions and Resolution 3 is a special resolution.\nResolution\nVotes For\nVotes For\n(as % of votes cast)\nVotes Against\nVotes Against\n(as % of votes cast)\nVote Withheld\n1*\n102,899,680\n98.07%\n2,024,299\n1.93%\n323,522,105\n2\n426,064,758\n99.51%\n2,108,199\n0.49%\n273,127\n3\n426,044,147\n99.52%\n2,044,320\n0.48%\n357,617\n*Resolution 1 was taken on a poll of Independent Shareholders (as defined in the Circular) in accordance with the requirements of the Takeover Code.\nResultant holding of AOP and members of its Concert Party\nThe following table sets out the shareholdings of AOP and each member of its concert party following Admission:\n\u200b\nShareholder\nNumber of Ordinary Shares held following Admission\nPercentage of the Enlarged Share Capital following Admission\nAOP\n568,007,521\n54.53\nDr. Christian Schweiger\n11,651,713\n1.12\nDr. G\u00fcnther Krumpl\n4,000,000\n0.38\nMichael Steiger\n625,000\n0.06\nTotal\n584,284,234\n56.09\nCapitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the Company's announcement at 11.30 a.m. on 6 December 2024, unless the context requires otherwise.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for ",
          "content_length": 6629
        },
        "ingested_at": "2026-01-21T02:12:57.495381Z"
      },
      {
        "event_id": "RNS-23rd Dec 2024-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495395Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of RetailBook Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/results-of-retailbook-offer-c1eyr3avka22r39.html",
          "rns_number": "RNS Number : 0885R",
          "full_content": "23 Dec 2024 07:00\nRNS Number : 0885R\nShield Therapeutics PLC\n23 December 2024\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAILBOOK OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF SHIELD THERAPEUTICS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF SHIELD THERAPEUTICS PLC.\n23 December 2024\nShield Therapeutics plc\n(\"\nShield\n\" or the \"\nCompany\n\")\nResults of RetailBook Offer\nThe Company is pleased to announce that the RetailBook Offer announced on 6 December 2024 closed at 4.30 p.m. on Friday 20 December 2024. The RetailBook Offer has raised gross proceeds of \u00a396,715.83 (before expenses) via the issue of 3,223,861 RetailBook Offer Shares at the Offer Price of 3.0 pence per RetailBook Offer Share.\nIn total the RetailBook Offer and the Subscription are expected to raise gross cash proceeds of approximately \u00a37,789,023.51. Completion of the Subscription and the RetailBook Offer remain subject to the passing of all resolutions at the Company's General Meeting to be held at 9.30 a.m. on 24 December 2024 and admission of the Subscription Shares and RetailBook Offer Shares to trading on AIM.\nSubject to the resolutions being passed at the General Meeting, application will be made to the London Stock Exchange for admission of the Subscription Shares and the\u00a0RetailBook Offer Shares to trade on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on 30 December 2024.\nShould all of the resolutions being proposed at the General Meeting not be passed, the Subscription and the RetailBook Offer will not occur and the Company will not receive any of the proceeds from the Subscription and the RetailBook Offer.\nThe Company expects to make a further announcement of the results of the General Meeting on 24 December 2024.\nCapitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement made by the Company at 11.31 a.m. on 6 December 2024.\nEnquiries\nShield Therapeutics plc\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nRetailBook\nKit Atkinson / Michael Ward\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\nT: +44 (0) 191 511 8500\nInfo@retailbook.com\nT: +44 (0)20 7418 8900\nFurther information on the Company can be found on its website at\nwww.shieldtherapeutics.com\nImportant Notices\nThis announcement has been prepared by, and is the sole responsibility of, the Company.\nThe RetailBook Offer is offered in the United Kingdom under the exemption from the requirement to publish a prospectus in section 86(1)(e) of FSMA. As such, there is no need for publication of a prospectus pursuant to the Prospectus Regulation Rules of the Financial Conduct Authority, or for approval of the same by the Financial Conduct Authority. The RetailBook Offer is not being made into any jurisdiction other than the United Kingdom.\nNo offering document, prospectus or admission document has been or will be prepared or submitted to be approved by the Financial Conduct Authority (or any other authority) in relation to the RetailBook Offer, and investors' commitments will be made solely on the basis of the information contained in this announcement and information that has been published by or on behalf of the Company prior to the date of this announcement by notification to a Regulatory Information Service in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Market Abuse Regulation (EU Regulation No. 596/2014) (\"\nMAR\n\") and MAR as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (as amended).\nThis announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the Distric",
          "content_length": 10415
        },
        "ingested_at": "2026-01-21T02:12:57.495411Z"
      },
      {
        "event_id": "RNS-6th Dec 2024-retailbo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495425Z",
        "source": "LSE_RNS",
        "data": {
          "title": "RetailBook Offer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/retailbook-offer-aqnmp5yjvhtamw8.html",
          "rns_number": "RNS Number : 1732P",
          "full_content": "6 Dec 2024 11:31\nRNS Number : 1732P\nShield Therapeutics PLC\n06 December 2024\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAILBOOK OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF SHIELD THERAPEUTICS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF SHIELD THERAPEUTICS PLC.\n6 December 2024\nShield Therapeutics plc\n(\"\nShield\n\" or the \"\nCompany\n\")\nRetailBook Offer\n\u00b7\nShield is pleased to announce a conditional RetailBook Offer of new ordinary shares of 1.5p each in the capital of the Company (\"\nOrdinary Shares\n\") via\nRetailBook\n(the \"\nRetailBook Offer Shares\n\")\n;\n\u00b7\nThe offer price for each new RetailBook Offer Share is\n3.0\np per share (the\n\"Offer Price\")\n, representing a premium of 5.3 per cent to the closing mid-price of the Company's existing Ordinary Shares on 5 December 2024;\n\u00b7\nInvestors can take part through RetailBook's partner network of participating retail brokers, wealth managers and investment platforms, which includes AJ Bell, Hargreaves Lansdown and interactive investor;\n\u00b7\nApplications for RetailBook Offer Shares through these partners can be made from tax efficient savings vehicles such as ISAs or SIPPs, as well as General Investment Accounts (\"\nGIAs\n\");\n\u00b7\nThe RetailBook Offer is available to existing shareholders only;\n\u00b7\nThere is a minimum subscription of \u00a350 per investor in the RetailBook Offer;\n\u00b7\nA maximum of\n33,333,333\nRetailBook Offer Shares will be issued and accordingly, the maximum gross proceeds of the RetailBook Offer are\n\u00a31,000,000\n\u00b7\nThe RetailBook Offer is expected to close at\n4.30 p.m.\non\n20 December\n2024;\n\u00b7\nCompletion of the RetailBook Offer is conditional on the completion of the Subscription and admission of the RetailBook Offer Shares to trading on AIM;\n\u00b7\nNo commission will be charged by RetailBook on applications to the RetailBook Offer.\nThe RetailBook\nOffer\nShield is pleased to announce a conditional RetailBook Offer for of new\nRetailBook Offer Shares\nvia RetailBook (the \"\nRetailBook Offer\n\")\nat an Offer Price of\n3.0\np per RetailBook Share, being a premium of 5.3 per cent to the closing mid-price of the Company's existing Ordinary Shares on 5 December 2024.\nEarlier today the Company also announced a conditional subscription for new Ordinary Shares (the \"\nSubscription Shares\n\") by its existing shareholder, AOP Health International Management AG (\"\nAOP\n\") (the \"\nSubscription\n\"). For the avoidance of doubt, the RetailBook Offer is not part of the Subscription.\nThe issue of the RetailBook Offer Shares will be conditional upon completion of the Subscription and will be undertaken pursuant to the authorities granted to the Directors at the Company's Annual General Meeting held on 20 June 2024. The issue of the Subscription Shares is conditional on the passing of all resolutions relating to the Subscription (the \"\nResolutions\n\") at a general meeting of the Company to be held at Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle NE8 3DF at 09:30 a.m. on 24 December 2024 (the \"\nGeneral Meeting\n\") and the admission of the Subscription Shares to trading on AIM.\nSubject to the Resolutions being passed at the General Meeting, it is expected that the Subscription Shares and such number of RetailBook Offer Shares as are subscribed for will be admitted to trading on AIM at 8.00 a.m. on 30 December 2024.\nReason for the RetailBook\nOffer\nThe Company values its retail shareholder base and believes that it is in the best interests of shareholders as well as wider stakeholders, to provide\nits existing retail shareholders\nin the United Kingdom, the opportunity to participate in the RetailBook Offer.\nThe RetailBook Offer is open to existing shareholders of the Company who are eligible investors in the United Kingdom following release of this announcement. The RetailBook Offer is expected to close at 4.30 p.m. on 20 December 2024 and may close earlier at the discretion of the Company or if it is oversubscribed.\nInvestors can participate through RetailBook's partner ",
          "content_length": 15826
        },
        "ingested_at": "2026-01-21T02:12:57.495441Z"
      },
      {
        "event_id": "RNS-6th Dec 2024-subscrip",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495455Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Subscription by AOP Health to raise US$10 million",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/subscription-by-aop-health-to-raise-us10-million-bn0fpeeo4itpj91.html",
          "rns_number": "RNS Number : 1764P",
          "full_content": "6 Dec 2024 11:30\nRNS Number : 1764P\nShield Therapeutics PLC\n06 December 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\",\nthe\u00a0\"Group\"\u00a0or the\u00a0\"Company\")\nSubscription by AOP Health International Management AG of 256,410,256 Ordinary Shares at 3.0p per share to raise US$10 million\nRetailBook Offer of up to 33,333,333 Ordinary Shares to raise up to \u00a31.0 million\nProposed waiver of obligations under Rule 9 of the Takeover Code\nand\nNotice of General Meeting\nLondon, UK, 6 December 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, today announces, further to the announcements on 29 October 2024 and 21 November 2024, a subscription by AOP for Ordinary Shares at a subscription price of 3.0 pence per Ordinary Share (the \"Subscription Price\") to raise aggregate gross proceeds of $10 million (the \"Subscription\"). The Company entered into a subscription agreement with AOP on 6 December 2024 pursuant to which AOP conditionally agreed to subscribe for 256,410,256 new Ordinary Shares at the Subscription Price (the \"Subscription Agreement\").\nSeparately, and conditional on completion of the Subscription, the Company is undertaking an intermediaries offer via RetailBook of up to 33,333,333 new Ordinary Shares at the Issue Price to existing retail shareholders of the Company (the \"RetailBook Offer\").\nAOP has stated to the Company that it is not prepared to proceed with an equity investment in the Company unless it obtains a controlling interest (i.e. greater than 50% of the Enlarged Share Capital) as a result. Such a Subscription is conditional upon the approval of the Resolutions by the Shareholders at the General Meeting (including the Waiver Resolution) and the Subscription Admission. If such approvals are not provided, AOP will not be required to proceed with an equity investment in the Company resulting in the Company not receiving the aggregate gross proceeds of at least $10 million, which would otherwise have helped the Company achieve its aim of becoming cash flow positive by the end of the calendar year of 2025.\nAOP (excluding its concert parties) currently holds\n311,597,265\nOrdinary Shares, representing 39.84 per cent. of the Company's issued share capital. The AOP Directors and persons acting in\nconcert with AOP currently hold, in aggregate, 327,873,978\nOrdinary Shares, representing 41.93 per cent. of the Company's issued share capital.\nIn the event that the maximum number of RetailBook Offer Shares are issued, following the completion of the Subscription, AOP (excluding its concert parties) will hold 568,007,521 Ordinary Shares, representing 53.00 per cent. of the Enlarged Share Capital, and AOP, the AOP Directors and its concert parties will hold 584,284,234 Ordinary Shares in aggregate, representing 54.51 per cent. of the Enlarged Share Capital.\nIn the event no RetailBook Offer Shares are issued, following the Subscription, AOP (excluding its concert parties) would hold 568,007,521 Ordinary Shares, representing approximately 54.70 per cent. of the Enlarged Share Capital, and AOP, the AOP Directors and persons acting in\nconcert with AOP would hold 584,284,234\nOrdinary Shares, representing approximately 56.26 per cent. of the Enlarged Share Capital.\nThe proposed Subscription gives rise to certain considerations under the Takeover Code.\nUnder Rule 9 of the Takeover Code, when any person who, together with persons acting in concert with that person, is interested in shares which in the aggregate carry not less than 30 per cent. of the voting rights of a company, but does not hold shares carrying more than 50 per cent. of such voting rights, and such person, or any person acting in concert with that person, acquires an interest in any other shares which increases the percentage of the shares carrying voting rights in which that person is interested, then, that person is normally required to extend offers in cash for all the remaining equity share capital of the company (a \"Mandatory Offer\").\nAOP has confirmed that it is not prepared to make a Mandatory Offer for the Company. The Panel has agreed to grant the Panel Waiver on condition that the Waiver Resolution is passed by the Independent Shareholders at the General Meeting on a poll vote. The Subscription is conditional upon the Waiver Resolution being passed.\nIn accordance with the provisions of the Takeover Code, AOP and each member of its concert party is considered to be interested in the outcome of the Waiver Resolution and, accordingly, each of them will not vote on the Waiver",
          "content_length": 54771
        },
        "ingested_at": "2026-01-21T02:12:57.495472Z"
      },
      {
        "event_id": "RNS-21st Nov 2024-business",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495485Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Business Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/business-update-erg7b4bn71bfxxg.html",
          "rns_number": "RNS Number : 0479N",
          "full_content": "21 Nov 2024 07:00\nRNS Number : 0479N\nShield Therapeutics PLC\n21 November 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBusiness Update\nRecruitment completed of the Phase 3 confirmatory Study in China in adult patientswith inflammatory bowel disease (IBD) and Iron Deficiency Anemia (IDA)\nProgress towards the provision of $10 million of new equity by AOP Health by the end of 2024\nStrong sales of ACCRUFeR\u00ae in the month of October 2024,guidance reiterated to meet the Group revenue covenant target of $31.5 million for the full year 2024\nLondon, UK, 21 November 2024:\nShield Therapeutics plc (LSE: STX), the commercial stage pharmaceutical company specialising in iron deficiency, provides an update covering recent activities.\nClinical Program in China\nThe Phase 3 confirmatory study in China is jointly sponsored by Shield and its partner Jiangsu Aosaikang Pharmaceutical Co. Ltd.\n(ASK), the\nexclusive license holder for the development and commercialisation of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan.\nThis trial is the final study required to support the filing of an NDA in China for the commercialisation of Feraccru\u00ae/Accrufer and recruitment has recently been completed of adult patients with IBD and IDA. The Company expects the NDA to be filed with the Chinese National Medical Products Administration (NMPA) in 2025. Further details will be announced in due course.\nAOP Health subscription\nOn 29 October 2024 the Company announced that it had entered into a non-binding term sheet with AOP Health International Management AG (\"AOP Health\") for the potential provision of $10 million of new equity. The Company is engaged with The Panel on Takeovers and Mergers (the \"Takeover Panel\") to seek a waiver from the obligation of AOP Health to make an offer under Rule 9 of the Takeover Code and expects to convene a meeting of Shield's shareholders (the \"General Meeting\") before the end of 2024.\nACCRUFeR\u00ae sales performance\nBased on strong sales of ACCRUFeR\u00ae in October 2024, driven primarily by an increase in Net Selling Price to more than $225 per prescription compared to $167 per prescription in Q3 2024, the Company remains on track to meet the total Group revenue covenant target of $31.5 million for full year 2024 under the debt facility agreement with SWK Funding LLC.\nAnders Lundstrom, interim CEO commented:\n\"We are delighted that our partner, ASK, has completed recruitment into the confirmatory Phase 3 study that will support the filing in China to commericalise ACCRUFeR\u00ae/FeRACRRU\u00ae\n, significantly increasing the global availability of\na welcome additional well-tolerated and effective therapeutic option for the treatment of IDA. In addition, solid growth of ACCRUFeR\u00ae revenues in October give us a promising outlook for the rest of the fourth quarter, leaving us on track to meet our 2024 Group revenue covenant target and market expectations for the year.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Rory Sale/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with ",
          "content_length": 7856
        },
        "ingested_at": "2026-01-21T02:12:57.495498Z"
      },
      {
        "event_id": "RNS-29th Oct 2024-q3tradin",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495512Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q3 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/q3-trading-update-qlu8shdzvdmknwj.html",
          "rns_number": "RNS Number : 9478J",
          "full_content": "29 Oct 2024 07:00\nRNS Number : 9478J\nShield Therapeutics PLC\n29 October 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\nQ3 Trading Update\nACCRUFeR\u00ae US Net Revenues of $7.2 million following 20% Increase in Q3 Prescriptions over Q2and 86% increase over Q3 2023\nFinancial foundation strengthened via accounts receivable financing expansion to $15 million andimplementation of a 10% cost saving plan to the Group's operating cost base\nNon-binding terms agreed with AOP Health for the provision of $10 million of new equity to drive growth, expecting\npositive cash flow by the end of 2025\nLondon, UK, 29 October 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, provides an unaudited\ntrading update for Q3 2024 as well as confirming a $5 million extension to its working capital financing facility with Sallyport\nCommercial Finance (\"Sallyport\")\n, the implementation of a 10% cost saving plan to its operating cost base, and the entering into of a non-binding term sheet with AOP Health International Management AG (\"AOP Health\") for the potential provision of $10 million of new equity.\nACCRUFeR\u00ae performance\nDuring the third quarter of 2024, Shield reported net revenues of $7.2 million from c.43,500 prescriptions of ACCRUFeR\u00ae with an average net selling price of $167 (\"NSP\") per prescription that included the impact of the summer buying pattern by wholesalers and pharmacies in June and July. Excluding July, the average NSP in Q3 was $192 per prescription and expectations are that NSP can be maintained at a similar level throughout Q4.\nKey Performance Indicators (KPIs) for Q3 2024 were:\n\u00b7\nTotal ACCRUFeR\u00ae Net Sales:\n$\n7.2\nmillion, representing 4% growth compared to $6.9 million in Q2 24 and 76% growth compared to Q3 2023. The growth rate difference between revenues and prescription demand are due to the impact of wholesalers buying ahead of the July 4th weekend during the last week of June\n.\n\u00b7\nTotal Prescriptions:\n-\nc. 43,500, an increase of\n20\n% over Q2 2024 and an 86% increase over Q3 2023.\n\u00b7\nAverage net selling price:\n$\n167\nper prescription vs. $171 in Q2 2024 and $148 in Q3 2023. Excluding July, the average net selling price in Q3 2024 was $192 per prescription.\n\u00b7\nTotal Group Revenues:\n$8.0 million including royalties and milestones from global partners for Q3 2024 resulting in $20.0 million of revenue for the 9 months ended 30 September 2024. The Board's internal estimates indicate that trading remains in line with market expectations for 2024 and is expected to meet the total revenue covenant target of $31.5 million for full year 2024 under the debt facility agreement with SWK Funding LLC.\nBalance sheet and cash resources\nAt 30 September 2024 Shield held cash and cash equivalents of $7.7 million vs. $8.1 million as at 30 June 2024.\nFollowing analysis of the Q3 2024 ACCRUFeR\u00ae performance and the consequential impact on internal projections, the Board has concluded that additional capital is required whilst also taking measures to lower its operating cost base to help achieve the Company's goal of becoming cash flow positive by the end of 2025. Accordingly, Shield has agreed an expansion of its working capital financing with Sallyport from $10 million to $15 million and is implementing a reduction of 10% to its operating cost base to extend its cash runway, based on current internal estimates, into Q2 2025. Shield has also entered into a non-binding term sheet with AOP Health for the provision of $10 million of new equity to help the Company achieve its aim of becoming cash flow positive by the end of calendar 2025. Shield's rate of cash burn remains highly dependent on the sales growth for ACCURUFeR\u00ae achieving the Company's internal forecast.\nAdditional support from AOP Health\nShield's largest shareholder, AOP Health, has executed a non-binding term sheet to subscribe for ordinary shares of 1.5 pence each in Shield (\"Ordinary Shares\") at a subscription price of 4.0 pence per Ordinary Share, to raise aggregate gross proceeds of a minimum of $10 million (the \"Subscription\"). Should the Subscription proceed, AOP Health (excluding any of its concert parties) would come to hold shares carrying more than 50% of the voting rights in Shield. Therefore, the Subscription is conditional, inter alia, upon the (i) granting of a waiver by The Panel on Takeovers and Mergers (the \"Takeover Panel\") from the obligation of AOP Health to make an offer under Rule 9 of the Takeover Code; (ii) approval of the waiver proposed to be granted by",
          "content_length": 11994
        },
        "ingested_at": "2026-01-21T02:12:57.495525Z"
      },
      {
        "event_id": "RNS-25th Sep 2024-resultsf",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495538Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results from Phase 3 paediatric study",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/results-from-phase-3-paediatric-study-u9cw5vod0fsd0lw.html",
          "rns_number": "RNS Number : 4852F",
          "full_content": "25 Sep 2024 07:00\nRNS Number : 4852F\nShield Therapeutics PLC\n25 September 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nResults from Phase 3 paediatric study\nPivotal Trial of ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) in Paediatric Patients with Iron Deficiency Anemia (IDA)\nproves highly clinically relevant effectiveness\nData will be used to\nsupport filing obligations with the US FDA and the European EMA for a\npaediatric indication in children older than 1 month for ACCRUFeR\u00ae/FeRACCRU\u00ae in H1 2025\nLondon, UK, 25 September 2024:\nShield Therapeutics plc (LSE: STX), the commercial stage pharmaceutical company specialising in iron deficiency, announces results from the Phase 3 paediatric clinical trial (FORTIS/ST10-01-305), confirming the efficacy, safety, and tolerability of the new oral liquid paediatric suspension in children with iron deficiency anaemia (IDA).\nThis trial is the final study in the comprehensive development program supporting the paediatric investigation plan (PIP/PSP) agreed with the European EMA and the US FDA. The full data set, including pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication. The data will be used to support a filing with the US FDA and European EMA for a paediatric indication in children older than 1 month for ACCRUFeR\u00ae/FeRACCRU\u00ae in H1 2025.\nAdditionally, Shield is due a total of \u20ac1 million as development milestones from its European partner, Norgine BV, upon the compliance notification of the PIP by the Pediatric Committee (PDCO) and the granting of the paediatric indication by EMA.\nAll primary endpoints were met, and the outcomes were:\n\u00b7\nChange in Hb concentration from baseline to week 12\n: Patients in the ferric maltol group demonstrated a highly clinically relevant mean change in Hb concentration at week 12 compared to baseline.\no\nThe mean change was 1.25 g/dl from baseline to week 12 in the 2 - 17-year-old cohort and was 1.77 g/dl from baseline to week 12 in the infants\no\nThe mean change was 1.15 g/dl from baseline to week 12 in patients in the ferrous sulphate group.\n\u00b7\nFrequency of discontinuations from the study because of Treatment Emergent Adverse Events (AEs):\nNo patients in the ferric maltol group discontinued from the study as a result of AEs.\no\nIn the 2 - 17-year-old cohort,\nno patient (0/31; 0%) discontinued the ferric maltol treatment due to an AE compared to one patient (1/30; 3.3%) who discontinued from the ferrous sulphate arm.\no\nNone of the infants discontinued ferric maltol treatment due to an AE.\n\u00b7\nFrequency of AEs/serious adverse events (SAEs):\nNo patient in the ferric maltol group reported a treatment related SAE and two (2) patients reported treatment related\nAEs.\no\nNo treatment related SAEs were reported in either group.\no\nIn the 2 - 17-year-old cohort\n, treatment related AEs were reported in 2 out of 31 patients treated with ferric maltol compared to 4 out of 30 patients treated with ferrous sulphate.\no\nNone of the ferric maltol-treated infants reported treatment related AEs .\nAnders Lundstrom, interim CEO commented:\n\"We are delighted that the results in this important ACCRUFeR\u00ae/FeRACCRU\u00ae Paediatric Phase 3 study show similar levels of efficacy and safety as in prior trials with adults. We will now initiate the work with the regulatory applications to be able to expand the patient population who can benefit from a safe and effective oral iron treatment.\"\nProfessor Richard Russell, a FORTIS Principal Investigator, commented:\n\"These results indicate that the newly developed paediatric liquid formulation will provide a welcome additional well-tolerated and effective therapeutic option for the treatment of IDA in young children and adolescents.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Rory Sale/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information ab",
          "content_length": 8840
        },
        "ingested_at": "2026-01-21T02:12:57.495554Z"
      },
      {
        "event_id": "RNS-4th Sep 2024-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495567Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/interim-results-7x7rhtgomp7p456.html",
          "rns_number": "RNS Number : 7870C",
          "full_content": "4 Sep 2024 07:00\nRNS Number : 7870C\nShield Therapeutics PLC\n04 September 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nInterim results for the six months ended 30 June 2024\nMore than threefold increase in Total Revenues compared to H1 2023\nc. 65,200 ACCRUFeR\u00ae prescriptions sold, up 161% compared to H1 2023\nNet average sales price increase of 33% from H1 2023\nLondon, UK, September 4, 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia) announces its unaudited interim results for the six months ended 30 June 2024, reporting a substantial increase in revenues, ACCRUFeR\u00ae prescription sales and net average sales price.\nFinancial Highlights H1 2024\n\u00b7\nTotal Revenues:\n$12.1 million, a 3.2x increase over H1 2023 ($3.7 million)\no\nACCRUFeR\u00ae revenue\n: $11.0 million, a 3.5x increase over H1 2023 ($3.1 million)\no\nEx-US revenue\n: $1.1 million from global partners for product sales in Europe (H1 2023: $0.6 million)\n\u00b7\nOperating Loss\n: $15.5 million compared to $12.6 million in H1 2023 driven primarily by the expansion of US field force supporting the launch of ACCRUFeR\u00ae, partially offset by higher ACCRUFER\u00ae revenues\n\u00b7\nCash and cash equivalents\n: $8.1 million (31 December 2023: $13.9 million). Post-Period End the Company completed a $5.7 million monetisation agreement with AOP Health International Management AG (July 2024). Based on our internal assumptions we remain funded to deliver on our growth plans and look forward to further progress in the second half of the year and beyond.\nOperational Highlights H1 2024\n\u00b7\nCommercialization of\nACCRUFeR\u00ae\nin the US:\nContinued growth and strong market results with our partner, Viatris Inc.\no\nACCRUFeR\u00ae total prescriptions\ngrew to c.65,200 with an average quarterly growth of 25% following field expansions with Viatris in Q2 2023. The growth was primarily driven in large States such as California, Florida, New York, and Texas.\no\nACCRUFeR\u00ae net price per prescription\nsteadily increased to $171 per prescription in Q2 2024 driven by successful execution of our market access strategies. H1 2024 was $158 per prescription, a 33% increase from $119 per prescription in H1 2023.\n\u00b7\nGlobal ACCRUFeR\u00ae/FeRACCRU\u00ae development programs:\nContinued progress in development stage partnerships in Canada, Republic of Korea, and China.\no\nKye Pharmaceuticals (\"Kye\") in Canada\n: ACCRUFeR\u00ae recently approved by Health Canada, the only oral iron therapy approved as a prescription drug in Canada. The team at Kye has been preparing for launch in late 2024 pending this approval. In accordance with the collaborative agreement with Kye, Shield is now due to receive a \u00a3250,000 milestone payment. For the remaining term of the agreement, Shield will receive additional revenue-based milestone payments along with double-digit royalties on net sales of ACCRUFeR\u00ae.\no\nKorea Pharma (\"KP\") in Korea\n: KP filed a New Drug Application for ACCRUFeR\u00ae in the Republic of Korea (South Korea) following the successful completion of a pharmacokinetic (PK) study.\no\nASK Pharma (\"ASK\") in China\n: Enrolling patients into a Phase 3 study that is similar in design to the previous studies conducted by Shield which led to European Medicines Agency (EMA) and US Food & Drug approval (FDA). The study is targeted to complete enrolment in late 2024.\no\nPaediatric study:\nPhase 3 paediatric clinical trial (FORTIS/ST10-01-305) comparing the safety, tolerability and\neffectiveness of an oral liquid suspension of ferric maltol with oral ferrous sulphate liquid in children with iron deficiency anaemia (IDA) expected to be completed in 2024. The trial is the final study in the comprehensive paediatric development program that Shield committed to implement with both the European EMA and the US FDA.\nAnders Lundstrom, Interim CEO of Shield Therapeutics\n, commented:\n\"\nH1 2024 has been another\nstrong period of growth for Shield which is demonstrated through the significant increase in sales figures,\nnet selling price and\nnumber of prescriptions for ACCRUFeR\u00ae in the US. We continue to focus on building momentum through creating greater awareness of ACCRUFeR\u00ae among health care professionals in the US as well as expanding our geographic reach with our international partners.\nWe have also continued to manage our cash burn during launch and scale of ACCRUFeR\u00ae while strengthening our balance sheet by implementing innovative financing solutions like the working capital financing with Sallyport in April and adding $5.7 million through the milestone monetization agreement with AOP Health International Management AG post period end. It is a very exciting time for Shield, and we look forward to providing updates for shareholders on our path to making ACCRUFeR\u00ae the oral iron of choice for patients with iron ",
          "content_length": 39400
        },
        "ingested_at": "2026-01-21T02:12:57.495584Z"
      },
      {
        "event_id": "RNS-27th Aug 2024-accrufer",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495597Z",
        "source": "LSE_RNS",
        "data": {
          "title": "ACCRUFeR\u00ae Approved by Health Canada",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/accrufer174-approved-by-health-canada-urfek9bgmofp9uo.html",
          "rns_number": "RNS Number : 6485B",
          "full_content": "27 Aug 2024 07:00\nRNS Number : 6485B\nShield Therapeutics PLC\n27 August 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\n\u00ae\nApproved by Health Canada\nACCRUFeR\n\u00ae\nis the only oral iron therapy approved as a prescription drug in Canada\nLondon, UK, 27 August 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), today announces\nthat Health Canada has approved ACCRUFeR\n\u00ae (ferric maltol)\nas a prescription drug for the treatment of adults with iron deficiency anemia (IDA).\nThis development allows Shield's partner, Kye Pharmaceuticals Inc. (Kye), to launch\nACCRUFeR\u00ae\nin Canada.\nShield will be responsible for all manufacturing and supply to the Canadian market.\nIn accordance with the collaborative agreement, Shield is now due to receive a \u00a3250,000 milestone payment.\nFor the remaining term of the agreement, Shield will receive additional revenue-based milestone payments along with double-digit royalties on net sales of ACCRUFeR\n\u00ae.\nAnders Lundstrom, Interim CEO of Shield, commented:\n\"\nWe are delighted with the progress made in partnership with Kye since the signing of the license agreement in January 2022. Both organisations have demonstrated excellent collaboration and are driven to make ACCRUFeR\u00ae available to patients in Canada with iron deficiency as quickly as possible. Shield Therapeutics is committed to bringing ACCRUFeR\u00ae/FeRACCRU\u00ae to patients with iron deficiency around the world, and Canada is an important component of that mission.\"\nJohn McKendry, President and CEO of Kye, commented:\n\"\nACCRUFeR\u00ae will be the only prescription oral therapy available in Canada to treat patients who continue to suffer from low iron despite attempts at treatment with other currently available options. Our partnership with Shield and the granting of marketing authorization for ACCRUFeR\u00ae in Canada grant us the opportunity to bring a novel, high-quality therapeutic option to patients in Canada who are struggling to address mild to moderate iron deficiency or iron deficiency anemia.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, Interim CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nIn Canada, the Canadian Health Measures Survey (CHMS) estimates that 6.1% of the total Canadian population have ID, with females being more disproportionately affected (8.3%) versus males (4%). As the only Health Canada approved prescription oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nACCRUFeR\u00ae/FeRACCRU\u00ae\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and commercialisation of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE P",
          "content_length": 8116
        },
        "ingested_at": "2026-01-21T02:12:57.495611Z"
      },
      {
        "event_id": "RNS-14th Aug 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495623Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of interim results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/notice-of-interim-results-qvnhh0sa7luov6t.html",
          "rns_number": "RNS Number : 3238A",
          "full_content": "14 Aug 2024 07:00\nRNS Number : 3238A\nShield Therapeutics PLC\n14 August 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nNotice of interim results\nLondon, UK, 14 August 2024:\nShield Therapeutics plc (LSE: STX),\na commercial stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product,\nto address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), will announce its interim\u00a0results for the six months ended 30 June 2024 on\nWednesday\n4 September 2024.\nInvestor presentation\nInterim CEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at\u00a04.30pm\n(BST) on Wednesday\n4\nSeptember 2024.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09.00am (BST) the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, Interim CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte\nEdgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nAccrufer\u00ae/Feraccru\u00ae\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/Feraccru\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial-stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia.\nThe Company has launched Accrufer\u00ae in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru\u00ae is commercialised in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and commercialisation of Accrufer\u00ae/ Feraccru\u00ae in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. To learn more about Shield Therapeutics, see our website at\nwww.shieldtherapeutics.com\nor follow us on LinkedIn and X.\nAccrufer\u00ae/Feraccru\u00ae has patent coverage\nuntil the mid-2030s.\nAccrufer\u00ae/Feraccru\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORFLFVRTTIVLIS",
          "content_length": 4796
        },
        "ingested_at": "2026-01-21T02:12:57.495636Z"
      },
      {
        "event_id": "RNS-24th Jul 2024-unaudite",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495649Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Unaudited Q2 2024 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/unaudited-q2-2024-trading-update-akgugjhrbpvcyib.html",
          "rns_number": "RNS Number : 5568X",
          "full_content": "24 Jul 2024 07:01\nRNS Number : 5568X\nShield Therapeutics PLC\n24 July 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUnaudited Q2 2024 Trading Update\nACCRUFeR\u00ae US Net Revenues of\n$6.9m following 26% Increase in Q2 Prescriptions\n23% sequential increase in average net selling price to $171/prescription\nIncreased balance sheet and operational flexibility with $\n8.1 million cash on hand plus $5.7 million from the China milestone monetization announced post period end\nLondon, UK, July 24 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers ACCRUFeR\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia) today announced\na Q2 2024 trading update highlighting a strong recovery in U.S. ACCRUFeR\u00ae growth.\nShield delivered stand-out sequential ACCRUFeR\u00ae revenue growth results of 69% in Q2 2024, driven by robust increases in prescriptions, up 26% along with a 23% increase in average net selling price per prescription. This has resulted in total H1 2024 ACCRUFeR\u00ae revenues of $11 million (unaudited) and total prescriptions to 65,200, which represent significant increases of ~250% and ~160% respectively compared to H1 2023.\nSnapshot of Positive Q2 2024 ACCURUFeR\u00ae Key Performance Indicators (KPIs)\n\u00b7\nTotal Net Sales:\n$6.9 million, an increase of 69% vs. Q1 24 and 259% vs. Q2 23\n\u00b7\nTotal Prescriptions:\n-\nOver 36,400, an increase of 26% vs. Q1 24 and 145% vs. Q2 23\n\u00b7\nAverage net selling price per prescription:\n$171 vs. $139 in Q1 2024 and $118 in Q2 2023\n\u00b7\nCash and cash equivalents:\n$8.1 million as of 30 June 2024 excluding the $5.7 million funding from the China milestone monetization announced on July 3, 2024\nShield's new Interim Chief Executive Officer Anders Lundstrom commented\n:\n\"I am excited about stepping in as the interim CEO and continue to build on the strong performance we delivered in the 2nd quarter of 2024. Large states such as California, NY, and Florida continue to drive a significant portion of the increase in prescriptions, while Texas begins to rebound. Our efforts on the operational side also showed outstanding progress, with an increase in our net selling price of 23% which is a direct result of strategies and investments over the past few quarters.\"\nMr. Lundstrom continued\n\"As we reflect on the first full year of the Shield/Viatris launch of our expanded field force, we are pleased that the market has responded in such a positive way to our efforts to increase physician awareness and adoption of ACCRUFeR\u00ae. This fortifies our continued belief the market potential of ACCRUFeR\u00ae is significant. We are committed to delivering further ACCRUFeR\u00ae growth making it the oral iron of choice for patients with iron deficiency, with or without anemia.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ George Dollemore/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJoyce Allaire\njallaire@lifesciadvisors.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/\nFeraccru\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significan",
          "content_length": 7822
        },
        "ingested_at": "2026-01-21T02:12:57.495663Z"
      },
      {
        "event_id": "RNS-24th Jul 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495676Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Directorate Change",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/directorate-change-cl1nc7zt7yk6f7o.html",
          "rns_number": "RNS Number : 5564X",
          "full_content": "24 Jul 2024 07:00\nRNS Number : 5564X\nShield Therapeutics PLC\n24 July 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nDirectorate Change\nLondon, UK, 24 July 2024:\nShield Therapeutics plc (LSE: STX),\na commercial stage pharmaceutical company that delivers ACCRUFeR\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia)\n,\ntoday\nannounced that Greg Madison, Chief Executive Officer, will be stepping down from the Board by mutual consent to pursue other opportunities and will be leaving the Company with immediate effect.\nAnders Lundstrom, one of the Company's independent non-executive Directors was appointed interim Chief Executive Officer. Anders, who is based in Boston, Massachusetts, has strong international and US senior commercial and general management experience gained from a range of pharmaceutical and biotech companies including AstraZeneca, Biogen and Orexo (where he was president and CEO).\nShield's non-executive Chairman, Hans Peter Hasler, commented\n: \"On behalf of the Board, I would like to thank Greg for his significant co\nntribution to the Group including securing the partnership with Viatris and overseeing the subsequent launch and growth of ACCRUFeR\u00ae and we wish him well with his future endeavors. Shield has a highly experienced Board of Directors and has had the privilege of working alongside Anders Lundstrom these past three years. Anders brings a wealth of US commercialisation experience and we are confident that he will lead the team to continue the success of Accrufer. I wish him and the team every success.\"\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ George Dollemore/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJoyce Allaire\njallaire@lifesciadvisors.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/\nFeraccru\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched Accrufer\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer\u00ae/ Feraccru\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.\nAccrufer\u00ae/Feraccru\u00ae has patent coverage\nuntil the mid-2030s.\nAccrufer\u00ae/Feraccru\u00ae are registered trademarks of Shield Therapeutics.\nForward-Looking Statements\nThis press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and inc",
          "content_length": 6640
        },
        "ingested_at": "2026-01-21T02:12:57.495690Z"
      },
      {
        "event_id": "RNS-3rd Jul 2024-$5.7mmil",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495703Z",
        "source": "LSE_RNS",
        "data": {
          "title": "$5.7m Milestone Monetization Agreement with AOP",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/57m-milestone-monetization-agreement-with-aop-fm0cf7tqtvd2rmy.html",
          "rns_number": "RNS Number : 8865U",
          "full_content": "3 Jul 2024 07:00\nRNS Number : 8865U\nShield Therapeutics PLC\n03 July 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nShield Enters into $5.7 million Milestone Monetization Agreement with AOP\nDr. Rudolf Widmann, Founder of AOP, joins the Shield Board as Non-Executive Director\nLondon, UK,\nJuly 3 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia) announces it has entered into a $5.7 million monetization agreement (the \"Milestone Monetization Agreement\" or \"the Agreement\") with AOP Health International Management AG (\"AOP\"), the largest shareholder in the Company, owning c. 39.8% of the Company's issued share capital. The Company also announces that AOP's founder, Dr. Rudolf Widmann, will join the Shield Board as a Non-Executive Director, effective immediately.\nUnder the terms of the Agreement, AOP will provide Shield $5.7 million (the \"Advance\") in cash, in exchange for the right to receive the $11.4 million China approval milestone payment (the \"Approval Milestone\") that may be paid to Shield by\nJiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma,\nShield's commercial partner for Accrufer\u00ae in China\n). ASK Pharma continues to enroll patients into a Phase 3 study and enrollment is expected to complete late in 2024. Subject to the Phase 3 reading out successfully and regulatory approval by the Chinese regulator Shield believes the Approval Milestone may be payable by the year ending 2026. Further details of the Milestone Monetization Agreement are set out below.\nGreg Madison, Shield CEO, commented:\n\"We are pleased to work with AOP on this Milestone Monetization Agreement to bring in additional capital to support our growing business. We are encouraged by the recent Accrufer\u00ae commercial trends in the US and will continue to be opportunistic to further support our growing business. This agreement, following our recently announced Sallyport deal, provides us with additional operational and financial flexibility. The $5.7 million, along with approximately $8 million cash on hand at the end of May 2024 allows us to further fortify our balance sheet and expand our working capital.\n\"It is also a pleasure to welcome AOP's Founder, Dr. Rudolf Widmann, to the Shield Board of Directors. I believe that Rudi's strong track record of building a successful pharmaceutical business and strategic perspective will complement Shield 's current Board of Directors.\"\nDr. Widmann, Founder of AOP, commented:\n\"I have long believed in Accrufer\u00ae's global growth potential and what it could do for patients worldwide suffering from iron deficiency, with or without anaemia. We are pleased to expand our stake in the Company's success through the Agreement announced today.\n\"I am delighted to join the Board of Directors and look forward to working closely with Shield's leadership team and the Board to achieve the Company's mission of making Accrufer\u00ae/Feraccru\u00ae the oral iron of choice.\"\nFurther details of the Milestone Monetization Agreement\nUnder the terms of the Agreement, in the event that the Approval Milestone falls due Shield is required to pay its full value to AOP 30 days after the Approval Milestone has been achieved.\nFurther, if the Approval Milestone has not been triggered by 31 December 2026, or in the event the Agreement is terminated, including at Shield's election or due to a breach by Shield of its terms, the Advance plus accrued interest and fees at the interest rate of SOFR+9.25% (calculated from the date of the Advance until the day of payment) and an exit fee of 6.5% of the Advance will be payable by Shield to AOP. The Advance will be secured inter alia by AOP's right to receive the ASK Approval Milestone.\nRelated Party Transaction\nIn view of the size of the Milestone Monetization Agreement and the fact that AOP is a substantial shareholder in Shield for the purposes of the AIM Rules for Companies (in that AOP currently has an interest of more than 10 per cent. of the Company's issued share capital), the Company's entry into the Agreement constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules for Companies. The Directors consider, having consulted with Peel Hunt LLP, the Company's Nominated Adviser, that the terms of the Milestone Monetization Agreement are fair and reasonable insofar as its shareholders are concerned.\nBiography of Dr. Rudolf Widmann\nDr. Rudolf Widmann is an experienced pharmaceutical scientist, seasoned executive and entrepreneur who has devoted his career to advancing the care of patients with rare diseases. He founded\nAOP Health (\nAOP Orphan Pharmaceuticals GmbH)\nin 1996, starting as Chief Executive Officer and Chief Therapeutics Development Officer and later elected to serve as a governing Board Member",
          "content_length": 10272
        },
        "ingested_at": "2026-01-21T02:12:57.495717Z"
      },
      {
        "event_id": "RNS-20th Jun 2024-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495730Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of 2024 Annual General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/results-of-2024-annual-general-meeting-muinlv1bl4kbr5h.html",
          "rns_number": "RNS Number : 2805T",
          "full_content": "20 Jun 2024 16:25\nRNS Number : 2805T\nShield Therapeutics PLC\n20 June 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nResults of 2024 Annual General Meeting\nLondon, UK, 20 June 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), announces the voting\nresults for each resolution set out in the Notice of Annual General Meeting 2024. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.\nThe following table shows the votes cast on each resolution:\nVOTESFOR\n%\nVOTES AGAINST\n%\nWITHHELD VOTES\nResolution 1\n371,135,672\n99.65%\n1,321,765\n0.35%\n387,002\nResolution 2\n367,256,140\n98.70%\n4,821,667\n1.30%\n766,632\nResolution 3\n368,781,407\n99.11%\n3,296,400\n0.89%\n766,632\nResolution 4\n368,781,161\n99.11%\n3,296,646\n0.89%\n766,632\nResolution 5\n369,852,377\n99.40%\n2,225,430\n0.60%\n766,632\nResolution 6\n369,852,377\n99.39%\n2,266,765\n0.61%\n725,297\nResolution 7\n368,193,486\n98.96%\n3,884,321\n1.04%\n766,632\nResolution 8\n371,077,210\n99.63%\n1,380,227\n0.37%\n387,002\nResolution 9\n370,260,710\n99.38%\n2,293,669\n0.62%\n290,060\nResolution 10\n368,304,167\n98.90%\n4,079,150\n1.10%\n461,122\nResolution 11\n368,067,995\n98.84%\n4,305,730\n1.16%\n470,714\nResolution 12\n367,071,290\n98.53%\n5,470,921\n1.47%\n302,228\nNotes:\n1. Number of shares in issue 782,056,367.\n2. Details of the votes received on the resolutions are available on the Company's website:\nhttps://www.shieldtherapeutics.com/corporate-documents/\n.\n3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nGreg Madison, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash / George Dollemore/ Nigel Birks /Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJoyce Allaire\njallaire@lifesciadvisors.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nAccrufer\u00ae/Feraccru\u00ae\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/\nFeraccru\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial-stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia.\nThe Company has launched Accrufer\u00ae in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru\u00ae is commercialised in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd. for the development and commercialisation of Accrufer\u00ae/ Feraccru\u00ae in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. To learn more about Shield Therapeutics, see our website at\nwww.shieldtherapeutics.com\nor follow us on LinkedIn and X.\nAccrufer\u00ae/Feraccru\u00ae has patent coverage\nuntil the mid-2030s.\nAccrufer\u00ae/Feraccru\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contai",
          "content_length": 5282
        },
        "ingested_at": "2026-01-21T02:12:57.495744Z"
      },
      {
        "event_id": "RNS-28th May 2024-newdruga",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495758Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Drug Application for Accrufer\u00ae in South Korea",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/new-drug-application-for-accrufer174-in-south-korea-2mdwo1h65wunyd5.html",
          "rns_number": "RNS Number : 9601P",
          "full_content": "28 May 2024 07:00\nRNS Number : 9601P\nShield Therapeutics PLC\n28 May 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nShield's Korean Partner files\nNew Drug Application\nfor Accrufer\u00ae in the Republic of Korea (South Korea)\nImportant milestone paves way to increasing global access of Accrufer\u00ae\nPending successful review, approval in Korea anticipated in 2025\nLondon, UK, 28 May 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), today announces that its Accrufer\u00ae partner for Korea, Korea Pharma Co., Ltd (Korea Pharma) has submitted a New Drug Application (NDA) to the Korean Ministry of Food and Drug Safety (MFDS) for the review and approval of Accrufer\u00ae to treat patients with iron deficiency anaemia in Korea. Pending a successful review, approval of Accrufer\u00ae in Korea is anticipated in 2025.\nKorea Pharma's MFDS filing follows the successful completion of a pharmacokinetic (PK) study in Korea. The PK study confirms that the absorption of iron from Accrufer\u00ae is comparable between patients in Korea and the patient population enrolled in the key clinical studies supporting Accrufer\u00ae effectiveness and safety.\nShield is eligible to receive a development milestone payment of c.$1.9 upon the first sale of Accrufer\n\u00ae in the territory, as well as\nfuture commercial sales milestone payments upon the achievement of specified net sales targets. For the duration of the intellectual property, Shield will also receive double-digit royalties on net sales of Accrufer\n\u00ae in Korea.\nShield will be responsible for the initial manufacturing and supply to Korea Pharma.\nGreg Madison, CEO of Shield, commented:\n\"\nIron deficiency anaemia is a global issue. Shield is committed to working with valued partners, such as Korea Pharma, to enable global access of Accrufer\u00ae and advance the care of patients with iron deficiency anaemia around the world. Completion of the MFDS filing by Korea Pharma marks the first filing for Accrufer\u00ae in Southeast Asia. We are thrilled to work with our partner to reach this important milestone.\nWe look forward to supporting Korea Pharma as they continue the pathway to making Accrufer\u00ae available to patients in Korea.\"\nEun-Hee Park, Korea Pharma CEO, commented:\n\"We are pleased by the positive results for the local PK study. These data enabled us to successfully complete a regulatory filing for Accrufer\u00ae with the MFDS.\nThere are an estimated 5.2 million people in the Republic of Korea with iron deficiency and iron deficiency anaemia in need of novel treatment options. Pending approval of the NDA,\nwe look forward to providing Accrufer\u00ae to the people of Korea as a potential first choice for the treatment of iron deficiency anaemia.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nGreg Madison, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ George Dollemore/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJoyce Allaire\njallaire@lifesciadvisors.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nAccrufer\u00ae/Feraccru\u00ae\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/\nFeraccru\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial-stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anaemia.\nThe Company has launched Accrufer\u00ae in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru\u00ae is commercialised in the UK and Euro",
          "content_length": 8089
        },
        "ingested_at": "2026-01-21T02:12:57.495772Z"
      },
      {
        "event_id": "RNS-23rd May 2024-hardman&",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495785Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Hardman & Co: Shield Therapeutics (STX): Cash management is key",
          "category": "EQS",
          "url": "https://www.lse.co.uk/rns/STX/hardman-co-shield-therapeutics-stx-cash-management-is-key-ar2z97r85f3jb2f.html",
          "rns_number": null,
          "full_content": "23 May 2024 07:15\nHardman & Co Research Hardman & Co: Shield Therapeutics (STX): Cash management is key\n23-May-2024 / 07:15 GMT/BST\nThe issuer is solely responsible for the content of this announcement.\nHardman & Co Research on Shield Therapeutics (STX):\nCash management is key\nShield is a commercial-stage pharma company delivering specialty products that address patients\u2019 unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness of the differentiating characteristics of Accrufer\u00ae as an oral ID drug, in order to ramp up prescriptions (Rxs) and generate sales traction. Positive Rx momentum in 2022 and 2023, is expected to accelerate in 2024 and 2025 with the revised aim of becoming cashflow positive in 2H\u201925. This, coupled with extended financing options has obviated any requirement for a capital increase.\nPlease click on the link below for the full report:\nhttps://hardmanandco.com/research/corporate-research/stx-cash-management-is-key/\nIf you are interested in meeting the company, you can register your interest by clicking on the above link.\nTo contact us:\nHardman & Co\n9 Bonhill Street\nLondon\nEC2A 4DJ\nwww.hardmanandco.com\nFollow us on Twitter\n@HardmanandCo\nContact:\nDr Martin Hall\nmh@hardmanandco.com\nHardman & Co Research can still be accessed for free after MiFID II. Please\nclick here\nto read the statement.\nAbout Hardman & Co:\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.\nDissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.\nEnd of Announcement - EQS News Service\n1909175 23-May-2024\ncorporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.",
          "content_length": 2138
        },
        "ingested_at": "2026-01-21T02:12:57.495798Z"
      },
      {
        "event_id": "RNS-10th May 2024-auditedr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495811Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Audited results for the year ended 31 Dec 2023",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/audited-results-for-the-year-ended-31-dec-2023-ebw4c3rp431nynr.html",
          "rns_number": "RNS Number : 0413O",
          "full_content": "10 May 2024 15:30\nRNS Number : 0413O\nShield Therapeutics PLC\n10 May 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nAudited results for the year ended 31 December 2023\nPosting of Annual Report & Accounts\nNotice of AGM\nLondon, UK,\n10\nMay 2024:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia) confirms its audited final results for the year ended 31 December 2023.\nFinancial Highlights\n\u00b7\nTotal 2023 revenue and other income:\n$17.5m, a 2.8x increase over FY22\no\nAccrufer\u00ae revenue:\n$11.6m, a 3.1x increase over FY22\no\nEx-U.S. revenue:\n$1.5m of royalty revenue from product sales in Europe\no\nOther income revenue including Viatris milestone payments:\n$4.4m\n\u00b7\nTotal 2023 Prescriptions:\nc.77,000, a 3.1x increase over FY22\n\u00b7\nOperating Loss:\n$31.3m compared to $49.8m in FY22\n\u00b7\nCash and cash equivalents\n: $13.9m as of 31 December 2023\nOperational Highlights\n\u00b7\nLaunch of Accrufer\u00ae in the US with Shield's partner Viatris Inc. with\na 100-person dedicated sales team promoting Accrufer\u00ae to over 12,000 Health Care Professionals (HCPs)\n\u00b7\nHiring and implementation of the Company's first direct sales team of 50 sales professionals along with six regional sales managers, all of whom are promoting Accrufer\u00ae to HCPs\n\u00b7\nIncreased net revenue per prescription (Rx) to $145/Rx in the second half of the year vs $119/Rx in the first half\n\u00b7\nThe Company's Canadian partner, KYE Pharmaceuticals, filed for regulatory approval with Health Canada - decision expected in 2024\n\u00b7\nShield's Chinese partner, ASK Pharma, continued to enroll patients into a Phase 3 study\n\u00b7\nStrengthening of the senior management team with the appointment of Santosh Shanbhag as Chief Financial Officer and Andy Hurley as Chief Commercial Officer, to lead Shield's commercial team and our partnership with Viatris Inc.\n2023 Annual Report and Notice of Annual General Meeting\nThe Annual Report and Accounts and Notice of AGM will be sent to shareholders today and\nin accordance with AIM Rule 26, these documents are also available to view on the Company's website:\nResults, Reports & Presentations | Shield Therapeutics plc\n.\nThis\u00a0year the Company's AGM will be held at 2.00\npm (BST) on 20 June 2024 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, NE8 3DF.\nIf you wish to attend the AGM in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to\u00a0the Meeting.\nThe Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions.\u00a0In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 2.00pm (BST) on 18 June 2024.\nTo register for dial-in details and to submit any questions please contact Walbrook PR via email at\u00a0shield@walbrookpr.com\u00a0or call +44 (0)20 7933 8780.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nGreg Madison, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ George Dollemore/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nCharlotte Edgar / Alice Woodings\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJoyce Allaire\njallaire@lifesciadvisors.com\nAbout Iron Deficiency and Accrufer\u00ae/Feraccru\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nAccrufer\u00ae/Feraccru\u00ae\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/\nFeraccru\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial-stage specialty pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron def",
          "content_length": 32746
        },
        "ingested_at": "2026-01-21T02:12:57.495825Z"
      },
      {
        "event_id": "RNS-30th Apr 2024-business",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495838Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Business Update for Q1 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/business-update-for-q1-2024-h0oe36xhqy6h5jm.html",
          "rns_number": "RNS Number : 4943M",
          "full_content": "30 Apr 2024 07:00\nRNS Number : 4943M\nShield Therapeutics PLC\n30 April 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBusiness Update for Q1 2024 and Confirmation of Key Financials for FY 2023\nTotal U.S. Accrufer\u00ae prescriptions increased to c. 77,000 in 2023 and totalled c. 28,800 in Q1 2024\nCash and financial foundation strengthened via a $10m accounts receivable financing and improvement of revenue covenants associated with the existing $20m debt financing\nGuidance reiterated to turn cashflow positive in H2 2025\nLondon, UK, April 30, 2024:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia)\nprovides a business update for Q1 2024 and confirms its key financials for the year ended 31 December 2023\n. Whilst the Company's audit process for the year\u00a0ended 31 December 2023\u00a0is significantly advanced, additional time is required to finalise the translation of the Group's presentational currency from GBP to USD. The Company now expects to issue its\u00a0fully audited results for FY23 before 10 May 2024. The details provided in the\nfull year trading\nupdate remain unchanged.\n2023 Key Business Metrics:\nconfirmed as previously reported on\n21 February 2024\n\u00b7\nTotal 2023 revenue and other income:\n$17.5m, a 2.8x increase over FY22\no\nAccrufer\u00ae revenue:\n$11.6m, a 3.1x increase over FY22\no\nEx-U.S. revenue:\n$1.5m of royalty revenue from product sales in Europe\no\nOther income revenue including Viatris milestone payments:\n$4.4m\n\u00b7\nTotal 2023 Prescriptions:\nc.77,000, a 310% increase over FY22\n\u00b7\nOperating Loss:\n$31.1m compared to $49.8m in FY22\n\u00b7\nCash and cash equivalents\n: $13.9m as of 31 December 2023\nQ1 2024 Update\nDuring the first quarter of 2024, Shield reported net revenues of $4.0m from c.28,800 prescriptions of Accrufer\u00ae. In addition, the Company strengthened its balance sheet through an\naccounts receivable financing\nwith Sallyport Commercial Finance (Sallyport) and amended its existing $20m debt facility agreement with SWK Funding LLC (SWK), with more favourable loan covenant terms. Shield also expects to turn cashflow positive in H2 2025\u00a0with its current resources.\nQ1 2024 Key Business Metrics:\n\u00b7\nTotal US Accrufer revenue:\n$4.0m with an Average Net Selling Price of c. $140/prescription\n\u00b7\nTotal Q1 Prescriptions:\nc.28,800, a 1% rise over Q4 2023 and 174% increase over Q1 2023.\no\nShield has worked very closely with its third-party data provider to rectify the prescription reporting issue and has implemented an enhanced multi-source system\n\u00b7\nNew Financing:\nsecured a $10m accounts receivable financing and signed an amendment to improve the revenue covenants associated with the existing SWK $20m debt financing (additional details at end of this announcement)\n\u00b7\nCash and cash equivalents\n: $10.4m as of 31 March 2024\nFirst quarter Accrufer\u00ae prescriptions of c.28,800 increased by 174% compared to Q1 2023 and 1% compared to Q4 2023. Strong quarterly growth of c.29% in the largest US states California and New York and positive changes in prior authorisation (PA) submission rates were offset by a 28% decline in Texas due to a transition and lack of a Texas State Medicaid Pharmacy Benefit Manager (PBM) during the quarter, which resulted in significant inconsistencies in PA approvals for Accrufer\u00ae Medicaid prescriptions. The new PBM began on 1 April 2024 and Shield is working on behalf of its Health Care Providers (HCPs) and patients in Texas to enable greater consistency in PA requirements and approvals.\nGreg Madison, CEO of Shield Therapeutics, commented:\n\"We observed several encouraging growth signals during Q1 2024 including rising prescriptions in key states such as California and New York, after receiving access to Medicaid in those populous states. Additionally, our stated initiatives to improve the average net selling price by increasing PA submission rates and more favourable Medicaid pricing following renegotiation of payer contracts, are progressing very well. While the situation in Texas dampened the impact of these positives, we are engaged with the new PBM with the aim of finding a resolution as quickly as possible.\"\n\"We continue to believe that Accrufer\u00ae addresses an important unmet market need for a safe and well tolerated oral iron therapy. We fully expect to continue growth in prescriptions in Q2 and beyond and will continue to focus on increasing our average net selling price with targeted investments such as the new field access team, deployed in early April, to assist HCP offices with PA support and education. The belief, passion and motivation to succeed by both Shield and Viatris was readily evident at our recent National Sales Meeting. We remain focused on our mission to make Accrufer\u00ae the oral iron of choice for patients with iron deficiency, with",
          "content_length": 11031
        },
        "ingested_at": "2026-01-21T02:12:57.495854Z"
      },
      {
        "event_id": "RNS-16th Apr 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495868Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/notice-of-results-s3vdr9h5f0ghoo5.html",
          "rns_number": "RNS Number : 6759K",
          "full_content": "16 Apr 2024 07:00\nRNS Number : 6759K\nShield Therapeutics PLC\n16 April 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nNotice of Results\nInvestor Presentation\nLondon, UK, 16 April 2024:\nShield Therapeutics plc (LSE: STX),\na commercial-stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia),\nwill announce its final results for the year ended 31 December 2023 on Tuesday 30 April 2024.\nInvestor presentation\nCEO, Greg Madison, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at\n14.30 (BST) on\nTuesday 30 April 2024.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nGreg Madison, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/\nPatrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/George Dollemore/Nigel Birks/\nHarriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nPaul McManus/Charlotte Edgar/\nAlice Woodings\n+44 (0)20 7933 8780\nshield@walbrookpr.com\nInvestor Contact (US Advisor)\nLifeSci Advisors, LLC\nJohn Mullaly\n+1 617 429 3548 or jmullaly@lifesciadvisors.com\nAbout Accrufer\u00ae/Feraccru\u00ae\nAccrufer\u00ae/Feraccru\u00ae (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer\u00ae/Feraccru\u00ae has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer\u00ae/Feraccru\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\nAbout Shield Therapeutics plc\nShield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation.\nThe Group has launched Accrufer\u00ae in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru\u00ae is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand.\nShield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer\u00ae / Feraccru\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.\nAccrufer\u00ae/Feraccru\u00ae has patent coverage until the mid-2030s\nAccrufer\u00ae/Feraccru\u00ae are registered trademarks of the Shield Group\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORBSGDSBXBDGSU",
          "content_length": 4191
        },
        "ingested_at": "2026-01-21T02:12:57.495880Z"
      },
      {
        "event_id": "RNS-21st Feb 2024-unaudite",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:12:57.495893Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Unaudited Full Year Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/unaudited-full-year-trading-update-okax0tzs0hm5o13.html",
          "rns_number": "RNS Number : 8985D",
          "full_content": "21 Feb 2024 07:00\nRNS Number : 8985D\nShield Therapeutics PLC\n21 February 2024\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUnaudited Full Year Trading Update\nFull year 2023 total revenue and other income of $17.5m compared to $6.2m in 2022\nFull year 2023 Accrufer\u00ae revenue of $11.6m, approximately three times more than the prior year\n21% increase in H2 Accrufer\u00ae average net selling price to $145/prescription\nLondon, UK, 21 February 2024:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company that delivers Accrufer\u00ae/Feraccru\u00ae (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia)\ntoday\nannounces topline results for Q4 2023 and provides an unaudited trading update for the year ended 31 December 2023 (\"FY23\").\nThe operational progress made by Shield and its partnership with Viatris to create a new 100-person sales team, increase payer coverage, launch new brand campaigns, and ultimately deliver a tripling of U.S. Accrufer\u00ae prescriptions and revenues in 2023 - has been notable. In addition, recent market research reaffirms the unmet need in Accrufer's\u00ae target patient population, as healthcare professionals and patients continue to seek a well-tolerated and effective oral iron. During the fourth quarter of 2023, Shield strengthened its sales leadership and marketing organizations which will help drive more focused execution and prescription growth. The Company has also seen positive improvements in its gross-to-net in 2023 and expects that to accelerate further in 2024.\nBusiness Metrics:\n\u00b7\nCash\n: $13.9m as of 31 December 2023\n\u00b7\nTotal 2023 revenue and other income:\n$17.5m, a 2.8x increase over FY22\no\nAccrufer\u00ae revenue\n: $11.6m, a 3.1x increase over FY22\no\nEx-U.S. revenue\n: $1.5m\no\nOther income revenue including Viatris milestone payments\n: $4.4m\n\u00b7\nU.S. Q4 2023 Revenue\n: $4.3m\n\u00b7\nAverage net selling price:\nc.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023\n\u00b7\nTotal 2023 Prescriptions\n: c.77k, a 3.1x increase over FY22\nShield has recently identified that the projection methodology used by its third-party data provider resulted in an overstatement of total prescriptions in 2023. This development was partly responsible for the Group not achieving previously indicated guidance of total prescriptions in FY23 of 100k to 130k. Revised prescription numbers and quarterly growth rates are included in the table below. Previously reported Group financials including revenues, net revenues per Accrufer\u00ae prescription, and compliance with financial covenants on the Group's debt instrument are not affected by this change. The Company is working closely with its third-party data provider to ensure future consistency of data reporting.\n2023 Accrufer\u00ae Rx\nIn thousands\nQ1\nQ2\nQ3\nQ4\n2023\nPrior Reported TRx\n10.5\n15.8\n27.8\n36.4\n90.5\nUpdated TRx\n10.1\n14.9\n23.3\n28.6\n77.0\nActual Growth Rate\n--\n47%\n58%\n22%\n206%\nWith these revised prescription numbers, Shield is revisiting its previously communicated guidance and plans to provide additional updates at the time of the Company's final results, expected to be published in April 2024. Shield has also undertaken several important measures to manage its cash flow, including the reduction of operating expenses, and working capital enhancements, to provide the necessary resources with the aim of turning cash flow positive in the second half of 2025.\nGreg Madison, CEO of Shield Therapeutics, said:\n\"The progress made in the market in 2023 has shown us that the opportunity for Accrufer\u00ae continues to be significant. Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half. I'm also excited our new CFO, Santosh Shanbhag, has joined the team bringing both strategic and financial leadership to our organization. Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer\u00ae the oral iron of choice for patients.\"\nInvestor presentation\nCEO, Greg Madison, and CFO,\nSantosh Shanbhag\n, will be hosting a live online presentation relating to the trading update via the Investor Meet Company platform at\n14:00 (GMT) on\nThursday 22 February 2024.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 (GMT) the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nThe information contained within this announcement is deemed by the Company to constitute inside information as stip",
          "content_length": 9866
        },
        "ingested_at": "2026-01-21T02:12:57.495906Z"
      },
      {
        "event_id": "RNS-21st Jan 2026-q42025tr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T21:55:41.544337Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q4 2025 Trading Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/q4-2025-trading-update-0iy9mqr107h8e16.html",
          "rns_number": "RNS Number : 6821P",
          "full_content": "Today 07:00\nRNS Number : 6821P\nShield Therapeutics PLC\n21 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ4 2025 Trading Update\nGenerated positive Cash flow in Q4 2025 with Total Group Revenues of c. $50m for full year 2025\nACCRUFeR\u00ae revenues grew 56% to c. $46m in 2025 with 21% increase in average net selling price to $223and 33% growth in total prescriptions to c.199,000\nCompany expects to deliver an operating profit in 2026\nLondon, UK, 21 January 2026:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nannounces that, in line with the Company's guidance, Shield has achieved positive operating cash flow in Q4 2025 and provides an\nunaudited full year\u00a0trading update for the year ended 31 December 2025 (\"FY25\").\nThis period reflects the transition of the Company to a sustainable enterprise\ndriven by continued ACCRUFeR\u00ae growth in the US and effective cost and working capital management. The Company also announces that it expects to deliver an operating profit in 2026.\nThe Company reported total revenues of c. $50m for FY25 ($32m revenues and other income in FY24) with ACCRUFeR\u00ae revenues growing 56% in the US and contributing $46m ($29m in FY24) through 21% growth in average net selling price to $223 and 33% growth in total prescriptions to c.199,000.\nQ4 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenues\nof $13.5m ($11.2m Q4 2024).\n\u00b7\nACCRUFeR\u00ae prescriptions\nof c. 61,000 (c. 41,000 in Q4 2024) representing the highest dispenses in any quarter since launch. Consignment-based prescriptions decreased c. 21% (c. 22% in Q4 2024) that were dispensed at a subsidised price to patients and were not yet reimbursed by payors.\n\u00b7\nACCRUFeR\u00ae average net selling price\nof $222\n($237 in Q4 2024) impacted by an increase in covered rebated prescriptions compared to prior quarters.\n\u00b7\nCash and cash equivalents\nof $11.6m as\nof 31 December 2025 (\n$8.6m\nas of 30 September 2025), achieving positive operative cash flow of $1m excluding the receipt of net proceeds of $1.96m from the amended Senior Secured Debt Financing announced in the quarter.\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"Reaching cash flow positivity is a significant milestone in the Company's history that allows us to continue to grow our business without the need for further external financing. The efforts of the sales teams, together with our strategic marketing initiatives, delivered our strongest year on record for ACCRUFeR\u00ae, achieving new highs in prescription volumes, net selling price, and revenues. ACCRUFeR\u00ae's strong performance in the fourth quarter along with a strengthened balance sheet exiting 2025 gives us the momentum and financial flexibility to achieve our 2026 strategic priorities.\"\nInvestor Presentation\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q4 2025 Trading Update\nvia the Investor Meet Company platform\nat\u00a02:00 pm\u00a0(GMT) on 22 January 2026.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 1.00 pm (BST) on 22 January 2026 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponen",
          "content_length": 7328
        },
        "ingested_at": "2026-01-21T21:55:41.544373Z"
      },
      {
        "event_id": "SOCIAL-27Nov20250936-Servalan--2470526",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.488314",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "September Rx for NHS England: $148,048 (\u00a3104,192 Sep '24  42% increase)",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "9.10",
          "thread_title": "September Rx England out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=F93322F3-71D7-426D-ABA4-760332C4138E"
        },
        "ingested_at": "2026-01-22T21:34:30.500363+00:00"
      },
      {
        "event_id": "SOCIAL-27Nov20251609-StMartin--7610146",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.487900",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "Cannot believe FOMO  have not arrived yet.",
          "sentiment": 0.0,
          "engagement": "928",
          "price_at_post": "9.25",
          "thread_title": "RE: Amazing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E94673FB-B8B2-46A8-A987-C7C1BD3EC282"
        },
        "ingested_at": "2026-01-22T21:34:30.500345+00:00"
      },
      {
        "event_id": "SOCIAL-27Nov20252256-PRO_TRAD-31908549",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.487491",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "They are not going to make any bid now, i suspect should come around 30p - 40p depending how fast the share price will climb. Holding here more than 3 years and will continue to do so, this is a multibagger, keep it for your retirement.",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "9.30",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-22T21:34:30.500327+00:00"
      },
      {
        "event_id": "SOCIAL-28Nov20251211-Pharmhal--8335436",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.487076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pharmhall",
          "content": "IMHO, I don't think AOP would want it, not their remit to own and run companies. Much more likely to be a pharma (probably generic) company , but this would only likely happen when there is clear evidence of sales traction (next two quarters should start give comfort) and that product has become profitable (Shield, as a whole, expected to reach cashflow break-even by end of this quarter). Meanwhile, it is the Rx growth coupled with higher prices (lower discounts), increased likelihood of hitting EDITDA breakeven, recent progress of ACCRUFeR/Feraccru in non-US territories and the recent voluntary share subscription reducing chance of a cash call further that are driving the share price movement. Cavendish has a current target of 23p and even getting 70% of the way there would be great.",
          "sentiment": 0.0,
          "engagement": "335",
          "price_at_post": "10.15",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-22T21:34:30.500310+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251232-Beevorma--2778828",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.486662",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "The dilution from 250m to 10pm since I first invested has been a hard pill to swallow, but I\u2019m now halfway to b/e after a top up at 7p, so feeling a tad more optimistic",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-22T21:34:30.500292+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251532-StMartin--1180578",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.486254",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "AOP  do not have the Capacity to buy STX  nor the inclination reading the RNS`s for last 2 years. At same time Viatris do seem to have the Cash and Motivation. This next 10  -15  Days will prove very interesting.  USA  Food & Drug Administration  (FDA)  May the the Cat amongst the Pigeons.  Ferric Malton is said to be able to grab 90%  USA  share and BIG  USA Pharma  are TERRIFIED Viatris are under considerable pressure from Investors who are livid at recent losses. STX  Looks like a Winner,  early Christmas Present ??",
          "sentiment": 0.0,
          "engagement": "928",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-22T21:34:30.500274+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251741-StMartin--8309751",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.485818",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "Viataris are still in bother with FDA  after  importing unknown Medications from their Indian Partner, without Permission or consultation.",
          "sentiment": 0.0,
          "engagement": "928",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-22T21:34:30.500256+00:00"
      },
      {
        "event_id": "SOCIAL-30Nov20252121-quelfrom-69865176",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.485414",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "I meant trading update ...",
          "sentiment": 0.0,
          "engagement": "1,161",
          "price_at_post": "9.90",
          "thread_title": "RE: Amazing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E94673FB-B8B2-46A8-A987-C7C1BD3EC282"
        },
        "ingested_at": "2026-01-22T21:34:30.500239+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251302-sitiain-38637077",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.484989",
        "source": "LSE_CHAT",
        "data": {
          "author": "sitiain",
          "content": "U.S. and UK To Agree To Zero Tariffs On Pharmaceuticals, Announcement Expected At White House Today - Reuters. $XBI",
          "sentiment": 0.0,
          "engagement": "313",
          "price_at_post": "9.85",
          "thread_title": "Might help a bit  ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BC0112A0-5AF8-4F7E-A4A4-D27A4D8D4560"
        },
        "ingested_at": "2026-01-22T21:34:30.500220+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251417-BenBacco-60405591",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.484579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BenBaccon",
          "content": ".",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.20",
          "thread_title": "10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-22T21:34:30.500202+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251905-StMartin--8702543",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.484165",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "This is a deal unfolding and quite Quickly.   I expect an RNS to that effect Soon",
          "sentiment": 0.0,
          "engagement": "928",
          "price_at_post": "11.20",
          "thread_title": "A Deal  unfolding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BABB434C-D4DC-4186-9507-CF3ED1F2318C"
        },
        "ingested_at": "2026-01-22T21:34:30.500184+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-BioTechI--5363963",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.483732",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "These AIM stocks are so leaky! It's wild how much they move with no published data.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.20",
          "thread_title": "RE: A Deal  unfolding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BABB434C-D4DC-4186-9507-CF3ED1F2318C"
        },
        "ingested_at": "2026-01-22T21:34:30.500166+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20252248-PRO_TRAD-29672887",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.483327",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Very big mistake if you get rid of it now, it will be 30p by next year!",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "11.20",
          "thread_title": "RE: 10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-22T21:34:30.500147+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251120-Beevorma-67439513",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.482906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Calm down P_T LOL",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.35",
          "thread_title": "RE: 10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-22T21:34:30.500129+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa-41176835",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.482499",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,296",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.500094+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala-63370774",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.482065",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.500077+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--1031620",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.481648",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-01-22T21:34:30.500059+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa-46672228",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.481237",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,296",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.500041+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--2151359",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.480807",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.500023+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa--5933318",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.480397",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,296",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.500005+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--2546293",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.479966",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499987+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD--6008230",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.479551",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499969+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--8803022",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.479137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499952+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-72238523",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.478704",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499934+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD--3220183",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:30.478265",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499916+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI-40110021",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.524675",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499898+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-58108291",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.524268",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499880+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD-20280233",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.523841",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499862+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI-11156295",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.523431",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499845+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--6741605",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.523009",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499827+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen--7456600",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.522597",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499808+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD-49488689",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.522184",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499787+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--5843356",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.521767",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-22T21:34:30.499769+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma-41180253",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.521346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-01-22T21:34:30.499751+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi--4752655",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.520929",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-22T21:34:30.499733+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma--8285172",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.520520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-22T21:34:30.499715+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala-28056595",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.520112",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-22T21:34:30.499697+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie-72565960",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.519689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "534",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-22T21:34:30.499679+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut-88650641",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.519272",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-22T21:34:30.499660+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall-48748736",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.518851",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-22T21:34:30.499642+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-70345878",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.518443",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-22T21:34:30.499624+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall-48329860",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.518023",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-22T21:34:30.499606+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-12014143",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.517612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-01-22T21:34:30.499588+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-71070833",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.517197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-22T21:34:30.499570+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--5241387",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.516776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-22T21:34:30.499552+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--5493180",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.516354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-22T21:34:30.499533+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5-70457425",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.515928",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-22T21:34:30.499515+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall--3051363",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.515512",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-22T21:34:30.499497+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI-75970271",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.515063",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-22T21:34:30.499479+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter--5204185",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:25.514626",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-22T21:34:30.499460+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall-63211812",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.612640",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-22T21:34:30.499442+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan--2299627",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.612224",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-22T21:34:30.499423+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut-53598228",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.611807",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-01-22T21:34:30.499405+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--4277712",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.611398",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499387+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu-69980762",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.610981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499368+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-87342940",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.610567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-22T21:34:30.499350+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-85492851",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.610128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499332+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160-36697451",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.609711",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499313+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB-49142367",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.609301",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499294+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-63660867",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.608876",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499277+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan--2084556",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.608463",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "109",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499259+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5-10193803",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.608041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-22T21:34:30.499242+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu--2411142",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.607622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499224+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea-91153397",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.607205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499206+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160--3620498",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.606787",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499188+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen-58960322",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.606372",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-22T21:34:30.499170+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra-65629235",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.605939",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-22T21:34:30.499152+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160--4931681",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.605528",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-22T21:34:30.499133+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--3419412",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.605090",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499109+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle-30935918",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.604675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-22T21:34:30.499079+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-Servalan--6509171",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.604247",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-22T21:34:30.499060+00:00"
      },
      {
        "event_id": "SOCIAL-Today1505-Tiddlero-76665860",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.603817",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-22T21:34:30.499043+00:00"
      },
      {
        "event_id": "SOCIAL-Today1612-Billy-Bu--4055721",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.603394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-22T21:34:30.499024+00:00"
      },
      {
        "event_id": "SOCIAL-Today1626-smythsmo--6730955",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.602941",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-22T21:34:30.498993+00:00"
      },
      {
        "event_id": "SOCIAL-Today2044-Servalan--1183319",
        "event_type": "social_post",
        "date": "2026-01-22T21:34:22.602501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "109",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-22T21:34:30.498956+00:00"
      },
      {
        "event_id": "SOCIAL-19Oct20251250-ARH619-64655054",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.903436",
        "source": "LSE_CHAT",
        "data": {
          "author": "ARH619",
          "content": "Looking forward to Q3 this week. Wayyyy to quiet on this board\u2026.",
          "sentiment": 0.5,
          "engagement": "1",
          "price_at_post": "7.60",
          "thread_title": "Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918240+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20250743-Brightst--9155576",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.903022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brightstone",
          "content": "Those are very disappointing growth numbers. $13.1M Q3 net revenue vs $12.8m Q2.",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918222+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20250746-quelfrom--6536996",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.902610",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Nearly double Vs Q3 2024",
          "sentiment": 0.0,
          "engagement": "1,161",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918204+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20250833-Ak247--4407402",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.902205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "I think the numbers are quite reasonable. We are on  track to get cash positive by the end of the year and the biggest approval yet to come in the us in 2026. That approval alone could double our sp",
          "sentiment": 0.5,
          "engagement": "390",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918186+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20251019-shandypa--4338712",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.901785",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "I agree AK, these seem ok, and reiterating YE breakeven only c 2 months before YE is a massive vote of confidence. I would focus less on revenue as this seems fluctuate a little - QoQ prescriptions are up c15% (47k to 54K) and NSP has slightly increased too.  So the direction of travel is positive. The free/cheap prescriptions are still stubbornly high at 22% but less than Q2 (thought this would be less than 10% by now as they have been selling accrufer for c 3 years). The other big takeaway is cash burn - they have $8.6m left so cash burn in period was c$4m as they also had the \u00a31.5m placing added. With prescriptions growing revenues should continue to increase so cash burn per month continues to fall. I've always had a 25k per month prescription figure in my head for breakeven based on some basic calculations, however, with the cost savings they supposedly implemented this could be maybe 10% lower now.  So IMHO they need c$6m rev to generate $3m gross profit to cover costs. They mentioned 40% of revenues came in Sept 2025 so that's $5.2m if this continues into October and November then the $6m is very achievable. In fact i suspect they may achieve it in October and then it may settle back a little as Nov is thankgiving and Dec is Christmas.",
          "sentiment": 0.0,
          "engagement": "3,295",
          "price_at_post": "7.35",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918168+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20251133-PRO_TRAD--4403709",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.901350",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "About what dissapointing figures are you talking? Net revenues of $13.1m coupled with 54,000 total prescriptions compared to  Net revenues of $7.2m coupled with 44,000 prescriptions respectively in Q3 2024. We are talking about huge increase in revenues, does this looks bad to you?",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "7.35",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918150+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20251343-Servalan-55163161",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.900927",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Fantastic update, but watch the smooth brains sell into a tiny rise on the back of it. This would not be under 8p (11c?) if it was US listed. UK stock market is a joke.",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "7.70",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T21:55:55.918132+00:00"
      },
      {
        "event_id": "SOCIAL-23Oct20252237-Duncan78--3215134",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.900518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Hi im very much new to sticks and have been watching from the sidelines. STX is interesting but looks like there has been a lot of sales which concerns. Any idea why?",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "7.70",
          "thread_title": "New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918112+00:00"
      },
      {
        "event_id": "SOCIAL-24Oct20250929-Ak247-59418143",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.900092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "To be honest with you, I cannot tell you the reason for the sells, we seem to be stuck between 7-8.5. If we do get cash positive by the end of the year then I imagine it moving north and once we get the permission to sell this to infants and toddlers and so on, i expect really big jumps north but patience is required. I am not sure if we have the permission in other countries as well so applications there would have to be applied as well and then finally I think we can expect a bid from the big boys",
          "sentiment": 0.5,
          "engagement": "390",
          "price_at_post": "7.55",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918082+00:00"
      },
      {
        "event_id": "SOCIAL-24Oct20250937-brafty--6412663",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.899681",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "I THINK IT WILL BE BOUGHT OUT BETWEEN 20 - 30 P JUST AS IT GETS GOING , HOPEFULLY NOT AS IM HAPPY TO RIDE THIS WAVE TO THE TOP .",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "7.45",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918065+00:00"
      },
      {
        "event_id": "SOCIAL-24Oct20251349-Duncan78-59214813",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.899274",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Thanks @brafty @ak247",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918047+00:00"
      },
      {
        "event_id": "SOCIAL-24Oct20251826-PRO_TRAD-49746678",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.898850",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Absolutely 100%  will be taken over by the AOP but not now, i suspect in a couple of years time once they will be well in profit, depending where the share price will be at that time, I am estimating as well around 30p how I see things going.",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918029+00:00"
      },
      {
        "event_id": "SOCIAL-25Oct20250755-MrBB-46139541",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.898446",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "Agree that it looks logical for AOP to buy us but if that\u2019s their plan & they have detailed insider discussions with Anders & Santos ,why would they not do it now at ,say 10-15p-they own over 50% of the stock ,we are very close to cashflow breakeven ,if not already achieved ,paediatric study results expected positive ,S Korea approval imminent with Japan & China to follow -so why wait & pay double (or more) in a few months time . I think buying would be a last resort & they hope for a trade sale to the ultimate owner & for 30p+ giving them an excellent return on investment & without  managing STX as an operating subsidiary .Either way ,we PIs should do reasonably well \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.918011+00:00"
      },
      {
        "event_id": "SOCIAL-25Oct20251809-PRO_TRAD--3318340",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.898022",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "They don't do it now because is not of any interest to them at this price. They will wait when the company will be well in profit  and then they will make a bid. In that way it will cost them almost nothing despite the fact they will buy the remaining shares at a higher price. Once the company will be well profitable they know very well that the takeover cost will be well covered by the profits over the next 1-3 years.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T21:55:55.917993+00:00"
      },
      {
        "event_id": "SOCIAL-27Oct20250934-Servalan--1896821",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.897618",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "FDA approved, growing sales in many markets, very close to profitability and now back under 7p. This is why the UK stock market is effed. Tiny brains who can't hold a stock more than 5 minutes.",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "6.90",
          "thread_title": "W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T21:55:55.917975+00:00"
      },
      {
        "event_id": "SOCIAL-27Oct20251131-shandypa-13491850",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.897214",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "I would ignore the many markets as the only significant revenues are in the US. Feraccru has been sold in the UK for over 5 years , yet revenues remain very low. As the NHS in England is not one single organisation, but is made up of hundreds of different organisations of differing sizes, at central, national, regional, and local levels with different roles and responsibilities it means approval for the product varies across the country. My doctor can't prescribe it (in Kent) as an example. Having said that with breakeven a massive milestone for STX and this was only reconfirmed last week the SP action seems bizarre. I think there may be a few reasons for this. Firstly, STX has missed so many deadlines/milestones before that investors will wait and see. Secondly the breakeven will almost certainly be a followed by a dip as Q1 is always the worst quarter. So it will not be a straight line - get to breakeven and then profits will suddenly materialise. However, based on 54k quarterly prescriptions the product is now selling over 200k units a year, which is an amazing achievement and will get people noticing - it is now the highest selling iron supplement, i believe. In the recent Investor Meets presentation the CFO seemed very relaxed with the money so that's a good sign. I asked about the IV infusion market as this is a natural complementary area for accrufer (have IV infusion to boost short term irn levels and then accrufer to maintain those levels and prevent repeat costly hospital appointments . It appears they have struggled to access this so have focused on easier areas (women's health etc) however this is a massive market and one they will revisit.",
          "sentiment": 0.0,
          "engagement": "3,295",
          "price_at_post": "6.95",
          "thread_title": "RE: W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T21:55:55.917958+00:00"
      },
      {
        "event_id": "SOCIAL-27Oct20251136-PRO_TRAD--4264937",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.896761",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Undoubtedly this is massively undervalued. It seems the reason is going down again which it should not is due to the mentioned small number of complaints in regards to the drug which actually are negligible compared to the sales figures. You can take a pain killer and you can have a side effect, so this is not a reason for the share price to drop.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.95",
          "thread_title": "RE: W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T21:55:55.917940+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251445-Ak247--3570758",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.896353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "I think the drop is that people don\u2019t believe they will achieve their target by the end of the year.  It will double up when they get the approvals next yr which is almost guaranteed. I think the issue is being on lse. People just hold shares in this country. Personally I have said it a few times and I will say it again. Bod should make some noise and sell the company",
          "sentiment": 0.0,
          "engagement": "390",
          "price_at_post": "6.45",
          "thread_title": "Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T21:55:55.917922+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251528-Tired@Co--1517753",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.895935",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tired@Confused",
          "content": "It take bo11ocks to sit it out which is obviously in short supply with some investors. Personally, I think there is a news vacuum and as such selling in more about keeping some of the profit made rather than accepting the volatility in the short term in hopes of a bigger gain further down the road. AIMHO and DYOR, and good luck all",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "6.40",
          "thread_title": "RE: Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T21:55:55.917904+00:00"
      },
      {
        "event_id": "SOCIAL-28Oct20251640-Servalan-73377726",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.895518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Completely agree they should get it sold. They will never see anything like fair value staying in the UK. Plenty of US biotechs in the same boat - an FDA approved drug for ffs with growing sales and not yet profitable would be valued at least 10 times Shield. Small minds and small wallets in the UK.",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "6.40",
          "thread_title": "RE: Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T21:55:55.917886+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251136-busicat-66738949",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.895110",
        "source": "LSE_CHAT",
        "data": {
          "author": "busicat",
          "content": "Buying seems solid this morning",
          "sentiment": 0.0,
          "engagement": "892",
          "price_at_post": "6.75",
          "thread_title": "Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T21:55:55.917868+00:00"
      },
      {
        "event_id": "SOCIAL-29Oct20251603-gggg21--6410507",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.894690",
        "source": "LSE_CHAT",
        "data": {
          "author": "gggg21",
          "content": "Delayed 51k buy at 6.99. Looking better. Pull back was over done.",
          "sentiment": 0.0,
          "engagement": "10,115",
          "price_at_post": "6.85",
          "thread_title": "RE: Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T21:55:55.917850+00:00"
      },
      {
        "event_id": "SOCIAL-30Oct20251021-Mokomagi-84442649",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.894272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Analyst Price: Target Revision Analysts have maintained their price target for Shield Therapeutics at \u00a30.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.80",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BD5CAD31-040C-4BBD-AC19-70D1D2579FEC"
        },
        "ingested_at": "2026-01-21T21:55:55.917832+00:00"
      },
      {
        "event_id": "SOCIAL-3Nov20251932-gggg21-31449688",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.893807",
        "source": "LSE_CHAT",
        "data": {
          "author": "gggg21",
          "content": "See another decent sized buy popped up after hours at 7.05. Just over 1m shares for 76k. Was some steady block buying today.",
          "sentiment": 0.0,
          "engagement": "10,115",
          "price_at_post": "7.05",
          "thread_title": "RE: Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T21:55:55.917814+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20250817-brafty-77760669",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:55.893378",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Great News ! ACCRUFeR\u00ae receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS)",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "6.95",
          "thread_title": "Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T21:55:55.917796+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20250836-MrBB--3879495",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.101293",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "$1.9m milestone on first sale -which should be within 4 or 5 months -or maybe sooner if their launch plans are in place & we supply their Accrufer so no supply problems anticipated -great news for what should be a material market for us",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T21:55:55.917778+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20251314-Servalan--1140729",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.100874",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Excellent news, another market  secured, 52 million population and this can barely lift 1.5%. The UK biotech market is like a brian dead zombie. Even if they found a cure for all cancer, AIDS and instant weight loss this market would shrug its shoulders and probably sell off too.",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T21:55:55.917761+00:00"
      },
      {
        "event_id": "SOCIAL-7Nov20251638-nice1--8627787",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.100470",
        "source": "LSE_CHAT",
        "data": {
          "author": "nice1",
          "content": "Great to see another milestone, this will do very well and in 6 months time the share price should be higher all going well and the market wakes up. Medpal Ai Plc RNS out today, worth a read. a bit of information as below,  they will start earning a bit of revenue. MedPal.clinic is now operational and actively offering: AI-powered consultations (free to users) Private prescriptions for weight-loss medications (GLP-1 agonists like Wegovy and Ozempic) Same-day/next-day delivery via their automated pharmacy in Swaffham. Prescription sales are the primary revenue stream. With private prescriptions costing \u00a3150\u2013\u00a3200/month per patient, even a modest uptake could generate substantial income. The company is targeting a \u00a3500 million/month addressable market in the UK weight-loss sector alone.",
          "sentiment": 0.0,
          "engagement": "977",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=015AD3C0-507C-4E6C-8B64-BFC0CAB4669D"
        },
        "ingested_at": "2026-01-21T21:55:55.917743+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251359-Duncan78--5907381",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.100013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "So o bought into sheild a few weeks ago the sp seems to be stagnate between 6-7p even with good news with Korean authorisation, and positive company announcements. What seems to be holding this back as all looks positive. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.85",
          "thread_title": "New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917725+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251523-brafty-41115840",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.099596",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Since Anders Lundstrom the new CEO took over they have had significant growth to date climbed from a 52-week low of 2.1p to a recent high of 9.4p . The management team experience have proven this in results over the last year , they know what they are doing and have grown shield in different areas of the globe . Next year the assumption on wider adoption and breakeven will defiantly be factors in the rise of the share price and more confidence in once a failing stock from the pervious bad management  . hopefully no banana skins next year .",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "6.85",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917707+00:00"
      },
      {
        "event_id": "SOCIAL-11Nov20251755-Duncan78--4546210",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.099185",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Thanks hopefully a positive new year",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.85",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917689+00:00"
      },
      {
        "event_id": "SOCIAL-14Nov20250753-smythsmo--7696200",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.098765",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "No more fund raises we were told but we had a defacto one 2 months ago. I really do hope breakeven by 2025 year end is not a pipe dream. Most companies are economical with the truth, is Sheild therapeutic any different? NO they ain't.",
          "sentiment": 0.0,
          "engagement": "264",
          "price_at_post": "7.15",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917671+00:00"
      },
      {
        "event_id": "SOCIAL-15Nov20252115-Servalan-40737229",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.098350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It's British, it's a biotech, it's on AIM. There's 3 good reasons why we are languishing at 6.5p. If this was listed anywhere else it would be flying. Once you've held for a long time you'll get used to the constant disappointment in sp performance. Kicking myself i didn't sell at the last spike.",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "6.75",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917653+00:00"
      },
      {
        "event_id": "SOCIAL-17Nov20251554-Duncan78--1098117",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.097921",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "How long have you been holding this share in came in earlier this year but seems to be pretty stagnate. I was hoing 2026 would be better",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.75",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T21:55:55.917636+00:00"
      },
      {
        "event_id": "SOCIAL-19Nov20250959-Mokomagi-17395348",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.097512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "To be honest, I think all shareholders will be waiting for the announcement in Jan 2026 to confirm that STX has become cashflow positive. I am no expert but am a long term holder of STX and based on recent announcements re new business and milestone payments due to STX under new agreements agreed, then in my humble opinion I do see that this will be the case based on the last 12 months performance and the final quarterly figures due to announced Jan 2026 for their financial year.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.65",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T21:55:55.917618+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251010-Emerald5-90819497",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.097091",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Why the rise today. What has changed?",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "7.50",
          "thread_title": "Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917600+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251030-Scarfell-73554034",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.096682",
        "source": "LSE_CHAT",
        "data": {
          "author": "Scarfell",
          "content": "No idea - but it's a volatile share that was at this level 4 weeks ago.",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917582+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251036-1nspecto--9010499",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.096272",
        "source": "LSE_CHAT",
        "data": {
          "author": "1nspectorGadget",
          "content": "Article by Motel Tool yesterday https://www.fool.co.uk/2025/11/23/at-6-6p-could-this-fast-growing-penny-stock-be-a-millionaire-maker/ It'll settle back down in a few days",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917564+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251055-chedders--7620825",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.095850",
        "source": "LSE_CHAT",
        "data": {
          "author": "chedders74",
          "content": "Motley Fool article",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917545+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251119-MatBlack-30507327",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.095440",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "And as usual with MF the article is incorrect. Accufer for pulmonary hypertension? Since when",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917527+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251121-MatBlack-51544228",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.095017",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "Correction - pulmonary arterial hypertension.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917508+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251136-smythsmo-65691162",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.094606",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "If you read the RNS's it might be help you to understand a lot more about Sheild, London, UK, 14 November 2025 Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, today announced that its partner, MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc. has initiated a Phase II clinical trial for ACCRUFER\u00ae (ferric maltol), a new drug candidate for Pulmonary Arterial Hypertension (PAH), for patients in Japan. This trial is an exploratory study to support a Phase III trial and follows confirmation by the Pharmaceuticals and Medical Devices Agency (PMDA) of the development plan for the drug as a PAH treatment in Japan, based on previous clinical results in Europe, UK and USA.",
          "sentiment": 0.0,
          "engagement": "264",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917490+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251323-MatBlack-56174189",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.094181",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "Thank you. Coincidentally if I hadn't been in Japan at the time I might have read it. Not sure why MF didn't mention its existing use.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T21:55:55.917472+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251608-Beevorma--7017770",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.093763",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Jan 26 would be nice. Does anyone know the exact holding AOP has now, got to be close to a controlling interest (50%)?",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "7.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T21:55:55.917454+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251752-Time2Buy--4824277",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.093349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Time2Buy",
          "content": "Well that's interesting https://uk.finance.yahoo.com/news/6-6p-could-fast-growing-090000906.html",
          "sentiment": 0.5,
          "engagement": "10,147",
          "price_at_post": "7.60",
          "thread_title": "How to become a millionaire",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=5DFE5196-E62E-48BD-90CF-2D08D3D36A00"
        },
        "ingested_at": "2026-01-21T21:55:55.917436+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20252112-simonlev-42739740",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.092924",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "AOP own 53.6% of 1,060,000,000 shares in issue (568,000,000 shares) and are the major lender to the company https://www.investing.com/news/company-news/shield-therapeutics-seeks-10m-through-share-subscription-93CH-3758762",
          "sentiment": 0.5,
          "engagement": "57",
          "price_at_post": "7.60",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T21:55:55.917418+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251004-StMartin-48529609",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.092504",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "It is starting to look as though AOP  will purchase STX,  at some point.",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "8.00",
          "thread_title": "AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917401+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251043-Mokomagi--2726080",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.092080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Just doing some quick maths and looking back over the last three quarters revenue totalled $32.3 million US Dollars, if the upward trajectory continues in the Q4 say $14.00 million US dollars $900,000 above Q3's numbers then total revenue would be looking at $46.3 million US Dollars for 2025. This purely based on sales revenue alone.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "8.00",
          "thread_title": "Annual Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=CEE7EDE3-860B-4A9A-8892-E2B34AB16829"
        },
        "ingested_at": "2026-01-21T21:55:55.917383+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251046-Beevorma--4768867",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.091663",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hopefully not before we see some SP recovery, my avg is still over 19p",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "8.00",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917365+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251058-StMartin-17938450",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:53.091226",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "AOP  hold such a large %    Any bid is Tax Efficient.  30-35p  likely.",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "8.05",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917348+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251117-MrBB--1300251",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.525827",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "More likely that AOP will seek an agreed takeover at ,hopefully ,a much higher price ,rather than take 100% ownership with view to disposing in a year .Had they wanted 100> surely they would have done so earlier this year when they could have taken us out at 4-5p as opposed to 10-12p now -if that really is their agenda ?",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "8.15",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917330+00:00"
      },
      {
        "event_id": "SOCIAL-26Nov20251002-quelfrom--9100551",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.525420",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Back to break even bar a few quid ... Roll on results",
          "sentiment": 0.0,
          "engagement": "1,161",
          "price_at_post": "8.95",
          "thread_title": "Amazing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E94673FB-B8B2-46A8-A987-C7C1BD3EC282"
        },
        "ingested_at": "2026-01-21T21:55:55.917311+00:00"
      },
      {
        "event_id": "SOCIAL-26Nov20251145-Duncan78--4585986",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.525004",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Excuse my nievity can you tell if a unknown trade is a buy or sell ? How are they unknown does the trade not need to be clear? Thanks in advance",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "8.95",
          "thread_title": "Unknown trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=EF628BE6-BDC4-4592-A287-C27190455AE4"
        },
        "ingested_at": "2026-01-21T21:55:55.917293+00:00"
      },
      {
        "event_id": "SOCIAL-26Nov20251222-TheMilli--2777486",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.524588",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheMillipede824",
          "content": "It is worse than that Duncan. The stock exchange doesn\u2019t tell us whether ANY trade is a buy or sell. The buy/sell tags on here, and other sites, are inferred from the spread. Which could be wrong.",
          "sentiment": 0.0,
          "engagement": "35",
          "price_at_post": "8.95",
          "thread_title": "RE: Unknown trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=EF628BE6-BDC4-4592-A287-C27190455AE4"
        },
        "ingested_at": "2026-01-21T21:55:55.917276+00:00"
      },
      {
        "event_id": "SOCIAL-26Nov20251226-Duncan78--6573441",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.524172",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Ah I see thanks",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "8.95",
          "thread_title": "RE: Unknown trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=EF628BE6-BDC4-4592-A287-C27190455AE4"
        },
        "ingested_at": "2026-01-21T21:55:55.917258+00:00"
      },
      {
        "event_id": "SOCIAL-27Nov20250936-Servalan-84477641",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.523752",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "September Rx for NHS England: $148,048 (\u00a3104,192 Sep '24  42% increase)",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "9.10",
          "thread_title": "September Rx England out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=F93322F3-71D7-426D-ABA4-760332C4138E"
        },
        "ingested_at": "2026-01-21T21:55:55.917240+00:00"
      },
      {
        "event_id": "SOCIAL-27Nov20251609-StMartin-52847936",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.523344",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "Cannot believe FOMO  have not arrived yet.",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "9.25",
          "thread_title": "RE: Amazing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E94673FB-B8B2-46A8-A987-C7C1BD3EC282"
        },
        "ingested_at": "2026-01-21T21:55:55.917223+00:00"
      },
      {
        "event_id": "SOCIAL-27Nov20252256-PRO_TRAD-29507426",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.522926",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "They are not going to make any bid now, i suspect should come around 30p - 40p depending how fast the share price will climb. Holding here more than 3 years and will continue to do so, this is a multibagger, keep it for your retirement.",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "9.30",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917205+00:00"
      },
      {
        "event_id": "SOCIAL-28Nov20251211-Pharmhal--7427432",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.522515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pharmhall",
          "content": "IMHO, I don't think AOP would want it, not their remit to own and run companies. Much more likely to be a pharma (probably generic) company , but this would only likely happen when there is clear evidence of sales traction (next two quarters should start give comfort) and that product has become profitable (Shield, as a whole, expected to reach cashflow break-even by end of this quarter). Meanwhile, it is the Rx growth coupled with higher prices (lower discounts), increased likelihood of hitting EDITDA breakeven, recent progress of ACCRUFeR/Feraccru in non-US territories and the recent voluntary share subscription reducing chance of a cash call further that are driving the share price movement. Cavendish has a current target of 23p and even getting 70% of the way there would be great.",
          "sentiment": 0.0,
          "engagement": "332",
          "price_at_post": "10.15",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917187+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251232-Beevorma-52400281",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.522092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "The dilution from 250m to 10pm since I first invested has been a hard pill to swallow, but I\u2019m now halfway to b/e after a top up at 7p, so feeling a tad more optimistic",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917169+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251532-StMartin--4397921",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.521683",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "AOP  do not have the Capacity to buy STX  nor the inclination reading the RNS`s for last 2 years. At same time Viatris do seem to have the Cash and Motivation. This next 10  -15  Days will prove very interesting.  USA  Food & Drug Administration  (FDA)  May the the Cat amongst the Pigeons.  Ferric Malton is said to be able to grab 90%  USA  share and BIG  USA Pharma  are TERRIFIED Viatris are under considerable pressure from Investors who are livid at recent losses. STX  Looks like a Winner,  early Christmas Present ??",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917151+00:00"
      },
      {
        "event_id": "SOCIAL-29Nov20251741-StMartin-49427612",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.521255",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "Viataris are still in bother with FDA  after  importing unknown Medications from their Indian Partner, without Permission or consultation.",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "9.90",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T21:55:55.917133+00:00"
      },
      {
        "event_id": "SOCIAL-30Nov20252121-quelfrom-43033367",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.520841",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "I meant trading update ...",
          "sentiment": 0.0,
          "engagement": "1,161",
          "price_at_post": "9.90",
          "thread_title": "RE: Amazing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E94673FB-B8B2-46A8-A987-C7C1BD3EC282"
        },
        "ingested_at": "2026-01-21T21:55:55.917094+00:00"
      },
      {
        "event_id": "SOCIAL-1Dec20251302-sitiain-66330692",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.520432",
        "source": "LSE_CHAT",
        "data": {
          "author": "sitiain",
          "content": "U.S. and UK To Agree To Zero Tariffs On Pharmaceuticals, Announcement Expected At White House Today - Reuters. $XBI",
          "sentiment": 0.0,
          "engagement": "313",
          "price_at_post": "9.85",
          "thread_title": "Might help a bit  ?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BC0112A0-5AF8-4F7E-A4A4-D27A4D8D4560"
        },
        "ingested_at": "2026-01-21T21:55:55.917075+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251417-BenBacco-46858345",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.520015",
        "source": "LSE_CHAT",
        "data": {
          "author": "BenBaccon",
          "content": ".",
          "sentiment": 0.0,
          "engagement": "20",
          "price_at_post": "10.20",
          "thread_title": "10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-21T21:55:55.917057+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251905-StMartin--6312142",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.519609",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "This is a deal unfolding and quite Quickly.   I expect an RNS to that effect Soon",
          "sentiment": 0.0,
          "engagement": "925",
          "price_at_post": "11.20",
          "thread_title": "A Deal  unfolding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BABB434C-D4DC-4186-9507-CF3ED1F2318C"
        },
        "ingested_at": "2026-01-21T21:55:55.917039+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251945-BioTechI-27745922",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.519200",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "These AIM stocks are so leaky! It's wild how much they move with no published data.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.20",
          "thread_title": "RE: A Deal  unfolding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BABB434C-D4DC-4186-9507-CF3ED1F2318C"
        },
        "ingested_at": "2026-01-21T21:55:55.917021+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20252248-PRO_TRAD--8579456",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.518786",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Very big mistake if you get rid of it now, it will be 30p by next year!",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "11.20",
          "thread_title": "RE: 10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-21T21:55:55.917004+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251120-Beevorma-24593762",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.518376",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Calm down P_T LOL",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.35",
          "thread_title": "RE: 10p goes bye bye",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=957463B2-BCBD-4F79-987F-6A8EE326B38A"
        },
        "ingested_at": "2026-01-21T21:55:55.916986+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa--8178457",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.517957",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,295",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916967+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala--3728517",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.517528",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916949+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--8067333",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.517095",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-01-21T21:55:55.916931+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa--4550117",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.516613",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,295",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916913+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--3642070",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.516189",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916895+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa--6569443",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:50.515743",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,295",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916877+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI-64490114",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:48.001714",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916859+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD--2763376",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:48.001300",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916840+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD-82515963",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:48.000874",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916822+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-90298363",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:48.000467",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916804+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD-52004048",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:48.000040",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916786+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI-71119417",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.999618",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916768+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-70425571",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.999210",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916750+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD-11025135",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.998786",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916732+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI--5967055",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.998373",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916714+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD-39859804",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.997949",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916695+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen--2344025",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.997541",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916677+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--6074973",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.997130",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916659+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma-82566725",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.996713",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T21:55:55.916641+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma--1171827",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.996291",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-01-21T21:55:55.916623+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi-90266472",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.995806",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T21:55:55.916606+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma-25997703",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.995400",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T21:55:55.916587+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala-24003237",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.994977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-21T21:55:55.916569+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie-26351366",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.994566",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "534",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-21T21:55:55.916552+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut-37160631",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.994146",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T21:55:55.916534+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall-28238186",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.993723",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T21:55:55.916516+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty--1812534",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.993298",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T21:55:55.916497+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall--1912461",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.992867",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T21:55:55.916479+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin--1983387",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.992452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-01-21T21:55:55.916461+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-82167084",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.992015",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T21:55:55.916443+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--4017844",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:47.991453",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "166",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T21:55:55.916424+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--3248038",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.046932",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T21:55:55.916406+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5--1258584",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.046526",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-21T21:55:55.916389+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall-90704977",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.046118",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-21T21:55:55.916371+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI-30460305",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.045705",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T21:55:55.916353+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter-55706502",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.045295",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T21:55:55.916334+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--2345502",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.044866",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T21:55:55.916316+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan--7789929",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.044453",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T21:55:55.916298+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut-18288451",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.044034",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-01-21T21:55:55.916280+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi-91144876",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.043628",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916258+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu--4367537",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.043219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "373",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916240+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-71565237",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.042793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-21T21:55:55.916222+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-37658308",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.042362",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916204+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160-73871388",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.041947",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916186+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--7017279",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.041543",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916169+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma--5283233",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.041137",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916151+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan--2412449",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.040721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "105",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916133+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5-41434602",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.040308",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-21T21:55:55.916094+00:00"
      },
      {
        "event_id": "SOCIAL-Today0730-Billy-Bu--7763109",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.039878",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "373",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916076+00:00"
      },
      {
        "event_id": "SOCIAL-Today0736-Crazyyea--8668593",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.039465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916058+00:00"
      },
      {
        "event_id": "SOCIAL-Today0741-rich160--6281773",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.039045",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.916040+00:00"
      },
      {
        "event_id": "SOCIAL-Today0819-MoneyPen-14465632",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.038641",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-21T21:55:55.916022+00:00"
      },
      {
        "event_id": "SOCIAL-Today0833-CrudeTra-65443803",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.038231",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-21T21:55:55.916001+00:00"
      },
      {
        "event_id": "SOCIAL-Today0845-rich160-45241538",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.037811",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "199",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-21T21:55:55.915967+00:00"
      },
      {
        "event_id": "SOCIAL-Today0923-Servalan--4656234",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.037383",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "105",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.915948+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Andle-76335663",
        "event_type": "social_post",
        "date": "2026-01-21T21:55:45.036939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T21:55:55.915926+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--8417727",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.431888",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T02:13:21.560975Z"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen-68474221",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.431472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T02:13:21.560948Z"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--4281704",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.431047",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T02:13:21.560921Z"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--7584762",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.430636",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-21T02:13:21.560893Z"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma--1771479",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.430208",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-01-21T02:13:21.560867Z"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi--1327721",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.429786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T02:13:21.560840Z"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma--8935068",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.429368",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T02:13:21.560812Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala--7886974",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:06.428919",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-21T02:13:21.560785Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--6059815",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.459042",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "534",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-21T02:13:21.560758Z"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut--7023066",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.458629",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,335",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-21T02:13:21.560730Z"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall--7427375",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.458222",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T02:13:21.560703Z"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-25515825",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.457800",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T02:13:21.560676Z"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall-63360714",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.457394",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-21T02:13:21.560650Z"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-50431500",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.456970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-01-21T02:13:21.560623Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-68151450",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.456562",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "390",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T02:13:21.560596Z"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--1110151",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.456152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "166",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T02:13:21.560569Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan-66682329",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.455733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "104",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-21T02:13:21.560543Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5--4948966",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.455323",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-21T02:13:21.560516Z"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall--8413522",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.454898",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-21T02:13:21.560487Z"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI-26060473",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.454483",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T02:13:21.560459Z"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter-76255754",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.454062",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T02:13:21.560432Z"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall-17817867",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.453641",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T02:13:21.560405Z"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan-67163607",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.453195",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "104",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-21T02:13:21.560378Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut--6930180",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.452778",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,335",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-01-21T02:13:21.560351Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--2305834",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.452369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560323Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu-74875153",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.451952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "372",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560295Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-10314243",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.451531",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-21T02:13:21.560267Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma--9726101",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.451081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560239Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160--4167944",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.450668",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "197",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560211Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--3283200",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.450257",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560183Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-29977929",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.449830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,486",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560153Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan-47603183",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.449411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-21T02:13:21.560113Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5-84943963",
        "event_type": "social_post",
        "date": "2026-01-21T02:13:01.448962",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-21T02:13:21.560063Z"
      },
      {
        "event_id": "SOCIAL-18Sep20251307-aimofthe-50874229",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.018552",
        "source": "LSE_CHAT",
        "data": {
          "author": "aimofthegame6",
          "content": "Bit of blue @ 8.1p",
          "sentiment": 0.0,
          "engagement": "2,471",
          "price_at_post": "7.95",
          "thread_title": "Few buyers around today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65BB518E-1DDB-4C4D-941A-F394D21FB457"
        },
        "ingested_at": "2026-01-21T02:13:21.563693Z"
      },
      {
        "event_id": "SOCIAL-19Sep20252108-PRO_TRAD-75854040",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.018149",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "We need keep holding, I think now everybody understands the tremendous potential of Shield as more institutional investors coming in. This is a multibagger but needs a lot of patience. Just keep it and wait the right time. I personally see the share price minimum 30p by mid of 2027 and then will continue its upward trajectory year after year. Tremendous potential and best product on the market.",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "7.90",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=6FAE363A-321D-44AA-A9E5-03C8D9354969"
        },
        "ingested_at": "2026-01-21T02:13:21.563666Z"
      },
      {
        "event_id": "SOCIAL-21Sep20251513-apropos1-66250995",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.017737",
        "source": "LSE_CHAT",
        "data": {
          "author": "apropos1",
          "content": "Can you advise what the basis is of your 30p price in two years? What do you see has happened or revenue/profits to have achieved by then?",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "7.90",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=6FAE363A-321D-44AA-A9E5-03C8D9354969"
        },
        "ingested_at": "2026-01-21T02:13:21.563640Z"
      },
      {
        "event_id": "SOCIAL-22Sep20251224-shandypa-79737689",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.017327",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "The Viatris deal has milestone payments being made to Shield if total annual sales/revenues exceed $100m. Using this figure at $250 per prescription that's 400k prescriptions per annual or 100k a quarter - about double our current levels. Based on this $100m that c$50m gross profit and maybe $20m actual profit. As a growing company this could be valued at 20 xPE = $400m or about \u00a3300m. With 1bn shares that's c30p a share. Very achievable IMHO",
          "sentiment": 0.0,
          "engagement": "3,275",
          "price_at_post": "7.90",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=6FAE363A-321D-44AA-A9E5-03C8D9354969"
        },
        "ingested_at": "2026-01-21T02:13:21.563613Z"
      },
      {
        "event_id": "SOCIAL-22Sep20251740-Tired@Co--3368622",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.016889",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tired@Confused",
          "content": "Cavendish note of the 4th September set their target at 23p. That is what I am looking to achieve before taking some profit. In the interim the share price is going to be volatile. Given the derth of news, people just make stuff up fumbling about to find anything to justify either selling of holding. As a result there very few times with Company's like Shield where the share price can truly be said to reflect the real value. ACCRUFeR\u00ae/FeRACCRU\u00ae is pretty much best in class and is likely to dominate the market if progress made is proportionate to the results seen by those prescribing the drug to patients. As with all drug development those researching and developing the next generation of compounds must weigh up the commercial viability of years of research and clinical trials to develop a drug which would be significantly better at treating the targeted conditions. My guess is this isn't the sexiest of R&D areas and hopefully we have years of exponetial growth as the product gains traction. It's just a question of whether you want or can afford to just sit it out until fair value is achieved, whenever that is! AIMHO and DYOR",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "7.65",
          "thread_title": "RE: Massively Undervalued",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=D1D2F246-1181-4B92-880B-FE014F09A672"
        },
        "ingested_at": "2026-01-21T02:13:21.563587Z"
      },
      {
        "event_id": "SOCIAL-24Sep20251344-aimofthe--4839003",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.016467",
        "source": "LSE_CHAT",
        "data": {
          "author": "aimofthegame6",
          "content": "Thought there would be way more buyers here, cashed up , good level",
          "sentiment": 0.0,
          "engagement": "2,471",
          "price_at_post": "7.35",
          "thread_title": "Where's everyone gone?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=F396003C-1721-473A-A2D1-74967F6E7F76"
        },
        "ingested_at": "2026-01-21T02:13:21.563559Z"
      },
      {
        "event_id": "SOCIAL-26Sep20250827-asiddall-38692164",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.016051",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "This is normal stabilisation following good news from a small AIM company.  No  concerns from my side.  Just topped up\u2026",
          "sentiment": 0.0,
          "engagement": "246",
          "price_at_post": "7.45",
          "thread_title": "RE: Where's everyone gone?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=F396003C-1721-473A-A2D1-74967F6E7F76"
        },
        "ingested_at": "2026-01-21T02:13:21.563533Z"
      },
      {
        "event_id": "SOCIAL-26Sep20250918-Servalan-85983503",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.015651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3149,691 (June 2025: \u00a3132,987 - July 2024: \u00a3107,958). 38%+ increase yoy !",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "7.25",
          "thread_title": "NHS England Rx - July",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=80AC93A0-C34D-4737-A7E9-C30BC61674F5"
        },
        "ingested_at": "2026-01-21T02:13:21.563506Z"
      },
      {
        "event_id": "SOCIAL-26Sep20251317-brafty--8934109",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.015242",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Great where is this documented could you put a link up ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "7.20",
          "thread_title": "RE: NHS England Rx - July",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=80AC93A0-C34D-4737-A7E9-C30BC61674F5"
        },
        "ingested_at": "2026-01-21T02:13:21.563479Z"
      },
      {
        "event_id": "SOCIAL-26Sep20251552-Servalan--3426198",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.014830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Openprescribing.net/chemical/0901011Y0/# If it doesn't work got to open prescribing and search for ferric maltol",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "7.20",
          "thread_title": "RE: NHS England Rx - July",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=80AC93A0-C34D-4737-A7E9-C30BC61674F5"
        },
        "ingested_at": "2026-01-21T02:13:21.563453Z"
      },
      {
        "event_id": "SOCIAL-29Sep20250930-Servalan--2287921",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.014416",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Absolute dodo brains selling at this price.",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "7.00",
          "thread_title": "RE: NHS England Rx - July",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=80AC93A0-C34D-4737-A7E9-C30BC61674F5"
        },
        "ingested_at": "2026-01-21T02:13:21.563425Z"
      },
      {
        "event_id": "SOCIAL-1Oct20251026-Ak247--8762584",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.013996",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "Amazing update today as this approval is huge. ACCRUFeR Is needed for all ages and once approved in 2026, it will up through the roof but really appreciative of the updates. Potentially huge for us!!",
          "sentiment": 0.5,
          "engagement": "389",
          "price_at_post": "7.55",
          "thread_title": "Huge approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0F49C541-7620-4C95-97D1-E9838BE2D948"
        },
        "ingested_at": "2026-01-21T02:13:21.563399Z"
      },
      {
        "event_id": "SOCIAL-2Oct20250659-lsecouk-23631152",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.013593",
        "source": "LSE_CHAT",
        "data": {
          "author": "lsecouk",
          "content": "Promising trends for sure.  Interesting how the volumes are being strongly driven by significantly more prescribing in a very small number of areas (Bristol/Barnsley/Northumberland), suggesting that there is much much more growth available should Norgine succeed in getting wider reimbursement in the UK and the sales reps nos increase to support the growth.  Still, overall the UK is a small market.",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "7.70",
          "thread_title": "RE: NHS England Rx - July",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=80AC93A0-C34D-4737-A7E9-C30BC61674F5"
        },
        "ingested_at": "2026-01-21T02:13:21.563372Z"
      },
      {
        "event_id": "SOCIAL-6Oct20251206-Tamlin-48047209",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.013180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.investing.com/news/analyst-ratings/stifel-upgrades-shield-therapeutics-stock-rating-to-buy-on-accrufer-growth-93CH-4271979 Stifel upgrades Shield Therapeutics stock rating to Buy on Accrufer growth Investing.com - Stifel has upgraded Shield Therapeutics PLC (STX:LN) from Hold to Buy and raised its price target to GBP0.10 from GBP0.03, citing improved commercial execution and financial stability. The upgrade follows consistent growth in sales of Shield\u2019s iron deficiency treatment Accrufer in the U.S. market, which has addressed one of Stifel\u2019s previous concerns about volatile commercial performance. Shield has strengthened its financial position through effective expense control and the implementation of a working capital facility, according to Stifel\u2019s analysis. Recent equity raises have also provided additional financial headroom for the company. Stifel now believes Shield\u2019s target of reaching cash flow break-even by the end of 2025 is achievable, marking a significant improvement in the firm\u2019s outlook for the pharmaceutical company. Despite the upgrade, Stifel characterizes Shield Therapeutics as a \"high-risk/high-reward proposition\" within its coverage universe, indicating that while the company\u2019s prospects have improved, investors should remain aware of potential volatility.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "8.25",
          "thread_title": "Stifel upgrades Shield Therapeutics stock rating to Buy on Accrufer...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=D209D460-299C-4F74-B7DE-A8256DCE6AD1"
        },
        "ingested_at": "2026-01-21T02:13:21.563345Z"
      },
      {
        "event_id": "SOCIAL-6Oct20251430-Andle-26617387",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.012734",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "This board did seem a little busier when the share was going nowhere!! Pay attention now!! As we creep towards parity and the fabled \u00a3100m mcap. A.",
          "sentiment": 0.0,
          "engagement": "425",
          "price_at_post": "8.55",
          "thread_title": "Attention y\u2019all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C09991DF-4951-4405-B3BB-1D0AE7804591"
        },
        "ingested_at": "2026-01-21T02:13:21.563318Z"
      },
      {
        "event_id": "SOCIAL-6Oct20251431-Andle-16646266",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.012316",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Oh yes and someone\u2019s building a position here. Mmmmmmmmm.",
          "sentiment": 0.0,
          "engagement": "425",
          "price_at_post": "8.55",
          "thread_title": "RE: Attention y\u2019all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C09991DF-4951-4405-B3BB-1D0AE7804591"
        },
        "ingested_at": "2026-01-21T02:13:21.563292Z"
      },
      {
        "event_id": "SOCIAL-19Oct20251250-ARH619-33738265",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.011895",
        "source": "LSE_CHAT",
        "data": {
          "author": "ARH619",
          "content": "Looking forward to Q3 this week. Wayyyy to quiet on this board\u2026.",
          "sentiment": 0.5,
          "engagement": "1",
          "price_at_post": "7.60",
          "thread_title": "Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563265Z"
      },
      {
        "event_id": "SOCIAL-23Oct20250743-Brightst--1309755",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.011488",
        "source": "LSE_CHAT",
        "data": {
          "author": "Brightstone",
          "content": "Those are very disappointing growth numbers. $13.1M Q3 net revenue vs $12.8m Q2.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563239Z"
      },
      {
        "event_id": "SOCIAL-23Oct20250746-quelfrom-49104260",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.011068",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Nearly double Vs Q3 2024",
          "sentiment": 0.0,
          "engagement": "1,161",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563212Z"
      },
      {
        "event_id": "SOCIAL-23Oct20250833-Ak247-61281549",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.010662",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "I think the numbers are quite reasonable. We are on  track to get cash positive by the end of the year and the biggest approval yet to come in the us in 2026. That approval alone could double our sp",
          "sentiment": 0.5,
          "engagement": "389",
          "price_at_post": "7.40",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563185Z"
      },
      {
        "event_id": "SOCIAL-23Oct20251019-shandypa-88858178",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.010249",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "I agree AK, these seem ok, and reiterating YE breakeven only c 2 months before YE is a massive vote of confidence. I would focus less on revenue as this seems fluctuate a little - QoQ prescriptions are up c15% (47k to 54K) and NSP has slightly increased too.  So the direction of travel is positive. The free/cheap prescriptions are still stubbornly high at 22% but less than Q2 (thought this would be less than 10% by now as they have been selling accrufer for c 3 years). The other big takeaway is cash burn - they have $8.6m left so cash burn in period was c$4m as they also had the \u00a31.5m placing added. With prescriptions growing revenues should continue to increase so cash burn per month continues to fall. I've always had a 25k per month prescription figure in my head for breakeven based on some basic calculations, however, with the cost savings they supposedly implemented this could be maybe 10% lower now.  So IMHO they need c$6m rev to generate $3m gross profit to cover costs. They mentioned 40% of revenues came in Sept 2025 so that's $5.2m if this continues into October and November then the $6m is very achievable. In fact i suspect they may achieve it in October and then it may settle back a little as Nov is thankgiving and Dec is Christmas.",
          "sentiment": 0.0,
          "engagement": "3,275",
          "price_at_post": "7.35",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563159Z"
      },
      {
        "event_id": "SOCIAL-23Oct20251133-PRO_TRAD-21983587",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.009800",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "About what dissapointing figures are you talking? Net revenues of $13.1m coupled with 54,000 total prescriptions compared to  Net revenues of $7.2m coupled with 44,000 prescriptions respectively in Q3 2024. We are talking about huge increase in revenues, does this looks bad to you?",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "7.35",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563132Z"
      },
      {
        "event_id": "SOCIAL-23Oct20251343-Servalan-11084529",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.009388",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Fantastic update, but watch the smooth brains sell into a tiny rise on the back of it. This would not be under 8p (11c?) if it was US listed. UK stock market is a joke.",
          "sentiment": 0.0,
          "engagement": "103",
          "price_at_post": "7.70",
          "thread_title": "RE: Q3",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0AD430AB-26F0-4F28-8E0A-7D4820DBC525"
        },
        "ingested_at": "2026-01-21T02:13:21.563103Z"
      },
      {
        "event_id": "SOCIAL-23Oct20252237-Duncan78-86397373",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.008958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Hi im very much new to sticks and have been watching from the sidelines. STX is interesting but looks like there has been a lot of sales which concerns. Any idea why?",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "7.70",
          "thread_title": "New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.563069Z"
      },
      {
        "event_id": "SOCIAL-24Oct20250929-Ak247-92375116",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:37.008522",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "To be honest with you, I cannot tell you the reason for the sells, we seem to be stuck between 7-8.5. If we do get cash positive by the end of the year then I imagine it moving north and once we get the permission to sell this to infants and toddlers and so on, i expect really big jumps north but patience is required. I am not sure if we have the permission in other countries as well so applications there would have to be applied as well and then finally I think we can expect a bid from the big boys",
          "sentiment": 0.5,
          "engagement": "389",
          "price_at_post": "7.55",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.563042Z"
      },
      {
        "event_id": "SOCIAL-24Oct20250937-brafty-74991507",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.038269",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "I THINK IT WILL BE BOUGHT OUT BETWEEN 20 - 30 P JUST AS IT GETS GOING , HOPEFULLY NOT AS IM HAPPY TO RIDE THIS WAVE TO THE TOP .",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "7.45",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.563016Z"
      },
      {
        "event_id": "SOCIAL-24Oct20251349-Duncan78--8796603",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.037849",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Thanks @brafty @ak247",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.562990Z"
      },
      {
        "event_id": "SOCIAL-24Oct20251826-PRO_TRAD-17556355",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.037438",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Absolutely 100%  will be taken over by the AOP but not now, i suspect in a couple of years time once they will be well in profit, depending where the share price will be at that time, I am estimating as well around 30p how I see things going.",
          "sentiment": 0.5,
          "engagement": "58",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.562963Z"
      },
      {
        "event_id": "SOCIAL-25Oct20250755-MrBB-75447020",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.037019",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "Agree that it looks logical for AOP to buy us but if that\u2019s their plan & they have detailed insider discussions with Anders & Santos ,why would they not do it now at ,say 10-15p-they own over 50% of the stock ,we are very close to cashflow breakeven ,if not already achieved ,paediatric study results expected positive ,S Korea approval imminent with Japan & China to follow -so why wait & pay double (or more) in a few months time . I think buying would be a last resort & they hope for a trade sale to the ultimate owner & for 30p+ giving them an excellent return on investment & without  managing STX as an operating subsidiary .Either way ,we PIs should do reasonably well \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "3,646",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.562937Z"
      },
      {
        "event_id": "SOCIAL-25Oct20251809-PRO_TRAD--6598360",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.036602",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "They don't do it now because is not of any interest to them at this price. They will wait when the company will be well in profit  and then they will make a bid. In that way it will cost them almost nothing despite the fact they will buy the remaining shares at a higher price. Once the company will be well profitable they know very well that the takeover cost will be well covered by the profits over the next 1-3 years.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "7.30",
          "thread_title": "RE: New to STX",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=8B9EEEC3-1011-4E31-A018-42077515859C"
        },
        "ingested_at": "2026-01-21T02:13:21.562910Z"
      },
      {
        "event_id": "SOCIAL-27Oct20250934-Servalan--2969010",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.036197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "FDA approved, growing sales in many markets, very close to profitability and now back under 7p. This is why the UK stock market is effed. Tiny brains who can't hold a stock more than 5 minutes.",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "6.90",
          "thread_title": "W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T02:13:21.562884Z"
      },
      {
        "event_id": "SOCIAL-27Oct20251131-shandypa-49283593",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.035780",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "I would ignore the many markets as the only significant revenues are in the US. Feraccru has been sold in the UK for over 5 years , yet revenues remain very low. As the NHS in England is not one single organisation, but is made up of hundreds of different organisations of differing sizes, at central, national, regional, and local levels with different roles and responsibilities it means approval for the product varies across the country. My doctor can't prescribe it (in Kent) as an example. Having said that with breakeven a massive milestone for STX and this was only reconfirmed last week the SP action seems bizarre. I think there may be a few reasons for this. Firstly, STX has missed so many deadlines/milestones before that investors will wait and see. Secondly the breakeven will almost certainly be a followed by a dip as Q1 is always the worst quarter. So it will not be a straight line - get to breakeven and then profits will suddenly materialise. However, based on 54k quarterly prescriptions the product is now selling over 200k units a year, which is an amazing achievement and will get people noticing - it is now the highest selling iron supplement, i believe. In the recent Investor Meets presentation the CFO seemed very relaxed with the money so that's a good sign. I asked about the IV infusion market as this is a natural complementary area for accrufer (have IV infusion to boost short term irn levels and then accrufer to maintain those levels and prevent repeat costly hospital appointments . It appears they have struggled to access this so have focused on easier areas (women's health etc) however this is a massive market and one they will revisit.",
          "sentiment": 0.0,
          "engagement": "3,275",
          "price_at_post": "6.95",
          "thread_title": "RE: W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T02:13:21.562857Z"
      },
      {
        "event_id": "SOCIAL-27Oct20251136-PRO_TRAD--3318090",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.035346",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Undoubtedly this is massively undervalued. It seems the reason is going down again which it should not is due to the mentioned small number of complaints in regards to the drug which actually are negligible compared to the sales figures. You can take a pain killer and you can have a side effect, so this is not a reason for the share price to drop.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.95",
          "thread_title": "RE: W t f",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=72D48719-4EF6-4185-8222-723A8FE888DB"
        },
        "ingested_at": "2026-01-21T02:13:21.562830Z"
      },
      {
        "event_id": "SOCIAL-28Oct20251445-Ak247--2343659",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.034928",
        "source": "LSE_CHAT",
        "data": {
          "author": "Ak247",
          "content": "I think the drop is that people don\u2019t believe they will achieve their target by the end of the year.  It will double up when they get the approvals next yr which is almost guaranteed. I think the issue is being on lse. People just hold shares in this country. Personally I have said it a few times and I will say it again. Bod should make some noise and sell the company",
          "sentiment": 0.0,
          "engagement": "389",
          "price_at_post": "6.45",
          "thread_title": "Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T02:13:21.562804Z"
      },
      {
        "event_id": "SOCIAL-28Oct20251528-Tired@Co--4042126",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.034524",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tired@Confused",
          "content": "It take bo11ocks to sit it out which is obviously in short supply with some investors. Personally, I think there is a news vacuum and as such selling in more about keeping some of the profit made rather than accepting the volatility in the short term in hopes of a bigger gain further down the road. AIMHO and DYOR, and good luck all",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "6.40",
          "thread_title": "RE: Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T02:13:21.562776Z"
      },
      {
        "event_id": "SOCIAL-28Oct20251640-Servalan-19334432",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.034108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Completely agree they should get it sold. They will never see anything like fair value staying in the UK. Plenty of US biotechs in the same boat - an FDA approved drug for ffs with growing sales and not yet profitable would be valued at least 10 times Shield. Small minds and small wallets in the UK.",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "6.40",
          "thread_title": "RE: Confidence",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CB4E119-BC0B-4C01-A64D-DC04B093FA23"
        },
        "ingested_at": "2026-01-21T02:13:21.562749Z"
      },
      {
        "event_id": "SOCIAL-29Oct20251136-busicat--4781583",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.033694",
        "source": "LSE_CHAT",
        "data": {
          "author": "busicat",
          "content": "Buying seems solid this morning",
          "sentiment": 0.0,
          "engagement": "888",
          "price_at_post": "6.75",
          "thread_title": "Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T02:13:21.562722Z"
      },
      {
        "event_id": "SOCIAL-29Oct20251603-gggg21-78206086",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.033284",
        "source": "LSE_CHAT",
        "data": {
          "author": "gggg21",
          "content": "Delayed 51k buy at 6.99. Looking better. Pull back was over done.",
          "sentiment": 0.0,
          "engagement": "10,105",
          "price_at_post": "6.85",
          "thread_title": "RE: Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T02:13:21.562695Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251021-Mokomagi-74890160",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.032836",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Analyst Price: Target Revision Analysts have maintained their price target for Shield Therapeutics at \u00a30.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.80",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=BD5CAD31-040C-4BBD-AC19-70D1D2579FEC"
        },
        "ingested_at": "2026-01-21T02:13:21.562669Z"
      },
      {
        "event_id": "SOCIAL-3Nov20251932-gggg21--5960404",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.032429",
        "source": "LSE_CHAT",
        "data": {
          "author": "gggg21",
          "content": "See another decent sized buy popped up after hours at 7.05. Just over 1m shares for 76k. Was some steady block buying today.",
          "sentiment": 0.0,
          "engagement": "10,105",
          "price_at_post": "7.05",
          "thread_title": "RE: Buyers returned?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=E61B3144-744F-4029-A9CA-06090EA9390F"
        },
        "ingested_at": "2026-01-21T02:13:21.562642Z"
      },
      {
        "event_id": "SOCIAL-7Nov20250817-brafty-49800293",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.032011",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Great News ! ACCRUFeR\u00ae receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS)",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "6.95",
          "thread_title": "Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T02:13:21.562616Z"
      },
      {
        "event_id": "SOCIAL-7Nov20250836-MrBB--1025341",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.031604",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "$1.9m milestone on first sale -which should be within 4 or 5 months -or maybe sooner if their launch plans are in place & we supply their Accrufer so no supply problems anticipated -great news for what should be a material market for us",
          "sentiment": 0.0,
          "engagement": "3,646",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T02:13:21.562589Z"
      },
      {
        "event_id": "SOCIAL-7Nov20251314-Servalan-23376081",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.031192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Excellent news, another market  secured, 52 million population and this can barely lift 1.5%. The UK biotech market is like a brian dead zombie. Even if they found a cure for all cancer, AIDS and instant weight loss this market would shrug its shoulders and probably sell off too.",
          "sentiment": 0.5,
          "engagement": "103",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B985E54D-37FF-47F6-A16F-ED959633B110"
        },
        "ingested_at": "2026-01-21T02:13:21.562563Z"
      },
      {
        "event_id": "SOCIAL-7Nov20251638-nice1-72489637",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.030773",
        "source": "LSE_CHAT",
        "data": {
          "author": "nice1",
          "content": "Great to see another milestone, this will do very well and in 6 months time the share price should be higher all going well and the market wakes up. Medpal Ai Plc RNS out today, worth a read. a bit of information as below,  they will start earning a bit of revenue. MedPal.clinic is now operational and actively offering: AI-powered consultations (free to users) Private prescriptions for weight-loss medications (GLP-1 agonists like Wegovy and Ozempic) Same-day/next-day delivery via their automated pharmacy in Swaffham. Prescription sales are the primary revenue stream. With private prescriptions costing \u00a3150\u2013\u00a3200/month per patient, even a modest uptake could generate substantial income. The company is targeting a \u00a3500 million/month addressable market in the UK weight-loss sector alone.",
          "sentiment": 0.0,
          "engagement": "977",
          "price_at_post": "6.85",
          "thread_title": "RE: Another Milestone",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=015AD3C0-507C-4E6C-8B64-BFC0CAB4669D"
        },
        "ingested_at": "2026-01-21T02:13:21.562536Z"
      },
      {
        "event_id": "SOCIAL-11Nov20251359-Duncan78--2028885",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.030330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "So o bought into sheild a few weeks ago the sp seems to be stagnate between 6-7p even with good news with Korean authorisation, and positive company announcements. What seems to be holding this back as all looks positive. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.85",
          "thread_title": "New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562510Z"
      },
      {
        "event_id": "SOCIAL-11Nov20251523-brafty--4334998",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.029900",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Since Anders Lundstrom the new CEO took over they have had significant growth to date climbed from a 52-week low of 2.1p to a recent high of 9.4p . The management team experience have proven this in results over the last year , they know what they are doing and have grown shield in different areas of the globe . Next year the assumption on wider adoption and breakeven will defiantly be factors in the rise of the share price and more confidence in once a failing stock from the pervious bad management  . hopefully no banana skins next year .",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "6.85",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562483Z"
      },
      {
        "event_id": "SOCIAL-11Nov20251755-Duncan78--8082390",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.029482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "Thanks hopefully a positive new year",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.85",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562457Z"
      },
      {
        "event_id": "SOCIAL-14Nov20250753-smythsmo-77338259",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.029057",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "No more fund raises we were told but we had a defacto one 2 months ago. I really do hope breakeven by 2025 year end is not a pipe dream. Most companies are economical with the truth, is Sheild therapeutic any different? NO they ain't.",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "7.15",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562430Z"
      },
      {
        "event_id": "SOCIAL-15Nov20252115-Servalan--3052778",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.028633",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It's British, it's a biotech, it's on AIM. There's 3 good reasons why we are languishing at 6.5p. If this was listed anywhere else it would be flying. Once you've held for a long time you'll get used to the constant disappointment in sp performance. Kicking myself i didn't sell at the last spike.",
          "sentiment": 0.0,
          "engagement": "103",
          "price_at_post": "6.75",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562403Z"
      },
      {
        "event_id": "SOCIAL-17Nov20251554-Duncan78-82728958",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:33.028194",
        "source": "LSE_CHAT",
        "data": {
          "author": "Duncan78",
          "content": "How long have you been holding this share in came in earlier this year but seems to be pretty stagnate. I was hoing 2026 would be better",
          "sentiment": 0.0,
          "engagement": "25",
          "price_at_post": "6.75",
          "thread_title": "RE: New to sheild",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=76C377B2-10B5-41EF-8C23-90E634FF38DE"
        },
        "ingested_at": "2026-01-21T02:13:21.562377Z"
      },
      {
        "event_id": "SOCIAL-19Nov20250959-Mokomagi--7715455",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.864071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "To be honest, I think all shareholders will be waiting for the announcement in Jan 2026 to confirm that STX has become cashflow positive. I am no expert but am a long term holder of STX and based on recent announcements re new business and milestone payments due to STX under new agreements agreed, then in my humble opinion I do see that this will be the case based on the last 12 months performance and the final quarterly figures due to announced Jan 2026 for their financial year.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "6.65",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T02:13:21.562350Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251010-Emerald5-81937455",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.863665",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Why the rise today. What has changed?",
          "sentiment": 0.0,
          "engagement": "114",
          "price_at_post": "7.50",
          "thread_title": "Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562323Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251030-Scarfell--5178040",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.863251",
        "source": "LSE_CHAT",
        "data": {
          "author": "Scarfell",
          "content": "No idea - but it's a volatile share that was at this level 4 weeks ago.",
          "sentiment": 0.0,
          "engagement": "336",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562296Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251036-1nspecto-42120155",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.862811",
        "source": "LSE_CHAT",
        "data": {
          "author": "1nspectorGadget",
          "content": "Article by Motel Tool yesterday https://www.fool.co.uk/2025/11/23/at-6-6p-could-this-fast-growing-penny-stock-be-a-millionaire-maker/ It'll settle back down in a few days",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562270Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251055-chedders--8580869",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.862395",
        "source": "LSE_CHAT",
        "data": {
          "author": "chedders74",
          "content": "Motley Fool article",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562242Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251119-MatBlack-17095157",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.861955",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "And as usual with MF the article is incorrect. Accufer for pulmonary hypertension? Since when",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562215Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251121-MatBlack--5574884",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.861555",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "Correction - pulmonary arterial hypertension.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562189Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251136-smythsmo--5837485",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.861148",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "If you read the RNS's it might be help you to understand a lot more about Sheild, London, UK, 14 November 2025 Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, today announced that its partner, MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc. has initiated a Phase II clinical trial for ACCRUFER\u00ae (ferric maltol), a new drug candidate for Pulmonary Arterial Hypertension (PAH), for patients in Japan. This trial is an exploratory study to support a Phase III trial and follows confirmation by the Pharmaceuticals and Medical Devices Agency (PMDA) of the development plan for the drug as a PAH treatment in Japan, based on previous clinical results in Europe, UK and USA.",
          "sentiment": 0.0,
          "engagement": "262",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562162Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251323-MatBlack-90467731",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.860725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MatBlack",
          "content": "Thank you. Coincidentally if I hadn't been in Japan at the time I might have read it. Not sure why MF didn't mention its existing use.",
          "sentiment": 0.0,
          "engagement": "104",
          "price_at_post": "7.50",
          "thread_title": "RE: Today\u2019s rise",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=65A4898D-1401-4A0E-AE3B-AA1F4C5EC343"
        },
        "ingested_at": "2026-01-21T02:13:21.562135Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251608-Beevorma-27311713",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.860318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Jan 26 would be nice. Does anyone know the exact holding AOP has now, got to be close to a controlling interest (50%)?",
          "sentiment": 0.0,
          "engagement": "1,484",
          "price_at_post": "7.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T02:13:21.562107Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251752-Time2Buy-21993971",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.859896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Time2Buy",
          "content": "Well that's interesting https://uk.finance.yahoo.com/news/6-6p-could-fast-growing-090000906.html",
          "sentiment": 0.5,
          "engagement": "10,147",
          "price_at_post": "7.60",
          "thread_title": "How to become a millionaire",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=5DFE5196-E62E-48BD-90CF-2D08D3D36A00"
        },
        "ingested_at": "2026-01-21T02:13:21.562072Z"
      },
      {
        "event_id": "SOCIAL-24Nov20252112-simonlev-74835300",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.859488",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "AOP own 53.6% of 1,060,000,000 shares in issue (568,000,000 shares) and are the major lender to the company https://www.investing.com/news/company-news/shield-therapeutics-seeks-10m-through-share-subscription-93CH-3758762",
          "sentiment": 0.5,
          "engagement": "57",
          "price_at_post": "7.60",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=AA79E41C-C1A6-418A-B3DB-F121D47F3F14"
        },
        "ingested_at": "2026-01-21T02:13:21.562045Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251004-StMartin-59643970",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.859068",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "It is starting to look as though AOP  will purchase STX,  at some point.",
          "sentiment": 0.0,
          "engagement": "919",
          "price_at_post": "8.00",
          "thread_title": "AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T02:13:21.562019Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251043-Mokomagi--3040618",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.858664",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Just doing some quick maths and looking back over the last three quarters revenue totalled $32.3 million US Dollars, if the upward trajectory continues in the Q4 say $14.00 million US dollars $900,000 above Q3's numbers then total revenue would be looking at $46.3 million US Dollars for 2025. This purely based on sales revenue alone.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "8.00",
          "thread_title": "Annual Revenue",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=CEE7EDE3-860B-4A9A-8892-E2B34AB16829"
        },
        "ingested_at": "2026-01-21T02:13:21.561992Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251046-Beevorma--5043021",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.858258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hopefully not before we see some SP recovery, my avg is still over 19p",
          "sentiment": 0.0,
          "engagement": "1,484",
          "price_at_post": "8.00",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T02:13:21.561966Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251058-StMartin--5335175",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.857844",
        "source": "LSE_CHAT",
        "data": {
          "author": "StMartins",
          "content": "AOP  hold such a large %    Any bid is Tax Efficient.  30-35p  likely.",
          "sentiment": 0.0,
          "engagement": "919",
          "price_at_post": "8.05",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T02:13:21.561939Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251117-MrBB-12933293",
        "event_type": "social_post",
        "date": "2026-01-10T03:43:28.857432",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "More likely that AOP will seek an agreed takeover at ,hopefully ,a much higher price ,rather than take 100% ownership with view to disposing in a year .Had they wanted 100> surely they would have done so earlier this year when they could have taken us out at 4-5p as opposed to 10-12p now -if that really is their agenda ?",
          "sentiment": 0.0,
          "engagement": "3,646",
          "price_at_post": "8.15",
          "thread_title": "RE: AOP   Takeover",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7C88BED8-DE09-4D07-8046-55722AC1708A"
        },
        "ingested_at": "2026-01-21T02:13:21.561912Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan-70143823",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-24T02:17:09.284060+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie-30746028",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-24T02:17:09.284115+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma--2439296",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-24T02:17:09.284160+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi-43596783",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-24T02:17:09.284182+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall--4078484",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-24T02:17:09.284200+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan-64592396",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-24T02:17:09.284219+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo--1108409",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-24T02:17:09.284237+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu-51334093",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-24T02:17:09.284255+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero-26829529",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-24T02:17:09.284274+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan-65523113",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-24T02:17:09.284292+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle--5265626",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284310+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan-18161073",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284328+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160-72516601",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-24T02:17:09.284346+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra--7246152",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-24T02:17:09.284364+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen-89784402",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-24T02:17:09.284382+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160-10376063",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284400+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea--6249211",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284419+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu--4721559",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284438+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5--4999773",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-24T02:17:09.284457+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan--3922470",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284475+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-49465044",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284493+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--4243312",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284511+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160--7774268",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284530+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-11691557",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-24T02:17:09.284548+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin--2643990",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-24T02:17:09.284566+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi-96217958",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-01-29T11:53:14.668680+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle-82253341",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668721+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan-42100114",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668754+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma--2979663",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668787+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD-55924041",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668819+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi-31347024",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-01-29T11:53:14.668853+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan-15567583",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668891+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma--1376818",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-29T11:53:14.668924+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev--2002680",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-29T11:53:14.668957+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu--6092044",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.668990+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi-83978590",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.669022+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut-45367981",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-01-29T11:53:14.669057+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan-43353367",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-29T11:53:14.669091+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--3074063",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-29T11:53:14.669145+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter--5827650",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-29T11:53:14.669183+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI--4763430",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-29T11:53:14.669222+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall-68004668",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-29T11:53:14.669261+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5--4476392",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-29T11:53:14.669298+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--4292520",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-29T11:53:14.669334+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7-56705590",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-29T11:53:14.669368+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea--7254006",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-29T11:53:14.669400+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-61542521",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-01-29T11:53:14.669432+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall-57657767",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-29T11:53:14.669464+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-62248734",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-29T11:53:14.669499+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall--5470058",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-29T11:53:14.669535+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut--4116230",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-29T11:53:14.669569+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--2325496",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-29T11:53:14.669588+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala-53525949",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-29T11:53:14.669608+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma--7259408",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-29T11:53:14.669626+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi--5825132",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-29T11:53:14.669646+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma-12348674",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-01-29T11:53:14.669665+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--8701013",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669684+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD-44664385",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669703+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen-45447906",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669722+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--3096498",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669740+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI--4836662",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669760+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD--2474808",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669779+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-49268007",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669798+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI--6711418",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669816+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD-19650653",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669835+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI--4003299",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669854+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--7365132",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669872+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD--1307338",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669891+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--2943494",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669910+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-35147254",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669929+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--6734144",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669948+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa-25356000",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.669966+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--8169862",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-01-29T11:53:14.669984+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala--2453966",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.670002+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa--5219408",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-29T11:53:14.670021+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan--8981544",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-29T11:53:14.670041+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie-26246637",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-29T11:53:14.670061+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-34919953",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-29T11:53:14.670079+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi-32713037",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-29T11:53:14.670122+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall--5179933",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-29T11:53:14.670146+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan--2303252",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-29T11:53:14.670165+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo--5284545",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-29T11:53:14.670185+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu-49183100",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-29T11:53:14.670204+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero--8659553",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-29T11:53:14.670223+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan-32200594",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-29T11:53:14.670241+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle--2550550",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670261+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--6956964",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670280+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160--8759557",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-29T11:53:14.670299+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra--1875548",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-29T11:53:14.670322+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen-39122748",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-29T11:53:14.670357+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160--8559571",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670395+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea--1944777",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670434+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu--1477150",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670476+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5-30574102",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-29T11:53:14.670516+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan-32864337",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670542+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-10399289",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670562+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB-67298708",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670581+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160--7530120",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670600+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-40459200",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-29T11:53:14.670619+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin--1503872",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-29T11:53:14.670637+00:00"
      },
      {
        "event_id": "RNS-30th Jan 2026-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-30T23:40:49.090131+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/total-voting-rights-iqryjegbbas3eei.html",
          "rns_number": "RNS Number : 0034R",
          "full_content": "Today 07:05\nRNS Number : 0034R\nShield Therapeutics PLC\n30 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 30 January, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,997,016\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/P2AzZr\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRPPUUPGUPQPGB",
          "content_length": 4189
        },
        "ingested_at": "2026-01-30T23:40:49.090160+00:00"
      },
      {
        "event_id": "RNS-30th Jan 2026-approval",
        "event_type": "rns_announcement",
        "date": "2026-01-30T23:40:49.090173+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Approval for ACCRUFeR in China expected in Q1 2026",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "rns_number": "RNS Number : 0029R",
          "full_content": "Today 07:00\nRNS Number : 0029R\nShield Therapeutics PLC\n30 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\nFiling for marketing authori\nsation\nfor the approval for ACCRUFeR\u00ae in China\nexpected in Q1 2026 and will include the pediatric data\nTerms of the China License Agreement with ASK updated to include a $7.9Mdevelopment milestone to Shield by 31 January 2026\nShield to use the\nASK development milestone payment to settle all payments andterminate the AOP Milestone Monetisation Agreement\nLondon, UK, January 30, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces that its partner in China, Beijing Aosaikang Pharmaceutical Co. Ltd (\"ASK\"), expects to submit the file for marketing authorisation to the China National Medical Products Administration (\"NMPA\") for the approval for ACCRUFeR\u00ae in China in Q1 2026. The Company and ASK have agreed to update various terms of the China License Agreement including a development milestone of $7.9M to Shield by 31 January 2026. Shield will use the ASK development milestone to settle its obligations under the AOP Milestone Monetisation Agreement and terminate the agreement.\nASK plans to include the positive data from Shield's Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that was used to receive US FDA approval to extend the indication for ACCRUFeR\u00ae in the US to include children 10 years and older with iron deficiency (ID) in its NMPA filing for Marketing Authorisation for ACCRUFeR\u00ae in China. The NMPA filing is anticipated in Q1 2026.\nIn addition to ASK agreeing to pay Shield a development milestone of $7.9M, the Company and ASK have agreed to update various terms of the China License Agreement including a milestone of up to $3M linked to the final price for ACCRUFeR\u00ae in China, and revised royalties of up to 10% based on annual net sales of ACCRUFeR\u00ae. The updated milestones replace the $11.4M milestone which was conditional upon receipt of a subsequently expected marketing approval in China.\nThe Company will use the $7.9M development milestone payment from ASK to settle all its obligations under the terms of the AOP Milestone Monetisation Agreement. The final payment amount to AOP will fully discharge the Company's financial obligations to AOP under that agreement. This payment is significantly below the amount which would have been due to AOP if the full $11.4M marketing approval milestone payment had been received by Shield from ASK.\nSantosh Shanbhag, CFO at Shield, commented:\n\"\nWe are pleased to see the continued progress of our partner ASK towards the planned submission for marketing authorisation of ACCRUFeR\u00ae in China in the first quarter of 2026. We believe that the inclusion of the recently approved US pediatric Phase 3 data strengthens the overall submission package and supports the long\u2011term value of ACCRUFeR\u00ae in this important market. In parallel, the amended terms of the agreement with ASK allows Shield to use the development milestone payment from ASK to fully cover the final payment due to AOP and terminate the AOP Milestone Monetisation Agreement earlier and at lower cost than previously planned. This further simplifies our capital structure and places Shield in a stronger financial position as we continue to execute our commercial strategy.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/y0z57r\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is America's #1 branded prescription oral iron for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and ",
          "content_length": 7202
        },
        "ingested_at": "2026-01-30T23:40:49.090187+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Andle-73067189",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.145770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559265+00:00"
      },
      {
        "event_id": "SOCIAL-Today1613-Servalan-77200491",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559290+00:00"
      },
      {
        "event_id": "SOCIAL-Today1015-Andle--6071725",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559309+00:00"
      },
      {
        "event_id": "SOCIAL-Today1009-BioTechI--4568018",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559328+00:00"
      },
      {
        "event_id": "SOCIAL-Today1003-Servalan-27194696",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559350+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-Andle--2129442",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559368+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Servalan--8152818",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559386+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Tamlin-47992923",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-01-30T23:41:00.559404+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261207-BioTechI-43403657",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149264",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "So much so that it's back to where it was a few weeks ago! Transformational",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "11.25",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-01-30T23:41:00.559423+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261017-Mokomagi--6224382",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-01-30T23:41:00.559441+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi--6224382",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-01-30T23:41:00.559461+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle--3717431",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559480+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan-45486432",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559498+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma-46513847",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559517+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD--1750104",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559535+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi--6946301",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-01-30T23:41:00.559553+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan--5307372",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559572+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma--4399959",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-01-30T23:41:00.559590+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev-86514676",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-30T23:41:00.559608+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu-76201058",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.559625+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--5803523",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.559644+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut--5538363",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-01-30T23:41:00.559662+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan--9087440",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-30T23:41:00.559680+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--6783761",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-30T23:41:00.559698+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter-46990028",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-30T23:41:00.559716+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI-12317676",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-01-30T23:41:00.559734+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall--1514518",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-30T23:41:00.559751+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5-16969332",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-01-30T23:41:00.559770+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan-84103048",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-30T23:41:00.559787+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--4766200",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-30T23:41:00.559806+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea--2883664",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-01-30T23:41:00.559824+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-50617657",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-01-30T23:41:00.559843+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall--4041969",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-30T23:41:00.559861+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-41692727",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-30T23:41:00.559879+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall-10099863",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-01-30T23:41:00.559897+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut--1549061",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-30T23:41:00.559915+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie-67339111",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-30T23:41:00.559933+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala-24728716",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-01-30T23:41:00.559951+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma-13880319",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-30T23:41:00.559969+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi-11628549",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-01-30T23:41:00.559987+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma--2192300",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-01-30T23:41:00.560005+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--6183781",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560023+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--1604270",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560041+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen-86143762",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560059+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--1924060",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560078+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI--7049908",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560096+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD--3032433",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560132+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-53522069",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560150+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI--7482216",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560168+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD--1988004",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560187+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-14817146",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560205+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--2176061",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560223+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD-35622945",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560241+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--7144136",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560260+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-32505539",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560278+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI-12451096",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560296+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa--6876609",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560315+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--3275431",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-01-30T23:41:00.560333+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala-83649598",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560351+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa-87498480",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-01-30T23:41:00.560370+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan-89760556",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-30T23:41:00.560388+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie--1157884",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-30T23:41:00.560406+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-59266556",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-30T23:41:00.560423+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi-31138105",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-01-30T23:41:00.560441+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall--6381773",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-30T23:41:00.560459+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan-27280201",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-30T23:41:00.560477+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo-84519619",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-30T23:41:00.560495+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu--9026787",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-30T23:41:00.560514+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero--1399165",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-01-30T23:41:00.560534+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan-23829813",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-01-30T23:41:00.560553+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle-69960641",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560571+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--2982803",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560589+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160--2457408",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-30T23:41:00.560618+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra--2797476",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-30T23:41:00.560654+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen--1211983",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-01-30T23:41:00.560685+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160-75935865",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560704+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea-40792337",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560722+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu-19426316",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560740+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5--4437197",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-01-30T23:41:00.560758+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan--1421523",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560776+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-11284048",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560794+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--4395135",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560812+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160--3201085",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560830+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma--7503320",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-01-30T23:41:00.560848+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-53706624",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-01-30T23:41:00.560866+00:00"
      },
      {
        "event_id": "SOCIAL-Today1602-quelfrom--6984602",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.450900",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708572+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-asiddall-40373773",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.451822",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708615+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261608-Epsilon--3275259",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.452659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "...[your]",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708655+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261321-Epsilon--6046656",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.453502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "I feel you're pain. Try the Ghostery extension on your browser. Similar extensions are also available. It cleared all the garbage that you're describing, for me at least. In addition, you might want to change your browser cookie settings to a more strict/secure setting to help with those pesky tracking cookies.",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708694+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261654-Andle--6182495",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.454344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708733+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Servalan-61378868",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708771+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261015-Andle-28621265",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708808+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261009-BioTechI--4570740",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456410",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708846+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261003-Servalan--7350133",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456828",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708883+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-Andle-20630353",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708919+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260934-Servalan--8570509",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708957+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260829-Tamlin--7161563",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.458441",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.708993+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Andle--6182495",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.145770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709031+00:00"
      },
      {
        "event_id": "SOCIAL-Today1613-Servalan-61378868",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709069+00:00"
      },
      {
        "event_id": "SOCIAL-Today1015-Andle-28621265",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709121+00:00"
      },
      {
        "event_id": "SOCIAL-Today1009-BioTechI--4570740",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709161+00:00"
      },
      {
        "event_id": "SOCIAL-Today1003-Servalan--7350133",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709198+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-Andle-20630353",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709238+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Servalan--8570509",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709278+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Tamlin--7161563",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-06T23:45:56.709317+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261207-BioTechI--9536493",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149264",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "So much so that it's back to where it was a few weeks ago! Transformational",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "11.25",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-06T23:45:56.709355+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261017-Mokomagi-42146091",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-06T23:45:56.709393+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi-42146091",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-06T23:45:56.709430+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle-67159076",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709469+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan--4014684",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709506+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma--4885000",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709545+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD-39276472",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709582+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi--6211993",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-02-06T23:45:56.709620+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan--6634198",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709657+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma-50602420",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-06T23:45:56.709694+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev--3169215",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-06T23:45:56.709733+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu--5830029",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.709771+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--7746790",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.709810+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut--2676981",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-02-06T23:45:56.709848+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan-11514041",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-06T23:45:56.709887+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--8203482",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-06T23:45:56.709925+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter-51571509",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-06T23:45:56.709962+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI--4088808",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-06T23:45:56.709999+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall-60595324",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-06T23:45:56.710038+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5-33663999",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-06T23:45:56.710076+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--6060220",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-06T23:45:56.710126+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--6191029",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-06T23:45:56.710165+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea--2926782",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-06T23:45:56.710204+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-36325118",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-02-06T23:45:56.710243+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall--9096308",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-06T23:45:56.710281+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-76112332",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-06T23:45:56.710320+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall-73507673",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-06T23:45:56.710358+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut--7064874",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-06T23:45:56.710396+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--6775533",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-06T23:45:56.710434+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala--5299123",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-06T23:45:56.710473+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma--3109544",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-06T23:45:56.710512+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi-45738509",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-06T23:45:56.710552+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma--7519410",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-02-06T23:45:56.710591+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma-33549187",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710630+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--5738192",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710668+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen-22493650",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710714+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--1946792",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710753+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI-33244591",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710790+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD-70423923",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710829+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-67282491",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710867+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI-41128224",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710907+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD--5939261",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710946+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-55534838",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.710984+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--1797691",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711024+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD-57773442",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711062+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--3995212",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711110+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-67890928",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711150+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--6770801",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711189+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa-68535523",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711227+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut-75477248",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-02-06T23:45:56.711266+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala--9091809",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711304+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa--5687170",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-06T23:45:56.711343+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan-60671890",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-06T23:45:56.711380+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie--3199864",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-06T23:45:56.711418+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-53039978",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-06T23:45:56.711457+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi-38156066",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-06T23:45:56.711495+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall-29348083",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-06T23:45:56.711534+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan--1347438",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-06T23:45:56.711571+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo--1269583",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-06T23:45:56.711609+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu--3550308",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-06T23:45:56.711647+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero--2334285",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-06T23:45:56.711686+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan--7362294",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-06T23:45:56.711725+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle-81398250",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.711763+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--1238564",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.711801+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160-41597154",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-06T23:45:56.711839+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra-44204413",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-06T23:45:56.711878+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen--7668087",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-06T23:45:56.711917+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160-17782977",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.711955+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea--4211336",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.711994+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu-68932924",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712033+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5--1403319",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-02-06T23:45:56.712073+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan--2510899",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712123+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma--4562060",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712163+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--6751487",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712200+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160-76998663",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712238+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma--2130640",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-06T23:45:56.712277+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-47083741",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-02-06T23:45:56.712316+00:00"
      },
      {
        "event_id": "RNS-9th Feb 2026-fdagrant",
        "event_type": "rns_announcement",
        "date": "2026-02-10T00:17:32.351117Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA Grants additional Exclusivity for ACCRUFeR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/STX/fda-grants-additional-exclusivity-for-accrufer-e2x3xqe6qdyq0x4.html",
          "rns_number": "RNS Number : 2151S",
          "full_content": "9 Feb 2026 07:00\nRNS Number : 2151S\nShield Therapeutics PLC\n09 February 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUS FDA Grants additional 3 Years Exclusivity for ACCRUFeR\u00ae\nLondon, UK, 09 February 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA) has granted to Shield an additional 3 years of Data Exclusivity for ACCRUFeR\u00ae (ferric maltol). This is due to the new clinical investigation conducted by Shield that was essential to the approval of the extension of the indication to include pediatric patients 10 years of age and older. This exclusivity remains in place until 19 December 2028 in addition to the\nACCRUFeR\u00ae/FeRACCRU\u00ae patent coverage valid until the mid-2030s.\nThe indication expansion was supported by positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children aged 1 month and above with iron deficiency, presenting as iron deficiency anemia (IDA).\nDr Jackie Mitchell, VP of Regulatory, Quality, Clinical and Regulatory Affairs of Shield, commented:\n\"This exclusivity is a significant milestone for Shield and recognises the value of the essential clinical investigation conducted to support the pediatric indication, reflecting the strength of the Phase 3 FORTIS trial. We are well positioned to continue expanding access to ACCRUFeR\u00ae and addressing unmet needs in both adult and pediatric populations.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/PZopny\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate(N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is the final study in the comprehensive pediatric development program that Shield ",
          "content_length": 5845
        },
        "ingested_at": "2026-02-10T00:17:32.351174Z"
      },
      {
        "event_id": "SOCIAL-9Feb20261434-Beevorma-40538972",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.273676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hopefully not before we see some movement in the price Serv, i'm still quite far away from avg!",
          "sentiment": 0.0,
          "engagement": "1,491",
          "price_at_post": "10.25",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T00:17:43.977671+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-Servalan-79781259",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Very good news. Should make it more attractive for a takeover.",
          "sentiment": 0.5,
          "engagement": "120",
          "price_at_post": "10.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T00:17:43.977713+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261206-asiddall--8089804",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274693",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Good price gains, extended exclusivity in target markets, revenue growth, good path to profitability\u2026 this should /  will be flying soon.   Not wishing to tempt fate of course..",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "10.00",
          "thread_title": "Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T00:17:43.977738+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261602-quelfrom--4097565",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275192",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977757+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261025-asiddall-81299804",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275680",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977775+00:00"
      },
      {
        "event_id": "SOCIAL-Today1602-quelfrom--4097565",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.450900",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977794+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-asiddall-81299804",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.451822",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977812+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261608-Epsilon-60251002",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.452659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "...[your]",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977830+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261321-Epsilon--2778446",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.453502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "I feel you're pain. Try the Ghostery extension on your browser. Similar extensions are also available. It cleared all the garbage that you're describing, for me at least. In addition, you might want to change your browser cookie settings to a more strict/secure setting to help with those pesky tracking cookies.",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977848+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261654-Andle-52645114",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.454344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977866+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Servalan-57346143",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977884+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261015-Andle-28805988",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977901+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261009-BioTechI-13388634",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456410",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977920+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261003-Servalan-66928420",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456828",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977938+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-Andle--5225556",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977955+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260934-Servalan--2676427",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977973+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260829-Tamlin--2136680",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.458441",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.977991+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Andle-52645114",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.145770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978009+00:00"
      },
      {
        "event_id": "SOCIAL-Today1613-Servalan-57346143",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978026+00:00"
      },
      {
        "event_id": "SOCIAL-Today1015-Andle-28805988",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978043+00:00"
      },
      {
        "event_id": "SOCIAL-Today1009-BioTechI-13388634",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978062+00:00"
      },
      {
        "event_id": "SOCIAL-Today1003-Servalan-66928420",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978079+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-Andle--5225556",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978111+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Servalan--2676427",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978135+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Tamlin--2136680",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T00:17:43.978153+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261207-BioTechI-27669419",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149264",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "So much so that it's back to where it was a few weeks ago! Transformational",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "11.25",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T00:17:43.978171+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261017-Mokomagi--5701360",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T00:17:43.978190+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi--5701360",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T00:17:43.978208+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle-21308563",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978225+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan-41945769",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978243+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma-34902917",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978261+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD-17604567",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978279+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi-25821266",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-02-10T00:17:43.978296+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan--4791562",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978315+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma-52311125",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T00:17:43.978333+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev-92520115",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T00:17:43.978351+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu-18336678",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.978369+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi-63724133",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.978392+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut--4539687",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-02-10T00:17:43.978410+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan--6321161",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T00:17:43.978427+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall-28903863",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T00:17:43.978445+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter-72994604",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T00:17:43.978463+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI--4820360",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T00:17:43.978482+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall-30571247",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-10T00:17:43.978500+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5-51849875",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-10T00:17:43.978518+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--2639418",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T00:17:43.978536+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7-90820954",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T00:17:43.978555+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-40761868",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T00:17:43.978574+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-20157721",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-02-10T00:17:43.978592+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall-69716914",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T00:17:43.978610+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-47973208",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T00:17:43.978629+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall-18729866",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T00:17:43.978647+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut-34508509",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T00:17:43.978665+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--7526605",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-10T00:17:43.978686+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala--2669243",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-10T00:17:43.978719+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma-72858659",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T00:17:43.978745+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi-64046421",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T00:17:43.978763+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma--2473569",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-02-10T00:17:43.978781+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma-57640906",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978800+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--6289983",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978818+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen--3065350",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978837+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD--1944409",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978855+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI-25547886",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978873+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD--9492779",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978891+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-74509046",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978909+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI--5218585",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978927+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD--3663269",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978946+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-44172520",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978963+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD-52806896",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978981+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD--7125242",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.978999+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--6790729",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979017+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-37845791",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979036+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--6919599",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979053+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa--2811382",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979071+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--4850914",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-02-10T00:17:43.979090+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala-54522419",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979126+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa--5790696",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T00:17:43.979145+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan--3659586",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T00:17:43.979163+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie--6194043",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T00:17:43.979181+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-65323060",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T00:17:43.979199+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi-62252945",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T00:17:43.979217+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall--8518964",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T00:17:43.979235+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan-89997226",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T00:17:43.979253+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo-65452545",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T00:17:43.979272+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu--5962420",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-10T00:17:43.979289+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero--2706007",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-10T00:17:43.979308+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan-63636690",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T00:17:43.979326+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle--1229639",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979345+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan-71924248",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979362+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160--3964686",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T00:17:43.979381+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra--3657574",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T00:17:43.979399+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen-29687031",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T00:17:43.979417+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160-54489670",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979435+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea-63165906",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979453+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu--1905436",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979471+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5--1909887",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-02-10T00:17:43.979489+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan-82522641",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979508+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma--5195007",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979526+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--7409117",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979544+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160-73202584",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979562+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-49897044",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T00:17:43.979580+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin--2308174",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-02-10T00:17:43.979598+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-PRO_TRAD--1433971",
        "event_type": "social_post",
        "date": "2026-02-10T23:36:23.305318",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Takeover should be somewhere between 30p - 40p, it will take probably a couple of more years for that. Don't forget that Viatris might make a bit as well or any other big pharmaceutical company, let\u2019s wait and see what happens.",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "10.75",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T23:36:29.828467+00:00"
      },
      {
        "event_id": "SOCIAL-Today0753-brafty-32155530",
        "event_type": "social_post",
        "date": "2026-02-10T23:36:23.305756",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "My prediction is AOP will want 30 - 40 p to avoid making a loss and make some profit",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "11.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T23:36:29.828506+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261434-Beevorma--6325408",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.273676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hopefully not before we see some movement in the price Serv, i'm still quite far away from avg!",
          "sentiment": 0.0,
          "engagement": "1,491",
          "price_at_post": "10.25",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T23:36:29.828527+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-Servalan--3538267",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Very good news. Should make it more attractive for a takeover.",
          "sentiment": 0.5,
          "engagement": "120",
          "price_at_post": "10.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T23:36:29.828546+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261206-asiddall-11129768",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274693",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Good price gains, extended exclusivity in target markets, revenue growth, good path to profitability\u2026 this should /  will be flying soon.   Not wishing to tempt fate of course..",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "10.00",
          "thread_title": "Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-10T23:36:29.828565+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261602-quelfrom-88972580",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275192",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828583+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261025-asiddall--1082830",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275680",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828602+00:00"
      },
      {
        "event_id": "SOCIAL-Today1602-quelfrom-88972580",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.450900",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828620+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-asiddall--1082830",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.451822",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828638+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261608-Epsilon--1614009",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.452659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "...[your]",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828657+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261321-Epsilon--4363426",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.453502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "I feel you're pain. Try the Ghostery extension on your browser. Similar extensions are also available. It cleared all the garbage that you're describing, for me at least. In addition, you might want to change your browser cookie settings to a more strict/secure setting to help with those pesky tracking cookies.",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828675+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261654-Andle-92279287",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.454344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828693+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Servalan-90284631",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828711+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261015-Andle--1997042",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828729+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261009-BioTechI-47542884",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456410",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828747+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261003-Servalan-54015340",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456828",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828767+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-Andle--5928992",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828803+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260934-Servalan-55075484",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828832+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260829-Tamlin--8344503",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.458441",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828851+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Andle-92279287",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.145770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828869+00:00"
      },
      {
        "event_id": "SOCIAL-Today1613-Servalan-90284631",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828887+00:00"
      },
      {
        "event_id": "SOCIAL-Today1015-Andle--1997042",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828905+00:00"
      },
      {
        "event_id": "SOCIAL-Today1009-BioTechI-47542884",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828923+00:00"
      },
      {
        "event_id": "SOCIAL-Today1003-Servalan-54015340",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828946+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-Andle--5928992",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828964+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Servalan-55075484",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.828982+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Tamlin--8344503",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-10T23:36:29.829000+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261207-BioTechI--6206639",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149264",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "So much so that it's back to where it was a few weeks ago! Transformational",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "11.25",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T23:36:29.829018+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261017-Mokomagi-34741367",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T23:36:29.829036+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi-34741367",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-10T23:36:29.829054+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle--1419147",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829072+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan-24768694",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829090+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma--7316033",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829121+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD-72125918",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829140+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi--1876653",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-02-10T23:36:29.829157+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan--7000619",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829175+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma-56036763",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-10T23:36:29.829193+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev--6954298",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T23:36:29.829211+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu--6960798",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.829229+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--3677555",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.829247+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut-38413283",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-02-10T23:36:29.829265+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan--6538225",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T23:36:29.829284+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--2032075",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T23:36:29.829303+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter--3026529",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T23:36:29.829321+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI--4015385",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-10T23:36:29.829340+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall--7273829",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-10T23:36:29.829359+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5--9171957",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-10T23:36:29.829378+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--4568670",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T23:36:29.829396+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--2698324",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T23:36:29.829414+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-62681521",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-10T23:36:29.829432+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-26154727",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-02-10T23:36:29.829450+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall--3482599",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T23:36:29.829469+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-82767933",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T23:36:29.829487+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall--3403008",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-10T23:36:29.829506+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut-84268616",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T23:36:29.829524+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--5773506",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-10T23:36:29.829542+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala-32888755",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-10T23:36:29.829560+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma-90665456",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T23:36:29.829579+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi--2007033",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-10T23:36:29.829597+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma-14120991",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-02-10T23:36:29.829614+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--8433762",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829633+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD--8977179",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829651+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen--3275035",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829669+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD-19470547",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829687+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI--2921835",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829706+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD--8188168",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829724+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-67573397",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829743+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI-33342981",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829761+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD-50194203",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829779+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI-23731079",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829797+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--8800961",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829815+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD--7158390",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829833+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI--2118764",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829852+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-43072406",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829871+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--6959631",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829889+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa--3250927",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829907+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut--2961165",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-02-10T23:36:29.829925+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala-75614234",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829943+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa-61980404",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-10T23:36:29.829962+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan-18824361",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T23:36:29.829980+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie--4856072",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T23:36:29.829999+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-54798553",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T23:36:29.830017+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi--8807800",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-10T23:36:29.830035+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall--3640914",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T23:36:29.830054+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan-86456910",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T23:36:29.830072+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo--5844425",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T23:36:29.830090+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu--9813108",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-10T23:36:29.830120+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero-72735183",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-10T23:36:29.830139+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan--8499571",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-10T23:36:29.830157+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle-17626391",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830175+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--3816521",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830193+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160--8093200",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T23:36:29.830211+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra-86116307",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T23:36:29.830230+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen--5247488",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-10T23:36:29.830249+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160--1780995",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830267+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea--3865440",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830285+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu-34615798",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830304+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5--1370152",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-02-10T23:36:29.830322+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan-51051832",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830341+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma--3266463",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830359+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--7774813",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830377+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160--3116329",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830396+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma--7482618",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-10T23:36:29.830414+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin-22807773",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-02-10T23:36:29.830432+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262008-PRO_TRAD--3599203",
        "event_type": "social_post",
        "date": "2026-02-11T17:10:16.051860",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Takeover should be somewhere between 30p - 40p, it will take probably a couple of more years for that. Don't forget that Viatris might make a bit as well or any other big pharmaceutical company, let\u2019s wait and see what happens.",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "10.75",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636643+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260753-brafty--6850709",
        "event_type": "social_post",
        "date": "2026-02-11T17:10:16.052311",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "My prediction is AOP will want 30 - 40 p to avoid making a loss and make some profit",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "11.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636685+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-PRO_TRAD--3599203",
        "event_type": "social_post",
        "date": "2026-02-10T23:36:23.305318",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Takeover should be somewhere between 30p - 40p, it will take probably a couple of more years for that. Don't forget that Viatris might make a bit as well or any other big pharmaceutical company, let\u2019s wait and see what happens.",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "10.75",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636715+00:00"
      },
      {
        "event_id": "SOCIAL-Today0753-brafty--6850709",
        "event_type": "social_post",
        "date": "2026-02-10T23:36:23.305756",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "My prediction is AOP will want 30 - 40 p to avoid making a loss and make some profit",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "11.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636735+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261434-Beevorma--5626637",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.273676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hopefully not before we see some movement in the price Serv, i'm still quite far away from avg!",
          "sentiment": 0.0,
          "engagement": "1,491",
          "price_at_post": "10.25",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636753+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-Servalan--8108630",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274197",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Very good news. Should make it more attractive for a takeover.",
          "sentiment": 0.5,
          "engagement": "120",
          "price_at_post": "10.00",
          "thread_title": "RE: Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636771+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261206-asiddall-88251718",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.274693",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Good price gains, extended exclusivity in target markets, revenue growth, good path to profitability\u2026 this should /  will be flying soon.   Not wishing to tempt fate of course..",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "10.00",
          "thread_title": "Extended exclusivity",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=08DF11E4-F284-49ED-8494-13695A3EAA0D"
        },
        "ingested_at": "2026-02-11T17:10:24.636789+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261602-quelfrom--6885792",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275192",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636807+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261025-asiddall-66228871",
        "event_type": "social_post",
        "date": "2026-02-10T00:17:35.275680",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636825+00:00"
      },
      {
        "event_id": "SOCIAL-Today1602-quelfrom--6885792",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.450900",
        "source": "LSE_CHAT",
        "data": {
          "author": "quelfromage1",
          "content": "Yes it's very tempting but I'm probably over invested already !",
          "sentiment": 0.0,
          "engagement": "1,163",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636843+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-asiddall-66228871",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.451822",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Some great moments to invest a little more, but my isa is maxed out\u2026",
          "sentiment": 0.0,
          "engagement": "248",
          "price_at_post": "9.60",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636860+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261608-Epsilon--2742358",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.452659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "...[your]",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636877+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20261321-Epsilon--2922752",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.453502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Epsilon",
          "content": "I feel you're pain. Try the Ghostery extension on your browser. Similar extensions are also available. It cleared all the garbage that you're describing, for me at least. In addition, you might want to change your browser cookie settings to a more strict/secure setting to help with those pesky tracking cookies.",
          "sentiment": 0.0,
          "engagement": "37",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636896+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261654-Andle--8765064",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.454344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636914+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Servalan-28279383",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636932+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261015-Andle--6212251",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.455793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636950+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261009-BioTechI-15713410",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456410",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636968+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261003-Servalan--3554838",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.456828",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.636986+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-Andle--8092128",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "438",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637003+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260934-Servalan--2420509",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.457997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637026+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260829-Tamlin--6466317",
        "event_type": "social_post",
        "date": "2026-02-06T23:45:48.458441",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637044+00:00"
      },
      {
        "event_id": "SOCIAL-Today1654-Andle--8765064",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.145770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Think things will be alright over there after Trump takes over the Federal Reserve. What could possibly\u2026\u2026.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.75",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637061+00:00"
      },
      {
        "event_id": "SOCIAL-Today1613-Servalan-28279383",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I take it back, this is holding up very well considering the biotech carnage over the pond this week, especially today. Sometimes being small and under the radar has its advantages. Anyone else fed up with this website dancing around with those stupid pop up videos on every single page you click? It's like something from the '90s.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637078+00:00"
      },
      {
        "event_id": "SOCIAL-Today1015-Andle--6212251",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.146641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Shield have renegotiated a lower milestone payment. Never a good start to a partnership. The market potential is massive but it is like peering through the murky mists trying to figure out what that might be.  Can only be positives from here imo but the market needs numbers before take off. A. Waiting patiently.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637096+00:00"
      },
      {
        "event_id": "SOCIAL-Today1009-BioTechI-15713410",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "If you read the detail in this release, it's a reduction in upside potential and a reduction in downside risk. A muted reaction seems pretty fair. On balance, it's likely to be NPV neutral.",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637175+00:00"
      },
      {
        "event_id": "SOCIAL-Today1003-Servalan--3554838",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.147594",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "You're right, I should temper my enthusiasm for a while. Of course a small British Biotech about to get access (hopefully!) to 1.4B population would be met with a fart not a fanfare.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637193+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-Andle--8092128",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Market reaction was yesterday I reckon Servalan More positive but some negative news in there!! A.",
          "sentiment": 0.0,
          "engagement": "434",
          "price_at_post": "10.90",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637211+00:00"
      },
      {
        "event_id": "SOCIAL-Today0934-Servalan--2420509",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "More positive news. Market reaction? meh as usual.",
          "sentiment": 0.5,
          "engagement": "119",
          "price_at_post": "11.15",
          "thread_title": "RE: Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637228+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Tamlin--6466317",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.148841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.lse.co.uk/rns/STX/approval-for-accrufer-in-china-expected-in-q1-2026-wegahcq2kruwm3u.html",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.40",
          "thread_title": "Shield Therapeutics PLC Approval for ACCRUFeR in China expected in ...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=07ADF245-C5DB-4B79-B87D-FA7B9C9D505D"
        },
        "ingested_at": "2026-02-11T17:10:24.637246+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261207-BioTechI--5304448",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149264",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "So much so that it's back to where it was a few weeks ago! Transformational",
          "sentiment": 0.0,
          "engagement": "38",
          "price_at_post": "11.25",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-11T17:10:24.637263+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261017-Mokomagi-18132277",
        "event_type": "social_post",
        "date": "2026-01-30T23:40:54.149669",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-11T17:10:24.637281+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-Mokomagi-18132277",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Are people finally starting to see the value in STX?????",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "11.25",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=6B383266-9FD4-4A45-AA7B-B94655F5001A"
        },
        "ingested_at": "2026-02-11T17:10:24.637299+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261653-Andle-85054250",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.610739",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Hopefully just clearing a sell off by a big holder?? A.",
          "sentiment": 0.0,
          "engagement": "428",
          "price_at_post": "9.90",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637317+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261138-Servalan--2321256",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "I wonder if the sp fluctuations are down to the US Health Insurers slam this week? or just mm's dicking around with it as usual",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637334+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261617-Beevorma--5281115",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.611769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "LOL Serv",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.10",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637352+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-PRO_TRAD--3782139",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612283",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "The dumbdumbs sell as usually, nothing strange when you don't have brains",
          "sentiment": 0.5,
          "engagement": "59",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637370+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261305-Mokomagi--1993486",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.612784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "PMSL Servalan, could not put it any better myself, Usually this will pick up this afternoon!! :)",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "9.75",
          "thread_title": "Kiss of death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=C342B636-2A04-4AE4-90F7-71A9A142AC1C"
        },
        "ingested_at": "2026-02-11T17:10:24.637388+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261257-Servalan-42529417",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Monday silliness. This often has bigger spreads than a slapper on onlyfans.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "9.75",
          "thread_title": "RE: Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637406+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261216-Beevorma-55843388",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.613790",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "So glad I decided to top up on Friday",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "9.75",
          "thread_title": "Kiss of Death",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=80F4600E-C898-436F-B98F-F50983E5EA4B"
        },
        "ingested_at": "2026-02-11T17:10:24.637423+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260653-simonlev--7836410",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:07.614310",
        "source": "LSE_CHAT",
        "data": {
          "author": "simonlevert",
          "content": "Why so fee NHS sales? I asked my close friend with 40+ years experience as an NHS pharmacist. Conventional treatments are cheaper. It\u2019s all about cost. An insurance-based system like the US is incentivised more to spend on better performing treatments.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-11T17:10:24.637441+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261242-Billy-Bu--3758344",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Mokomagic. STX seem to release their results on the 23 of the month after each quarter. So, we should get an update on FRiday 23rd in just under two weeks.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.637459+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261545-Mokomagi--3812487",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.379905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Looking back at the RNS's 2025 results should be announced around the end of this month or Feb 2026",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.75",
          "thread_title": "2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.637478+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261125-Destitut-30162452",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.380689",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "Might see this closed back to 12.50 this Week, all part of the listing management.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.00",
          "thread_title": "12.50",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=DA122E2C-97EE-4485-91E5-3A59796C2664"
        },
        "ingested_at": "2026-02-11T17:10:24.637497+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251134-Servalan-47056966",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.381467",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "10.75",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-11T17:10:24.637515+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251006-asiddall--3650970",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.382266",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yeah, nothing too fishy over the norm.  Plus, if there had been any leak, we\u2019re going to have to fix all the other 2000 companies that allegedly don\u2019t leak info to their nearest and dearest\u2026. Nothing too unusual, think",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.875",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-11T17:10:24.637533+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20252148-vaiter--5966953",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383053",
        "source": "LSE_CHAT",
        "data": {
          "author": "vaiter",
          "content": "How it could have been leaked if we all knew about it for months. I don't understand your logic. Chill \ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "51",
          "price_at_post": "10.65",
          "thread_title": "RE: Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-11T17:10:24.637550+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20252051-BioTechI-29698563",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.383829",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The news must have leaked over the past few weeks because the shares ran up on no news and then sold off on the actual RNS. AIM needs to be fixed - it's a joke. A few years ago, ahead of a dilutive rights issue in this stock, the shares fell massively ahead of the annoucement. Criminal!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.00",
          "thread_title": "Leaky shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=B5884773-C84F-4D0E-8FFE-EAF8FF573A9B"
        },
        "ingested_at": "2026-02-11T17:10:24.637569+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251613-asiddall--3584071",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.384623",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Can get a little complex.. this is almost certainly a by\u2011product of execution mechanics or broker algorithms, slicing big orders, not someone consciously paying retail rates to buy say 90p of stock.    Also, don\u2019t forget Professional/institutional traders are not paying say \u00a312 like a retail punter; commission is often negligible or zero on a per\u2011trade basis.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.00",
          "thread_title": "RE: Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-11T17:10:24.637587+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251200-wilding5-53890775",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.385388",
        "source": "LSE_CHAT",
        "data": {
          "author": "wilding5656",
          "content": "Just out of interest , does anyone know why tiny buys occur in stocks. Today someone bought 8 shares for less than a pound. Why?Surely the cost of the trade is more than its value",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "11.00",
          "thread_title": "Small buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=317CC780-D2AB-49E1-BF8E-241DCBFCEFB0"
        },
        "ingested_at": "2026-02-11T17:10:24.637606+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20251015-Servalan--8961515",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.",
          "sentiment": 0.5,
          "engagement": "116",
          "price_at_post": "11.25",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-11T17:10:24.637624+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250827-Arsenal7--9221618",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.386908",
        "source": "LSE_CHAT",
        "data": {
          "author": "Arsenal786",
          "content": "Great news. This share continues to build momentum - expecting a near term 15p by the end of the year and looking forward to an amazing 2026",
          "sentiment": 0.0,
          "engagement": "167",
          "price_at_post": "12.00",
          "thread_title": "RE: US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-11T17:10:24.637642+00:00"
      },
      {
        "event_id": "SOCIAL-22Dec20250825-Crazyyea-90156777",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.387684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "Great news today. Including a follow up with  suspension formulations",
          "sentiment": 0.0,
          "engagement": "401",
          "price_at_post": "12.00",
          "thread_title": "US FDA approves extension of the indication for ACCRUFeR\u00ae to inclu...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=85429BE0-376E-4771-9425-70F32C2EA4E8"
        },
        "ingested_at": "2026-02-11T17:10:24.637660+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20250840-Tamlin-66089135",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.388469",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Https://www.fool.co.uk/2025/12/20/prediction-these-near-penny-stocks-could-be-among-2026s-big-winners/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "11.25",
          "thread_title": "Positive Mention From Peel Hunt",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C527FCC3-33B9-4E2B-A51C-13A2A9618E71"
        },
        "ingested_at": "2026-02-11T17:10:24.637678+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250930-asiddall-43486787",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.389258",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, maybe a nice Xmas present to all existing shareholders, as a thank you for staying with them through thick and thin\u2026.",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-11T17:10:24.637696+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250920-brafty-67523440",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390015",
        "source": "LSE_CHAT",
        "data": {
          "author": "brafty",
          "content": "Could be a new RNS soon Pre-Christmas after dropping this ?",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "11.75",
          "thread_title": "RE: Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-11T17:10:24.637714+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250849-asiddall--2752011",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:10.390803",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "All good..  Employee focused.  No immediate dilution until shares vest and are issued, and follows recent positive developments.  They have around 1.06 billion shares outstanding, 15 million new shares represent about 1.4% potential dilution.  Quite tiny\u2026 Great potential here\u2026 DOYR (obviously)",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "11.75",
          "thread_title": "Block listing",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=C92C7A64-982A-45E1-8C95-EE2F1831A3E9"
        },
        "ingested_at": "2026-02-11T17:10:24.637733+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251257-Destitut--5594054",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639077",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The Investment Industry manage & work the listing position. Analysts are external business\u2019s outside the Industry & can only make educated predictions, like Joe Public. The Investment Industry are the ones with ultimate control. Only they know what\u2019s been pre planned. So, is this now time to break above 12.50 or pullback, we will see.",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.95",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-11T17:10:24.637751+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251233-Broomfie--2267158",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.639886",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "Been invested here for a while but never posted. For what it's worth, I feel  STX  are very much at a turning point and are now poised for dynamic growth. They are getting their 'ducks in a row' now and if they confirm now being cash flow positive early in '26, then the wider Market will wake up to this Co delivering with a proven product, a substantial backer, debt re-priced and under control. Definitely on the launch pad with the engines firing imo.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "11.95",
          "thread_title": "RE: 12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-11T17:10:24.637770+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251207-Valhala--7419408",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.640651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": ".....is everyone out on their Xmas parties! Roll on Black Eye Friday!",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.00",
          "thread_title": "12 p and all is quiet....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=0B1B5C39-B7AB-4229-95AB-9B33F1E72385"
        },
        "ingested_at": "2026-02-11T17:10:24.637788+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251107-Beevorma-62493458",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.641379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've never once seen a positive association between analyst prices and reality",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.05",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-11T17:10:24.637806+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251250-Mokomagi--3118220",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "The IC has STX at a high of 23.18p and a medium of 14.96p based on one analysts target price.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "10.15",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=2B2D82B2-2CCF-4E9B-BBA3-64ECCCEF2A1A"
        },
        "ingested_at": "2026-02-11T17:10:24.637824+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251146-Beevorma-18860766",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.642776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I guess it will be first week of Feb for the usual unaudited FY update, which will hopefully contain something confirming they're CF neutral/positive!?",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "10.25",
          "thread_title": "First Signs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7CF4D5F9-42E2-4B5E-83E2-C6BA955ECB33"
        },
        "ingested_at": "2026-02-11T17:10:24.637841+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20251042-Beevorma--8396240",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.643509",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Wow looks like i missed a lot of fun chat yesterday! If you look at the case of Amryt Pharma before they were gobbled up by a larger company, they heavily promoted themselves as being CF positive but were not EBIT generative, it is in many ways possible to be one but not the other from an accounting perspective. That being said, given we're a bit of a 1 product solution I don't suspect there will be a big gap between CF and EBIT generation for us. Hopefully within the course of 2026 we'll see only black numbers...",
          "sentiment": 0.0,
          "engagement": "1,489",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.637859+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250901-PRO_TRAD-26874132",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644226",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "You are talking about your self of course! Get the required experience.from stock market because it seems you have zero!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.637879+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250032-MoneyPen-80037859",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.644925",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "Right, I think you\u2019ve embarrassed yourself enough for one day. I\u2019ll refrain from engaging any further.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.637913+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251815-PRO_TRAD-71657551",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.645632",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "I suspect you are young and you don't understand how the stock market works. Every business is different with different potential, if you compare Zanaga and Shield we are talking about completely different businesses. I am trash talking when I must , I am straight about my opinions like about METALS ONE as well,  I POSTED IT WILL GO DOWN TO 2-3 Pence FROM 55 pence and now is 2 pence. Experience is everything in stock market, about what change of heart are you talking  about if you are aware that the post was for Zanaga and not for Shield? Never posted nothing negative about Shield, read my posts carefully.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.637948+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251730-BioTechI--2361711",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.646315",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "I'm completely aware that this was a different company. In that example, you are trash talking that business for being unprofitable for a number of years. Why is Shield Different? You've held it since 2022 and it hasn't been profitable for the 4+ years since you've invested. So I ask again... Why the change of heart for Shield?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.637982+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251525-PRO_TRAD--2242950",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647005",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "YOU SHOULD MAKE YOUR RESEARCH BETTER SINCE YOU ARE CLAIMING THAT YOU ARE .INTELLECTUAL....I have posted this about ZANAGA IRON and definitely not about shield therapeutics. I am holder of shield since 2022 if I remember correctly, I am keeping buying and I never sold not a single share until today.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.15",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638004+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251514-BioTechI-56374791",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.647726",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "@PRO_TRADER ..... Here is your post from Jan 9th 2023: \"I see many comments here about the share price that is cheap and going 20p etc About what we are talking here? The price increased in simply news, lt should be below 2p normally, the company is unprofitable and will continue to be unprofitable over the next 5 years,. If you study the charts the main trend is bearish, games and speculation only will lead the price higher and only in short term. If you like to make money on speculation then this is for you, if you want to invest in companies with future and good returns then look somwhere else\"..... Why the change of heart?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638023+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251510-BioTechI--9259937",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.648425",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Am I missing something? the link you've shared there ALSO shows EPS being negative until 2027 before it turns positive. I'm a long term holder so I don't care either way. Just being intellectually curious here.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638041+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251411-PRO_TRAD-20311151",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649137",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Cavendish can write what they want, you believe these butcher analysts? What analysts know? Good you are long term holder, it means you beleive in company like me. It will be 30p after 1.5 year even more. Have a look at this one https://valueinvesting.io/STX.L/estimates Maximum target 25p in a year time, I believe 30p - 40p over the next 1.5 year.",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638059+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251356-BioTechI--5342332",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.649833",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "Firstly, I'm not short. I am a holder and have been for years. Secondly, if you ACTUALLY read that Cavendish report, have a look at the EBITDA projections and you'll see they are forecasting -\u00a30.5m for 2026 FY. This implies that Cavendish (not me...) are suggesting EBITDA won't turn positive until 2027. Does that make sense?",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "10.70",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638078+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251314-PRO_TRAD--5510605",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650386",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Maybe you are short on this one trying to make some money?",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638096+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251239-PRO_TRAD-62076788",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.650807",
        "source": "LSE_CHAT",
        "data": {
          "author": "PRO_TRADER",
          "content": "Negative in 2027??? This must be joke sure!",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "11.20",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638133+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251213-BioTechI-18429455",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651243",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-swk-refinancing-better-terms-increased-available-funds/129_cc6572f6-0bca-4843-8648-4aed397e3703/a8cd0cb1-6c18-4c75-bd4e-a646dbbd212f",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.10",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638151+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251211-shandypa-84918439",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.651665",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "this research?? https://*********************/companies/uk/pharmaceuticals/shield-therapeutics-plc/research/cavendish/shield-therapeutics-pathway-towards-profitability/129_a83feacd-0a86-4d82-b308-e55fd750181e",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "11.25",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638170+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251150-BioTechI--2227161",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652086",
        "source": "LSE_CHAT",
        "data": {
          "author": "BioTechInvestor",
          "content": "The Cavendish note shows the business as EBITDA negative into 2027...",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "11.575",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638188+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20251009-shandypa--6990672",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.652823",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Why do we need to prevent further dilution? We have repeatedly been told we will be cashflow positive by year end (3 weeks from now) and this was reiterated only a few weeks ago. Furthermore they also took extra money via a placing a few months back to give them a bit more headroom. Yet despite all the above they have already accessed an extra $2m of the funding.",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638207+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20252039-Destitut-33438996",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.653535",
        "source": "LSE_CHAT",
        "data": {
          "author": "DestituteBroker",
          "content": "The stock that goes up every day !",
          "sentiment": 0.0,
          "engagement": "2,336",
          "price_at_post": "11.90",
          "thread_title": "S T X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=3258E0B3-BAC0-414E-8B3E-932ADCC3338D"
        },
        "ingested_at": "2026-02-11T17:10:24.638225+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251632-Valhala--6603980",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Valhala",
          "content": "It has to be shown as a positive for sure! The loan prevents further dilution but should also demonstrate by the restructuring of the finance that there is a positive sentiment towards STX.   They have a better risk profile for lending against and with that comes a higher level of financial offering. I'm now only 1p away from breakeven so l hope this can continue momentum! Good luck to everyone holding this one after a lot of torrid years.",
          "sentiment": 0.0,
          "engagement": "17",
          "price_at_post": "12.05",
          "thread_title": "RE: Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638243+00:00"
      },
      {
        "event_id": "SOCIAL-3Dec20251554-shandypa-22343195",
        "event_type": "social_post",
        "date": "2026-01-29T11:53:14.654916",
        "source": "LSE_CHAT",
        "data": {
          "author": "shandypants2",
          "content": "Not 100% sure what to make of today's RNS. Amending the interest paid is clearly a positive and having the potential money available for M&A isn't a terrible thing but it does also appear that in the short term extra money is required despite supposedly being cashflow neutral/positive by about now. Within the small print see excerpt below it does say that $2m has been immediately drawn. Clearly whilst i think the company has now had a positive cashflow month, probably October 2025, Q1 is usually lower revenues so there may be a dip. The company has been quite vague on becoming cashflow positive - is this for a whole quarter or a smaller period? Who knows. Clearly this is not a straight line there will still be dips and upward progress over the coming months. I thought that was the point of the placing only a month or so ago. \"As a part of the amendment, Shield will draw an additional $2 million of the total available funds bringing the total debt outstanding under this facility to $22 million. \"",
          "sentiment": 0.0,
          "engagement": "3,313",
          "price_at_post": "12.05",
          "thread_title": "Amended loan facility",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&share=STX&thread=7BC9E4AD-4395-4E28-8F78-38845F9B0343"
        },
        "ingested_at": "2026-02-11T17:10:24.638261+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261803-Servalan-13900307",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.266557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any.  Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-11T17:10:24.638279+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261509-Broomfie-39601050",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Broomfielder",
          "content": "I have to concede, I was expecting a bit more positivity from the Market in response to the Q4 trading data. It's certainly proving a slow burner this one. Hopefully, I'm not speaking out of turn here, but does the Market harbour wider reservations about Stx? The latest figures were positive and the co is broadly moving along its forecast track but, well is there a 'but'? The Co is essentially a one trick pony as far as products are concerned, so is there an issue with the Patents being c10 years unexpired? These can be 'extended' for a further 5 years, the Co although heavily borrowed, is not over borrowed, so other than delivering on its forecast earnings path, I'm genuinely not sure what will be the catalyst for any appreciable upward movement in the sp. As a holder, I hope I'm missing something but beginning to wonder if the sorts of levels (of sp) many lth's will need will be achieved. Just a thought.....certainly not a de-ramp as my only motivation is to see the the sp rise which will hopefully benefit the majority here.",
          "sentiment": 0.0,
          "engagement": "535",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-11T17:10:24.638298+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261307-Beevorma-16304822",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "I've said a few time before I'm heavily down here as i originally bought in at around 56p and was loathed to avg down as that's bitten me in the past with companies that don't generate profit. The update has given me a lot of confidence they're finally on track so i topped up 10k this morning using my ISA allowance. Onwards and upwards hopefully.",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "10.75",
          "thread_title": "RE: Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-11T17:10:24.638316+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261200-Mokomagi--6380085",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.267868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mokomagic",
          "content": "Following an upward trajectory in 2025 and going into 2026 cashflow positive, we will see further investor sentiment improve as it did through the course of 2025. I look forward to seeing the share price move upwards / as they say its not a sprint its a marathon :)",
          "sentiment": 0.0,
          "engagement": "59",
          "price_at_post": "10.75",
          "thread_title": "Year ahead",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F2CFD682-7D26-4314-9FAD-44B722DEB346"
        },
        "ingested_at": "2026-02-11T17:10:24.638334+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261132-asiddall-54576955",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268296",
        "source": "LSE_CHAT",
        "data": {
          "author": "asiddall",
          "content": "Yep, nice upward trend from June last year.  Nothings ever a diagonal line but this stock is worth far more than its ever been\u2026",
          "sentiment": 0.0,
          "engagement": "247",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-11T17:10:24.638353+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20262044-Servalan--1065433",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.268714",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\"no penetrative\"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-11T17:10:24.638370+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261626-smythsmo--8974531",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269141",
        "source": "LSE_CHAT",
        "data": {
          "author": "smythsmoneybox",
          "content": "Basically no penetrative into the  UK market......yet. Why?",
          "sentiment": 0.0,
          "engagement": "265",
          "price_at_post": "10.75",
          "thread_title": "RE: Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-11T17:10:24.638388+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261612-Billy-Bu--8069367",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "I agree, Tiddlerontheroof. I'm optimistic that the share price will be significantly higher this time next year.",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "10.75",
          "thread_title": "RE: Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-11T17:10:24.638406+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261505-Tiddlero-87186866",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.269981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tiddlerontheroof",
          "content": "A positive presentation. They're looking to add another good to go product as well as opening up sales in other countries. This hopefully will be a transformative year for Shield.",
          "sentiment": 0.0,
          "engagement": "159",
          "price_at_post": "10.50",
          "thread_title": "Investor Meet",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=DCBBD0EE-2E4B-44F3-A579-44A82FC72CC8"
        },
        "ingested_at": "2026-02-11T17:10:24.638424+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20260947-Servalan--8870800",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "\u00a3150,349 ( Nov-24: \u00a3108,185) c. 39% yoy increase",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.50",
          "thread_title": "Nov-25 NHS England Rx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=F0FBD2E9-3EE2-42A3-BE0A-00C90834ECF6"
        },
        "ingested_at": "2026-02-11T17:10:24.638442+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260934-Andle--9012178",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.270831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Andle",
          "content": "Looks like a cheap opportunity to me too.  Shame I\u2019m out of play tokens atm.  Would have been tempted to\u2026\u2026\u2026 Nice update I\u2019d say and will settle back down imho. Nothing unexpected in the back end all to play for in 26!! A",
          "sentiment": 0.0,
          "engagement": "427",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638460+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260923-Servalan--7404880",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!",
          "sentiment": 0.5,
          "engagement": "110",
          "price_at_post": "10.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638478+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260845-rich160-27893357",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.271677",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we'd hoped in the latter part of the year, ACCRUFEeR\u00c2\u00ae US revenue and US prescription volume growth of 56% and 33%, respectively, remain impressive achievements during a year of concerted commercial execution. We update our forecasts to reflect today's news, broadly maintaining FY26E revenues at $79.9m (previously $79.4m) while upgrading our expectations for operating profit to $1.4m (prev. operating loss of $2.5m) on updated assumptions for volumes, net selling price and COGS\" Very hard to see how STX could have realistically done additional $4.5m in Q4, even if selling price was higher. Overall, company in a great place",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "10.75",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-11T17:10:24.638496+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260833-CrudeTra--6683953",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272090",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "\"Total revenues for FY25E are expected to be c$50m against our $54.6m estimate, with 4Q25 seeing a reduction in the average net selling price to $222 (4Q24: $237) and total prescriptions for the year coming in at c199,000. While the absolute quantum of commercial sales was lower than we\u2019d hoped in the latter part of the year\"",
          "sentiment": 0.0,
          "engagement": "468",
          "price_at_post": "10.95",
          "thread_title": "RE: Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-11T17:10:24.638514+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260819-MoneyPen--1581891",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272515",
        "source": "LSE_CHAT",
        "data": {
          "author": "MoneyPenni",
          "content": "If you look at the analyst forecasts, they were expecting a slightly stronger Q4 on revenue and net selling price. Hence why the stock hasn\u2019t flown on the results. Breakeven was already priced in. I\u2019m a long term holder so makes no difference to me! Just sharing.",
          "sentiment": 0.0,
          "engagement": "2",
          "price_at_post": "11.25",
          "thread_title": "Good results but a miss on earnings!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D8434B6C-996A-426C-B31F-8480517EB091"
        },
        "ingested_at": "2026-02-11T17:10:24.638532+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260741-rich160-43508340",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.272932",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Excellent results. Still only a \u00a3120m market cap,",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638550+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260736-Crazyyea-73532203",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crazyyear",
          "content": "What a great set of results. With further growth to come from liquid and Paediatric formulations",
          "sentiment": 0.0,
          "engagement": "391",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638569+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260730-Billy-Bu--8488573",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.273776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Billy-Bunter",
          "content": "Excellent results :-)",
          "sentiment": 0.0,
          "engagement": "374",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638587+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261523-Emerald5-64474598",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Emerald51",
          "content": "Nobody seems to be buying at all today and the volumes seem small Everyone I presume is sitting back in anticipation of results",
          "sentiment": 0.0,
          "engagement": "115",
          "price_at_post": "11.25",
          "thread_title": "No buys and small volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=110DC029-A78D-4F00-BA21-32DD8A635930"
        },
        "ingested_at": "2026-02-11T17:10:24.638605+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261847-Servalan-49902894",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.274625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.",
          "sentiment": 0.0,
          "engagement": "110",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638624+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261623-Beevorma-21351859",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275041",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Hmmm Blue Monday or the usual someone knows something before we do",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "11.25",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638642+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261838-MrBB--4796954",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275472",
        "source": "LSE_CHAT",
        "data": {
          "author": "MrBB",
          "content": "There are several RNSs pending over the coming days weeks-apart from the FY25 trading update-eg China approval, launch in S Korea,results from 2 key studies which ,if successful, will expand our prospective market further.",
          "sentiment": 0.0,
          "engagement": "3,651",
          "price_at_post": "12.15",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638660+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261557-rich160-57682587",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.275891",
        "source": "LSE_CHAT",
        "data": {
          "author": "rich160",
          "content": "Do we expect update on 23rd Jan or early Feb? Have seen both dates referenced.",
          "sentiment": 0.0,
          "engagement": "200",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638677+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261423-Beevorma-69860909",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276313",
        "source": "LSE_CHAT",
        "data": {
          "author": "Beevorma",
          "content": "Seems to be gently gently moving up in anticipation of the RNS. Undoubtedly someone will get wind of it a day or two before and us normal investors will know only from the rapid swing in SP!",
          "sentiment": 0.0,
          "engagement": "1,487",
          "price_at_post": "12.20",
          "thread_title": "RE: 2025 results",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=53039022-C341-4998-9957-D63E8400191A"
        },
        "ingested_at": "2026-02-11T17:10:24.638696+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261728-Tamlin--5437295",
        "event_type": "social_post",
        "date": "2026-01-24T02:17:09.276750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Tamlin",
          "content": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I buy now? Shield Therapeutics\u2019 share price has more than QUADRUPLED in a year! But is it too late for investors to buy the shares? Zaven Boyrazian investigates. Posted by Zaven Boyrazian, CFA \u276f @ZBoyrazian Published 12 January, 8:11 am GMT htTps://www.fool.co.uk/2026/01/12/the-shield-therapeutics-share-price-is-up-318-in-1-year-should-i-buy-now/",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "10.75",
          "thread_title": "Shield Therapeutics\u2019 share price is up 318% in 1 year! Should I b...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=STX&thread=D6F8F0F3-AD28-406B-8686-AD6527146E22"
        },
        "ingested_at": "2026-02-11T17:10:24.638713+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2026-01-16"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "STX.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 2,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 48.3,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 26.3,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 2
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 26/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 662% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "CROWDED",
        "icon": "\u26a0\ufe0f",
        "text": "Crowded",
        "color": "#f59e0b"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 60",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "FDA Grants additional Exclusivity for ACCRUFeR",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Approval for ACCRUFeR in China expected in Q1 2026",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Q4 2025 Trading Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Block listing 6 Monthly Return",
        "status": "published",
        "icon": "\ud83d\udce2"
      }
    ],
    "decision_matrix": {
      "decision": "AVOID",
      "reason": "\u274c SELL/TAKE_PROFITS - timing CROWDED",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "48/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "CROWDED",
          "pass": false,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "60/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 47,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 22,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 7,
          "signals_per_week": 0.54,
          "total_signals": 28,
          "rsi_extreme_count": 4,
          "rsi_ultra_count": 3,
          "escalation_count": 1,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 4,
          "description": "0.5 signals/week | 4 RSI<20 | 1 escalations | \ud83d\udcca MODERATE COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.03,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 15,
          "max": 15,
          "best_historical_rally": 895.9,
          "avg_rally": 396.1,
          "signal_count": 28,
          "description": "BIG POPPER - Historical 5x+ (896%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "STX.L",
      "signal_date": "2024-07-15",
      "total_signals_history": 28
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=87.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +16 (best_rally_pct=662%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 87.55,
      "reason": "Drawdown of 87.5% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 16,
      "best_rally_pct": 662.5,
      "reason": "Best rally of 662% gives 16/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Historically strong runner - massive upside when it moves",
        "tag": "HIGH",
        "evidence": [
          "best_rally_pct=662%",
          "Rally_Count=1.0"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-07-15"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "SELL/TAKE_PROFITS",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CROWDED",
    "run_multiple": 0.8,
    "current_run_pct": 532.03,
    "avg_historical_run_pct": 662.5
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CROWDED timing with 60/100 APEX score. Historical data shows 1 rallies averaging 662% upside. Current position: +532.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Strong historical rally behavior (662% best run)"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Late stage. Consider taking profits as risk/reward deteriorates.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}